Engineered cancer antigens with modified structural domains, along with related methods and applications.
By designing engineered cancer antigens containing target domains and tumor-targeting molecules, the limitations of CAR-T therapy in the treatment of solid tumors have been overcome, achieving highly efficient targeted and immunotherapy for solid tumors.
Patent Information
- Application Number
- CN202580024950.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-11-27
- Filing Date
- 2025-02-10
- Publication Date
- 2026-11-10
AI Technical Summary
Current CAR-T therapies face challenges in treating solid tumors, such as tumor microenvironment immunosuppression, restricted T cell migration, and "extratumor-mediated" toxicity, making them difficult to effectively target solid tumors.
An engineered cancer antigen was designed, comprising a target domain and a tumor-targeting molecule. The extracellular domain of the target antigen or a truncated portion thereof binds to tumor cell surface antigens and binds to a heterologous membrane-targeting domain, thereby enhancing the targeting and immune response to solid tumors.
It improves the targeting and immune response of CAR-T cells to solid tumors, enhances the therapeutic effect on solid tumors, and overcomes the limitations of existing technologies.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Cross-reference to related applications
[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 552,039, filed February 9, 2024, entitled “ENGINEERED CANCER ANTIGENS AND RELATED METHODS AND USES,” and U.S. Provisional Patent Application No. 63 / 726,226, filed November 27, 2024, entitled “ENGINEERED CANCER ANTIGENS WITH MODIFIED DOMAINS AND RELATED METHODS AND USES,” the contents of which are incorporated herein by reference in their entirety. Reference to the electronic sequence list
[0002] This application is submitted together with an electronic sequence list. The sequence list is provided as a file with the title 307612001940SeqList.XML, created on February 10, 2025, and is 323,917 bytes in size. Information from the electronic sequence list is incorporated herein by reference in its entirety. Technical Field
[0003] This disclosure generally relates to engineered cancer antigens and the use of such engineered cancer antigens in the treatment of cancer, such as in combination with chimeric antigen receptor therapies that recognize said engineered cancer antigens on tumor cells. Background Technology
[0004] Adoptive transfer of T lymphocytes modified with chimeric antigen receptors (CARs) targeting tumor-associated antigens (TAAs) has shown promising results against several hematologic malignancies (Rossig et al., Mol Ther. (2004) 10(1):5-18). Despite their potential, these therapies have not been successfully adapted for the treatment of solid tumors due to several factors. Key factors include, for example, CAR-T cell immunosuppression in the tumor microenvironment, restricted migration of T cells to the tumor site, and on-target, off-tumor toxicity (Wang et al., Front Med. (2020) 14(6):726-45; Tahmasebi et al., Stem Cell Rev Rep. (2019) 15(5):619-36). Summary of the Invention
[0005] This document provides an engineered cancer antigen comprising a target domain and a tumor-targeting molecule, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof. In some of the provided embodiments, the engineered cancer antigen is secretible. In some of the provided embodiments, the tumor-targeting molecule binds to a tumor-associated antigen expressed on the surface of tumor cells. In some of the provided embodiments, the tumor-associated antigen is selected from EpCAM, CEA (carcinoembryonic antigen), gpA33 (glycoprotein A33 (transmembrane)), mucin, TAG-72 (tumor-associated glycoprotein 72), CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), and FBP (folate-binding protein), EGFR / ERBB1 / HER1 (epidermal growth factor receptor 1), ERBB3 (epidermal growth factor receptor 3), MET (tyrosine protein kinase), IGF1R (insulin-like growth factor 1 receptor), EPHA3 (EPH receptor A3), TRAILR1 (death receptor 4), and RANK-L (nuclear factor κB receptor activator ligand). In some of the provided embodiments, the tumor cells are tumor cells of a solid tumor. In some of the provided embodiments, the tumor cells are tumor cells selected from the following cancers: multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, medulloblastoma, liver cancer, gastric cancer, thyroid cancer, bile duct cancer, liver cancer, bone cancer, skin cancer, colon cancer, rectal cancer, endometrial cancer, and cervical cancer. In some of the provided embodiments, the tumor cells are tumor cells selected from the following cancers: bladder cancer, breast cancer, skin cancer, head and neck cancer, colorectal cancer, endometrial cancer, liver cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, thyroid cancer, and ovarian cancer.
[0006] In some of the provided embodiments, the tumor-targeting molecule comprises an antibody or an antigen-binding fragment thereof. In some of the provided embodiments, the antibody or antigen-binding fragment thereof is a single-chain variable fragment (scFv), DARPin, a variable heavy chain (VH) domain, or VHH, more preferably a single-chain variable fragment (scFv).
[0007] In some of the provided embodiments, the tumor-associated antigen is EpCAM. In some of the provided embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises heavy chain complementarity-determining regions 1 (CDR-H1), 16, and 17, which respectively contain the amino acid sequences shown in SEQ ID NO: 15, 16, and 17, and the VL region comprises light chain complementarity-determining regions 1 (CDR-L1), 19, and 20, which respectively contain the amino acid sequences shown in SEQ ID NO: 18, 19, and 20. In some of the provided embodiments, the antibody or its antigen-binding fragment comprises a VH region containing an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 10; and a VL region containing an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 8. In some of the provided embodiments, the antibody or its antigen-binding fragment comprises a VH region containing the amino acid sequence of SEQ ID NO: 10 and a VL region containing the amino acid sequence of SEQ ID NO: 8.
[0008] In some of the provided embodiments, the tumor domain and the tumor-targeting molecule are directly linked. In some of the provided embodiments, the tumor domain and the tumor-targeting molecule are linked via a connector. In some of the provided embodiments, the length of the connector is between 1 and 100 amino acids, between 1 and 75 amino acids, between 1 and 50 amino acids, between 1 and 25 amino acids, between 5 and 100 amino acids, between 5 and 75 amino acids, between 5 and 50 amino acids, between 5 and 25 amino acids, between 10 and 100 amino acids, between 10 and 75 amino acids, between 10 and 50 amino acids, or between 10 and 25 amino acids. In some of the provided embodiments, the connector comprises an amino acid sequence of any one of SEQ ID NO: 9 and 138-144.
[0009] In some of the provided embodiments, the target antigen is a membrane-expressed antigen. In some of the provided embodiments, the target antigen is a cell surface receptor. In some of the provided embodiments, the target domain is recognizable by a homology binder. In some of the provided embodiments, the target domain is a truncated portion of the extracellular domain of the target antigen, retaining epitopes recognizable by homology binders. In some of the provided embodiments, the target antigen is selected from carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cells infected with cytomegalovirus (CMV) (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein ligand 1 (PSGL-1) Glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0010] In some of the provided embodiments, the target antigen is BCMA. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 3. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 32; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 35.
[0011] In some of the provided embodiments, the target antigen is CD70. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 106. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 107 or 124.
[0012] In some of the provided embodiments, the target antigen is CD19. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 71. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: (a) a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 48 or 49; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 50 and a VL region comprising the amino acid sequence of SEQ ID NO: 51; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 52.
[0013] In some of the provided embodiments, the target antigen is CD20 (e.g., the CD20 extracellular domain). In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 72. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a VH region comprising the amino acid sequence of SEQ ID NO: 53 and a VL region comprising the amino acid sequence of SEQ ID NO: 54; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 55.
[0014] In some of the provided embodiments, the target antigen is CD22. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 73. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: (a) a VH region comprising the amino acid sequence of SEQ ID NO: 56 and a VL region comprising the amino acid sequence of SEQ ID NO: 57; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 58; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 59 and a VL region comprising the amino acid sequence of SEQ ID NO: 60; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 61.
[0015] In some of the provided embodiments, the target antigen is CD70. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 124. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a VH region comprising the amino acid sequence of SEQ ID NO: 125 and a VL region comprising the amino acid sequence of SEQ ID NO: 126; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 127.
[0016] In some of the provided embodiments, the homologous binder is a chimeric antigen receptor (CAR) that binds to the target domain. In some of the provided embodiments, the CAR binds to an extracellular domain or a truncated portion thereof selected from cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein. Specialized glycoforms of leukoligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0017] In some of the provided implementations, the engineered cancer antigen does not contain an intracellular domain.
[0018] This document provides an engineered cancer antigen comprising a target domain and a heterologous membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof. In some of the provided embodiments, the engineered cancer antigen is membrane-bound upon expression from a cell. In some of the provided embodiments, the heterologous membrane-targeting domain is a heterologous transmembrane domain. In some of the provided embodiments, the heterologous transmembrane domain is derived from the following transmembrane domains: α, β, or ζ chains of T cell receptors, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, CD1 lα, CD18, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL-2Rβ, IL-2Rγ, IL-7Rα, ITG A1, VLA1, CD49a, ITGA4, IA4, CD49d, ITGA6, VLA-6, CD49f, ITGAD, CD1D, ITGAE, CD103, ITGAL, ITGAM, CD1B, ITGAX, CD1C, ITGB1, CD29, ITGB2, CD 18. LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, CD229, CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D, or NKG2C. In some of the provided embodiments, the transmembrane domain is a CD8 transmembrane domain. In some of the provided embodiments, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 4.
[0019] In some of the provided embodiments, the target domain and the heterologous membrane-targeting domain are each derived from different cell surface receptors. In some of the provided embodiments, the target antigen is a membrane-expressed antigen. In some of the provided embodiments, the target antigen is a cell surface receptor. In some of the provided embodiments, the target domain is recognizable by a homologous binder. In some of the provided embodiments, the target domain is a truncated portion of the extracellular domain of the target antigen, retaining epitopes recognizable by homologous binders.In some of the provided embodiments, the target antigen is selected from carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cells infected with cytomegalovirus (CMV) (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein ligand 1 (PSGL-1) Glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0020] In some of the provided embodiments, the target antigen is BCMA. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 3. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 32; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 35.
[0021] In some of the provided embodiments, the target antigen is CD70. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 106. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 107 or 124. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 124. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a VH region comprising the amino acid sequence of SEQ ID NO: 125 and a VL region comprising the amino acid sequence of SEQ ID NO: 126; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 127.
[0022] In some of the provided embodiments, the target antigen is CD19. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 71. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: (a) a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 48 or 49; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 50 and a VL region comprising the amino acid sequence of SEQ ID NO: 51; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 52.
[0023] In some of the provided embodiments, the target antigen is CD20. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 72. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: a VH region comprising the amino acid sequence of SEQ ID NO: 53 and a VL region comprising the amino acid sequence of SEQ ID NO: 54; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 55.
[0024] In some of the provided embodiments, the target antigen is CD22. In some of the provided embodiments, the target domain comprises the amino acid sequence of SEQ ID NO: 73. In some of the provided embodiments, the target domain is recognizable by a homology binding agent comprising: (a) a VH region comprising the amino acid sequence of SEQ ID NO: 56 and a VL region comprising the amino acid sequence of SEQ ID NO: 57; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 58; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 59 and a VL region comprising the amino acid sequence of SEQ ID NO: 60; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 61.
[0025] In some of the provided embodiments, the homologous binder is a chimeric antigen receptor (CAR) that binds to the target domain. In some of the provided embodiments, the CAR binds to an extracellular domain or a truncated portion thereof selected from cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein. Specialized glycoforms of leukoligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0026] In some of the provided embodiments, the engineered cancer antigen does not contain an intracellular domain. In some of the provided embodiments, the engineered cancer antigen further contains an intracellular domain. In some of the provided embodiments, the intracellular domain is a heterologous intracellular domain derived from the target antigen or a truncated portion thereof. In some of the provided embodiments, the intracellular domain is a truncated and / or non-functional intracellular domain. In some of the provided embodiments, the intracellular domain contains a death domain. In some of the provided embodiments, the death domain is derived from a death receptor selected from: FAS (CD95), tumor necrosis factor receptor superfamily member 10A (TNFRSF10A; also known as death receptor 4 (DR4)), DR5, TNFR1, DR3, leucine-rich repeat sequence and death domain-containing protein 1, ankyrin repeat sequence and death domain-containing protein IB, interleukin-1 receptor-associated kinase-like protein 2, tumor necrosis factor receptor superfamily member 21, Netrin receptor UNC5A, Netrin receptor UNC5B, Netrin receptor UNC5C, Netrin receptor UNC5D, UNC5C-like protein, tumor necrosis factor receptor superfamily member 16, ankyrin 1, ankyrin 2, ankyrin 3, nuclear factor NF-κB p105 subunit, tumor necrosis factor receptor superfamily member 6, interleukin-1 receptor-associated kinase 1, death-associated protein kinase 1, death domain-containing protein CRADD, and nuclear factor NF-κB. The p100 subunit, FAS-associated death domain protein (FADD), receptor-interacting serine / threonine protein kinase 1, ankyrin repeat sequence and death domain-containing protein 1A, death domain-containing protein 1, exoprotein A receptor-associated adaptor protein, tumor necrosis factor receptor superfamily member 25, THO complex subunit 1, myeloid differentiation primary response protein MyD88, p53-induced death domain-containing protein 1, and interleukin-1 receptor-associated kinase 3. In some of the provided embodiments, the death domain is derived from FAS, FADD, or TNFRSF10A. In some of the provided embodiments, the death domain is derived from FAS. In some of the provided embodiments, the death domain comprises an amino acid sequence selected from SEQ ID NO: 93, 97, and 99. In some of the provided embodiments, the death domain is derived from FADD. In some of the provided embodiments, the death domain comprises an amino acid sequence of SEQ ID NO: 101. In some of the provided embodiments, the death domain is derived from TNFRSF10A. In some of the provided embodiments, the death domain comprises the amino acid sequence of SEQ ID NO: 103 or 105.
[0027] This document provides a cell that expresses any provided engineered cancer antigen. This document also provides a cell that expresses and contains any provided engineered cancer antigen.
[0028] In some of the provided embodiments, the cells are tumor cells. In some of the provided embodiments, the tumor cells are tumor cells selected from the following cancers: non-Hodgkin lymphoma (NHL), diffuse large cell lymphoma (DLCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma, multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, skin cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, medulloblastoma, liver cancer, gastric cancer, thyroid cancer, bile duct cancer, liver cancer, bone cancer, colon cancer, rectal cancer, endometrial cancer, and cervical cancer. In some of the provided embodiments, the tumor cells are tumor cells selected from the following cancers: bladder cancer, breast cancer, skin cancer, head and neck cancer, colorectal cancer, endometrial cancer, liver cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, thyroid cancer, and ovarian cancer.
[0029] This document provides a polynucleotide that encodes any of the provided engineered cancer antigens. This document also provides a polynucleotide comprising a nucleic acid sequence encoding any of the provided engineered cancer antigens and a nucleic acid sequence encoding any of the provided engineered cancer antigens.
[0030] In some of the provided embodiments, the nucleic acid sequences encoding the engineered cancer antigen are separated by cleavable adapters. In some of the provided embodiments, the cleavable adapters are self-cleaving adapters. In some of the provided embodiments, the self-cleaving adapter is or contains a 2A peptide. This document provides a vector comprising any provided polynucleotide. In some of the provided embodiments, the vector is used to deliver the polynucleotide to cancer cells. In some of the provided embodiments, the vector is used for specific delivery to blood cancer cells. In some of the provided embodiments, the vector is used for specific delivery to solid tumor cancer cells. In some of the provided embodiments, the vector is a viral vector.
[0031] In some of the provided embodiments, the viral vector is an oncolytic virus. In some of the provided embodiments, the oncolytic virus is selected from adenovirus, herpes simplex virus, vaccinia virus, mumps virus, Newcastle disease virus, poliovirus, Seneca Valley virus, measles virus, Sindebeth virus, parvovirus, Coxsackie virus, vesicular stomatitis virus, reovirus, and Maraba and rhabdovirus.
[0032] In some of the provided embodiments, the viral vector exhibits tropism for tumor cells. In some of the provided embodiments, the viral vector enters the cell by binding to a cell surface receptor expressed by the tumor cell. In some of the provided embodiments, the viral vector is an adenovirus vector, an adeno-associated virus (AAV) vector, a lentiviral vector, a retroviral vector, or a herpes simplex virus (HSV) vector. In some of the provided embodiments, the viral vector is an adenovirus vector. In some of the provided embodiments, the viral vector is a lentiviral vector.
[0033] This document provides a pharmaceutical composition comprising any provided polynucleotide or any provided carrier. In some of the provided embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0034] This article provides a combination comprising any provided vector and a population of lymphocytes expressing a chimeric antigen receptor (CAR) that recognizes the target domain of the engineered cancer antigen.
[0035] This article provides a combination comprising a vector and a population of lymphocytes, wherein the vector contains a polynucleotide encoding an engineered cancer antigen, the engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof, and the lymphocytes express a chimeric antigen receptor (CAR) that recognizes the target domain of the engineered cancer antigen.
[0036] In some of the provided embodiments, the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein. Specialized glycoforms of leukoligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0037] In some of the provided embodiments, the CAR binds to the extracellular domain of BCMA or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 32; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 35.
[0038] In some of the provided embodiments, the CAR binds to an extracellular domain of CD19 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: (a) a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 48 or 49; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 50 and a VL region comprising the amino acid sequence of SEQ ID NO: 51; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 52.
[0039] In some of the provided embodiments, the CAR binds to the extracellular domain of CD20 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: a VH region comprising the amino acid sequence of SEQ ID NO: 53 and a VL region comprising the amino acid sequence of SEQ ID NO: 54; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 55.
[0040] In some of the provided embodiments, the CAR binds to the extracellular domain of CD22 or a truncated portion thereof. In some of the provided embodiments, (a) a VH region comprising the amino acid sequence of SEQ ID NO: 56 and a VL region comprising the amino acid sequence of SEQ ID NO: 57; and / or a scFv comprising the amino acid sequence of SEQ ID NO: 58; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 59 and a VL region comprising the amino acid sequence of SEQ ID NO: 60; and / or a scFv comprising the amino acid sequence of SEQ ID NO: 61.
[0041] In some of the provided embodiments, the CAR binds to the extracellular domain of CD70 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: a VH region comprising the amino acid sequence of SEQ ID NO: 125 and a VL region comprising the amino acid sequence of SEQ ID NO: 126; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 127.
[0042] This document provides a kit comprising any of the provided pharmaceutical compositions and instructions for use with the polynucleotide or the carrier. In some of the provided embodiments, the kit further comprises instructions for use with the carrier and the lymphocyte population.
[0043] This article provides a treatment method comprising administering to a subject with cancer a therapeutically effective amount of any provided polynucleotide, any provided carrier, or any provided pharmaceutical composition, and administering a therapeutically effective amount of a population of chimeric antigen receptors (CARs) expressing binding to a target domain of the engineered cancer antigen.
[0044] This article provides a treatment method comprising administering to a subject with cancer a therapeutically effective amount of a vector containing a polynucleotide encoding an engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof, and administering a therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR) that binds to the target domain of the engineered cancer antigen.
[0045] This article provides a treatment method comprising administering to a subject with cancer a therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR), the subject having previously been administered any provided polynucleotide, any provided carrier, or any provided pharmaceutical composition, wherein the CAR binds to a target domain of the engineered cancer antigen.
[0046] This article provides a treatment method comprising administering to a subject with cancer a therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR), the subject having previously been administered a vector containing a polynucleotide encoding an engineered cancer antigen, the engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof, wherein the CAR binds to the target domain of the engineered cancer antigen.
[0047] In some of the provided embodiments, the lymphocytes are T cells. In some of the provided embodiments, the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA; P-selectin glycoprotein). Specialized glycoforms of leukoligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0048] In some of the provided embodiments, the CAR binds to the extracellular domain of BCMA or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 31 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 32; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 35.
[0049] In some of the provided embodiments, the CAR binds to an extracellular domain of CD19 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: (a) a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 48 or 49; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 50 and a VL region comprising the amino acid sequence of SEQ ID NO: 51; and / or a single-chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO: 52.
[0050] In some of the provided embodiments, the CAR binds to the extracellular domain of CD20 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: a VH region comprising the amino acid sequence of SEQ ID NO: 53 and a VL region comprising the amino acid sequence of SEQ ID NO: 54; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 55.
[0051] In some of the provided embodiments, the CAR binds to the extracellular domain of CD22 or a truncated portion thereof. In some of the provided embodiments, the CAR comprises: (a) a VH region comprising the amino acid sequence of SEQ ID NO: 56 and a VL region comprising the amino acid sequence of SEQ ID NO: 57; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 58; or (b) a VH region comprising the amino acid sequence of SEQ ID NO: 59 and a VL region comprising the amino acid sequence of SEQ ID NO: 60; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 61.
[0052] In some of the provided embodiments, the target antigen is CD70. In some of the provided embodiments, the target domain may be recognized by a homologous binding agent comprising: a VH region comprising the amino acid sequence of SEQ ID NO: 125 and a VL region comprising the amino acid sequence of SEQ ID NO: 126; and / or an scFv comprising the amino acid sequence of SEQ ID NO: 127.
[0053] This article provides a method for labeling tumor cells in vivo, the method comprising contacting the tumor cells with any provided polynucleotide, any provided carrier, or any provided pharmaceutical composition.
[0054] This article provides a method for labeling tumor cells in a subject with cancer, the method comprising administering to the subject a therapeutically effective amount of any provided polynucleotide, any provided carrier, or any provided pharmaceutical composition. Attached Figure Description
[0055] Figure 1 The design of an exemplary truncated membrane-bound BCMA-ECD target construct is shown.
[0056] Figure 2A The expression levels of mCherry and BCMA are shown in cells transduced with a lentiviral vector expressing a truncated membrane-bound BCMA-ECD construct or in untransduced (“UTD”) cells. Figure 2B The expression levels of FSC and BCMA are shown in cells transduced with the truncated membrane-bound BCMA-ECD construct or in untransduced cells. Representative flow cytometry plots are shown, with mCherry or FSC staining on the y-axis and anti-BCMA APC staining on the x-axis. Figure 2A and Figure 2B ).
[0057] Figure 3A The study demonstrated the killing effect of different anti-BCMA CAR-T cells on A549 tumor cells expressing membrane-bound BCMA-ECD. Figure 3B This study demonstrated the killing effect of anti-BCMA CAR-T cells on PC3 cells expressing membrane-bound BCMA-ECD.
[0058] Figure 4 The expression of the transgenic polynucleotide encoding the truncated membrane-bound BCMA-ECD is shown in A549 tumor cells cultured with different concentrations of AdV-truncated BCMA-ECD. Expression is shown on the y-axis, and the number of days post-infection is shown on the x-axis.
[0059] Figure 5This study demonstrated the killing effect of anti-BCMA CAR-T cells on cancer cells expressing Ad3 / 11 truncated BCMA-ECD.
[0060] Figure 6A and Figure 6B This demonstrates the killing effect of anti-BCMA CAR T cells on tumor cells infected with truncated BCMA-ECD at different concentrations (granules / cells; PPC). Concentration: 10 PPC ( Figure 6A ) and 100 PPC ( Figure 6B ).
[0061] Figure 7A The expression of AdV-BCMA in PC3 tumor cells cultured with Ad3 / 11 BCMA-ECD is shown. Figure 7B The study demonstrated the killing effect on PC3 tumor cells infected with the Ad3 / 11 BCMA viral vector.
[0062] Figure 8 The design of an exemplary modified membrane-bound BCMA intracellular domain with a death receptor signaling domain is shown.
[0063] Figure 9 The design of an exemplary secretible BCMA target construct is shown.
[0064] Figure 10A Flow cytometry histograms are shown, depicting the expression of exemplary secretible BCMA target constructs at different dilutions on the surface of A549, HCT-116, HT-29, and SK-OV-3 cells.
[0065] Figure 10B The expression of exemplary secretible BCMA target constructs at different dilutions on the surface of HT29, HCT-116, and SK-OV-3 cells is shown. PE-molecules / cells are shown on the y-axis, and secretible BCMA dilutions are shown on the x-axis. Detailed Implementation
[0066] This document provides engineered cancer antigens that serve as targets for cancer (e.g., solid cancer) therapy, such as in combination with CAR therapies (e.g., CAR-T cell therapy) that recognize the extracellular target domains of the engineered cancer antigens on labeled cancer cells. Therefore, the provided embodiments relate to a CAR therapy for use in combination with engineered cancer antigens, the CAR therapy comprising cells (e.g., populations of immune effector cells) containing (e.g., expressing) a chimeric antigen receptor (CAR). This document also provides polynucleotides encoding engineered cancer antigens and vectors (e.g., viral vectors) containing said polynucleotides. In some embodiments, the viral vector is a tumor-tendency vector capable of specifically targeting tumor cells and expressing the engineered cancer antigen in the tumor cells. The provided embodiments allow for tumor-specific gene delivery, wherein the engineered cancer antigen is capable of selectively labeling different types of tumor cells with targetable antigens. In some embodiments, the engineered cancer antigen is expressed as a membrane protein, such as one containing a transmembrane domain. In some embodiments, the engineered cancer antigen is expressed as a soluble protein that can be secreted from the cells expressing it. In some embodiments, a secretible chimeric cancer antigen tag is linked to a tumor-targeting molecule capable of binding to the tumor antigen to label cancer cells. In some implementations, the polynucleotide and / or viral vector encodes both engineered cancer antigen membrane proteins and secretible engineered cancer antigens.
[0067] In some embodiments, when a polynucleotide or viral vector is delivered to tumor cells containing an engineered cancer antigen, the engineered cancer antigen can be recognized by a homologous binder (such as a CAR containing an extracellular antigen-binding domain for recognizing or binding the engineered cancer antigen). CAR activation targeting the engineered cancer antigen (i.e., containing an extracellular domain for recognizing or binding it) initiates cytotoxic killing of tumor cells by cells expressing the CAR. In some embodiments, killing activates viral release, enabling the virus to infect neighboring tumor cells and diffusing the expression of the engineered cancer antigen to other tumor cells for recognition by CAR cell therapy. Furthermore, embodiments described herein include embodiments in which infected cells can express either the membrane form of the engineered cancer antigen or secrete a soluble form of the engineered cancer antigen to label adjacent or neighboring tumors. Such aspects also allow for improved targeting of tumor cells for recognition by CAR cell therapy. Combined with autologous CAR cell therapy targeting the engineered cancer antigen (e.g., CAR-T cells), the provided embodiments allow for targeted killing of tumor cells, including solid tumors.
[0068] All publications (including patent documents, scientific articles, and databases) mentioned in this application are incorporated herein by reference in their entirety for all purposes, to the extent that each individual publication is incorporated individually by reference. Where the definitions described herein are contrary to or otherwise inconsistent with those described in patents, applications, published applications, and other publications incorporated herein by reference, the definitions described herein shall prevail over those incorporated herein by reference.
[0069] The chapter titles used in this article are for organizational purposes only and should not be construed as limiting the topics described. I. Definition
[0070] Unless otherwise defined, all field terms, symbols, and other technical and scientific terms or names used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ease of reference, and the inclusion of such definitions herein should not necessarily be construed as indicating a material difference from the commonly understood meaning in the art.
[0071] As used herein, the terms “a”, “an”, and “the” include plural indicators unless the context clearly specifies otherwise.
[0072] As used herein, the terms “or” and “and / or” include any and all combinations of one or more of the associated listed items.
[0073] As used herein, the term “about” with respect to numbers or ranges of numbers should be understood to mean the number stated and the number plus or minus 10% of it, or the value listed for a range that is 10% lower than the listed lower limit and 10% higher than the listed upper limit.
[0074] As used herein, the terms “including,” “includes,” “included,” and other forms are not restrictive.
[0075] As used herein, the term "comprising" and its grammatical equivalents indicate the presence of the stated feature, integer, step, operation, element, and / or component, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or combinations thereof.
[0076] As used herein, the terms “administer,” “administration,” or “administering” refer to the act of injecting or otherwise physically delivering a substance (e.g., the pharmaceutical composition provided herein) to a subject (e.g., a person), such as by oral, mucosal, topical, intradermal, parenteral, intravenous, intravitreal, intra-articular, subretinal, intramuscular, intrathecal delivery, and / or any other physical delivery method described herein or known in the art. Delivery may be systemic or to a specific tissue.
[0077] The terms “antibody,” “immunoglobulin,” or “Ig” are used interchangeably herein and in the broadest sense, and specifically cover, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length or intact monoclonal antibodies), antibody compositions having multi-epitope or single-epitope specificity, polyclonal or monovalent antibodies, multivalent antibodies, and multispecific antibodies (e.g., bispecific antibodies, provided they exhibit the desired biological activity). Antibodies can be human, humanized, chimeric, and / or affinity-mature, as well as antibodies from other species (e.g., mice and rabbits, etc.). The term “antibody” is intended to include B-cell polypeptide products within the following immunoglobulin classes of polypeptides, which are capable of binding to specific molecular antigens and consist of two pairs of identical polypeptide chains, each pair having a heavy chain (about 50-70 kDa) and a light chain (about 25 kDa), each amino-terminal portion of each chain including a variable region of about 100 to about 130 or more amino acids, and each carboxyl-terminal portion of each chain including a constant region. See, for example, Antibody Engineering (Borrebaeck, ed., 2nd edition, 1995); and Kuby, Immunology (3rd edition, 1997). Antibodies also include, but are not limited to, synthetic antibodies, recombinant antibodies, camel-derived antibodies or their humanized variants, and intrabody antibodies. "An antibody-derived molecule" refers to a functional antigen-binding fragment of any antibody described above. It is a portion of the antibody's heavy and / or light chain polypeptide, which retains some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments include single-chain Fv (scFv), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, biantibodies, triantibodies, tetraantibodies, and microantibodies. Such functional antigen-binding fragments can be found in, for example: Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (edited by Myers, 1995); Huston et al., 1993, Cell Biophysics 22:189-224; Pliickthun and Skerra, 1989, Meth. Enzymol.178:497-515; and Day, Advanced Immunochemistrv (2nd edition, 1990).The antibodies and molecules derived from said antibodies provided herein may belong to any class of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).
[0078] As used herein, the term "chimeric antigen receptor" or "CAR" refers to a genetically engineered receptor that can be used to specifically transplant one or more antigens onto immune effector cells such as T cells and NK cells. CARs are also known as "artificial T cell receptors," "chimeric T cell receptors," or "chimeric immune receptors." In some embodiments, a CAR includes an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain and / or other receptors specific to one or more engineered cancer antigens disclosed herein. "CAR-T cell" refers to a T cell expressing a CAR. "CAR-NK cell" refers to an NK cell expressing a CAR.
[0079] As used herein, a polynucleotide that "codes a sequence" or "codes" a polypeptide is a nucleic acid molecule that, when placed under the control of appropriate regulatory sequences, is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide. The boundaries of a coding sequence are determined by a start codon at the 5' (amino) end and a translation stop codon at the 3' (carboxyl) end. The transcription termination sequence may be located at the 3' end of the coding sequence.
[0080] As used herein, the term "constant region" or "constant domain" refers to the carboxyl-terminal portion of both the light and heavy chains. This portion does not directly participate in antibody-antigen binding but exhibits various effector functions, such as interaction with Fc receptors. This region has a more conserved amino acid sequence than the variable region. The constant region may contain the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.
[0081] As used herein, the term "effective amount" or "therapeutic effective amount" refers to an amount of a therapeutic agent (e.g., a pharmaceutical composition provided herein) sufficient to treat, diagnose, prevent, a given condition, disorder, or disease and / or associated symptoms, delay its onset, reduce and / or improve its severity and / or shorten its duration. The term also covers amounts necessary for: reducing, slowing, or improving the worsening or progression of a given disease; reducing, slowing, or improving the recurrence, development, or onset of a given disease; and / or improving or enhancing the preventive or therapeutic effects of another therapy; or serving as a bridge to another therapy.
[0082] When applied to nucleic acids or peptides, the term "engineered" refers to nucleic acids or peptides produced using genetic engineering techniques. When applied to cells or organisms, the term "engineered" refers to cells or organisms that cannot be directly isolated from naturally occurring sources. In some embodiments, the engineered nucleic acid, peptide, cell, or organism is altered or modified compared to its corresponding naturally occurring form. In some embodiments, the engineered nucleic acid, peptide, cell, or organism is produced by functionally linking or combining different fragments of a source nucleic acid, peptide, cell, or organism. For example, an engineered peptide may comprise peptides from different sources functionally linked together. In such examples, the engineered peptide may be a chimeric protein.
[0083] As used herein, the term "Fab" or "Fab region" refers to the antibody region that binds to the antigen. Conventional IgG typically contains two Fab regions, each residing on one of the two arms of a Y-shaped IgG structure. Each Fab region typically consists of a variable region and a constant region for both the heavy and light chains. More specifically, the variable and constant regions for the heavy chain in the Fab region are the VH and CH1 regions, and the variable and constant regions for the light chain in the Fab region are the VL and CL regions. The VH, CH1, VL, and CL regions in the Fab region can be arranged in different ways to impart antigen-binding capability. For example, the VH and CH1 regions can be located on a single polypeptide, and the VL and CL regions can be located on separate polypeptides, similar to the Fab regions of conventional IgG. Alternatively, the VH, CH1, VL, and CL regions can all be located on the same polypeptide and oriented in different orders.
[0084] As used herein, the term "fragment" refers to a portion of a polypeptide or polynucleotide molecule containing less than the entire polypeptide or polynucleotide sequence. In some embodiments, the fragment of the polypeptide or polynucleotide comprises at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the entire length of a reference polypeptide or polynucleotide. In some embodiments, the fragment of the polypeptide or polynucleotide comprises about 10%-99%, 20%-99%, 30%-99%, 40%-99%, 50%-99%, 60%-99%, 70%-99%, 80%-99%, 90%-99%, 95%-99%, 96%-99%, 97%-99%, or 98%-99% of the entire length of a reference polypeptide or polynucleotide. In some embodiments, the polypeptide or polynucleotide fragment may contain 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more nucleotides or amino acids.
[0085] The term "heavy chain," when used in relation to antibody use, refers to a polypeptide chain of approximately 50-70 kDa, in which the N-terminal portion includes a variable region of approximately 120 to 130 or more amino acids, and the C-terminal portion includes a constant region. Based on the amino acid sequence of the heavy chain's constant region, the constant region may be one of five different types (e.g., isotypes) referred to as α, δ, ε, γ, and μ. The different heavy chains vary in size: α, δ, and γ contain approximately 450 amino acids, while ε and μ contain approximately 550 amino acids. When combined with light chains, these different types of heavy chains respectively produce five well-known classes (e.g., isotypes) of antibodies, namely IgA, IgD, IgE, IgG, and IgM, including four subclasses of IgG: IgG1, IgG2, IgG3, and IgG4.
[0086] The term "light chain," when used in relation to antibodies, refers to a polypeptide chain of approximately 25 kDa, in which the N-terminal portion includes a variable region of approximately 100 to approximately 110 or more amino acids, and the C-terminal portion includes a constant region. The approximate length of a light chain is 211 to 217 amino acids. Based on the amino acid sequence of the constant domain, two distinct types exist, referred to as κ or λ.
[0087] As used herein, the term "leucine zipper domain" refers to an amphiphilic α-helix containing a heptapeptide repeat of Leu residues on one face of the helix and acting as a dimerizing module. In some embodiments, the leucine zipper domain is an active leucine zipper domain. Upon dimerization with another leucine zipper domain, the leucine zipper α-helix forms a parallel coiled helix based on the stacking of hydrophobic interfacial side chains. In some embodiments, the leucine zipper domain is an inactive leucine zipper domain and cannot dimerize with another leucine zipper domain.
[0088] The term "naturally occurring" as used with nucleic acids, peptides, cells, or organisms refers to nucleic acids, peptides, cells, or organisms found in nature. For example, peptide or polynucleotide sequences that are present in organisms (including viruses) and can be isolated from natural sources and have not been intentionally modified by laboratory personnel are naturally occurring.
[0089] As used in this article, "oncolytic virus" refers to a class of viruses that preferentially infect cancer cells rather than non-cancer cells. Oncolytic viruses can exist naturally or can be prepared in the laboratory by altering and modifying existing viruses.
[0090] As used herein, the term "operably linked" and similar phrases (e.g., gene fusion) refer to the operational linking of nucleic acid or amino acid sequences that have a functional relationship with each other. For example, a promoter operably linked to a polynucleotide encoding a polypeptide results in the transcription of said polynucleotide and ultimately the expression of said polypeptide. As another example, an operably linked peptide is one in which functional domains are positioned at appropriate distances from each other to confer a predetermined function on each domain.
[0091] As used herein, the term "pharmaceutically acceptable excipient, carrier, or diluent" refers to any substance formulated with the active ingredient of a pharmaceutical composition that allows the active ingredient to retain its biological activity and not to react with the immune system of a subject. Such substances may be included for purposes such as: long-term stability; filling solid formulations containing small amounts of potent active ingredients; or imparting therapeutic enhancements to the active ingredient in the final dosage form, such as promoting absorption, reducing viscosity, or increasing solubility. The selection of appropriate substances may depend on the route of administration and dosage form, as well as the active ingredient and other factors. Compositions containing such substances can be formulated using well-known, conventional methods (see, for example, Remington, The Science and Practice of Pharmacy, 23rd edition, edited by A. Adejare, Academic Press, 2020).
[0092] As used herein, “pharmaceutical composition” or “therapeutic composition” refers to a composition that can be administered to a subject for the treatment of a specific disease or disorder.
[0093] As used herein, the terms “polynucleotide” or “nucleic acid” refer to a polymer of nucleotides of any length and include both DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerase or through a synthetic reaction. Polynucleotides may contain modified nucleotides, such as methylated nucleotides and their analogues. Unless otherwise specified, the left end of any single-stranded polynucleotide sequence disclosed herein is the 5' end; the leftward direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The 5' to 3' addition direction of nascent RNA transcripts is referred to as the transcription direction.
[0094] As used herein, the terms “nucleotide” or “nucleic acid” refer to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and DNA / RNA hybrids.
[0095] As used herein, the terms “polypeptide” and “protein” refer to polymers of amino acids of any length. These polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acid groups. The terms also cover polymers of naturally modified or intervened amino acids; interventions are, for example, disulfide bond formation, glycosylation, esterification, acetylation, phosphorylation, or any other manipulation or modification. The definition also includes, for example, polypeptides containing one or more analogues of amino acids (including, but not limited to, non-natural amino acids) and other modified polypeptides known in the art.
[0096] As used herein, the term "population" of cells refers to any number of cells greater than 1, but preferably at least 1 x 102. 3 1 cell, at least 1 x 10 4 1 cell, at least 1 x 10 5 1 cell, at least 1 x 10 6 1 cell, at least 1 x 10 7 1 cell, at least 1 x 10 8 1 cell, at least 1 x 10 9 1 cell, at least 1 x 10 10 1 cell, at least 1 x 10 11 One or more cells. A cell population can refer to an in vitro population (e.g., a cell population in culture) or an in vivo population (e.g., a cell population residing in a particular tissue).
[0097] As used herein, the term "sequence identity" refers to the percentage of identical bases or amino acids in the same relative positions between two polynucleotide or polypeptide sequences. Therefore, one polynucleotide or polypeptide sequence has a certain percentage of sequence identity compared to another polynucleotide or polypeptide sequence. For sequence comparisons, typically one sequence is used as a reference sequence, to which the test sequence is compared. The term "reference sequence" refers to the molecule being compared to the test sequence. Sequence alignment methods used to compare and determine percentages of sequence identity and complementarity are well known in the art. The optimal alignment of sequences for comparison can be performed, for example, by: the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443; the similarity search method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444; computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics software package, Genetics Computer Group, 575 Science Dr., Madison, Wisconsin); manual alignment and visual inspection (see, for example, Brent et al., (2003) Current Protocols in Molecular Biology); using algorithms known in the art, including BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402 and Altschul et al., (1990), respectively. J. Mol. Biol. 215:403-410. The software used for BLAST analysis is publicly available from the National Center for Biotechnology Information.
[0098] As used herein, the term "subject" refers to a mammal, such as a non-primate (e.g., cow, pig, horse, cat, dog, goat, rabbit, rat, mouse, etc.) or a primate (e.g., monkey and human). In some embodiments, the subject is a mammal (e.g., a human) diagnosed with the disease or disorder described herein. In some embodiments, the subject is a mammal (e.g., a human) at risk of developing the disease or disorder described herein. In some embodiments, the subject is a human.
[0099] As used in relation to the engineered cancer antigens disclosed herein, the term "target domain" refers to the extracellular domain of the engineered cancer antigen. It can be expressed on the surface of cancer cells and recognized by homologous binders. It can be bound by chimeric antigen receptors containing homologous binders and expressed on the surface of cancer cells.
[0100] As used in this article, "transduction" refers to the process by which transgenes are introduced from viral particles into host cells.
[0101] As used herein, the term "transgenic" refers to any heterologous polynucleotide incorporated into a viral vector, for example, for transcription or expression in target cells. Examples of transgenics are polynucleotides encoding therapeutic peptides or detectable markers.
[0102] As used in this article, a "transmembrane domain" refers to any protein structure that is thermodynamically stable within a cell membrane (e.g., a eukaryotic cell membrane). Transmembrane domains can be derived from natural or synthetic sources.
[0103] As used herein, the terms “treatment” and “treating” refer to a drug or other intervention intended to achieve a beneficial or desired outcome in a recipient. Beneficial or desired outcomes include, but are not limited to, therapeutic benefits and / or preventative benefits. A therapeutic benefit may refer to the eradication or improvement of symptoms or an underlying disorder being treated. Additionally, a therapeutic benefit may be achieved by eradicating or improving one or more physical symptoms associated with an underlying disorder, resulting in an observed improvement in the subject, although the subject may still have the underlying disorder. Preventative effects include delaying, preventing, or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping, or reversing the progression of a disease or condition, or any combination thereof. For preventative benefits, subjects at risk of developing a particular disease, or subjects reporting one or more physical symptoms of a disease, may undergo treatment, even if the disease may not yet have been diagnosed.
[0104] As used herein, the terms "variable region," "variable domain," "V region," or "V domain" refer to a portion of the light or heavy chain of an antibody, typically located at the amino terminus of the light or heavy chain, and having a length of approximately 120 to 130 amino acids in the heavy chain and approximately 100 to 110 amino acids in the light chain, and are used for the binding and specificity of each specific antibody to its specific antigen. The variable region of the heavy chain may be referred to as "VH." The variable region of the light chain may be referred to as "VL." The term "variable" refers to the fact that the sequence of certain segments of the variable region varies considerably between antibodies. The V region mediates antigen binding and defines the specificity of a particular antibody to its specific antigen. However, the variability is not uniformly distributed across the 110-amino acid span of the variable region. Instead, the V region consists of approximately 15-30 amino acid extensions of lower variability (e.g., relatively invariant) separated by shorter regions (called “hypervariant regions” or “complementarity-determining regions”) of approximately 9-12 amino acids each of higher variability (e.g., very high variability). The variable regions of both the heavy and light chains each contain four FRs (primarily in a β-sheet configuration) linked by three hypervariant regions, which form loops connecting the β-sheet structure and, in some cases, form part of it. The hypervariant regions in each chain are tightly held together by the FRs and, together with hypervariant regions from other chains, facilitate the formation of antigen-binding sites for antibodies (see, for example, Rabat et al., Sequences of Proteins of Immunological Interest (5th edition, 1991)).
[0105] As used herein, the term "viral vector" refers to a nucleic acid intended to be delivered to a host cell via a recombinant virus or viral particle. The nucleic acid may be single-stranded or double-stranded, linear or circular, segmented or unsegmented. The nucleic acid may include DNA, RNA, or a combination thereof. Non-limiting examples of viruses or viral particles that can deliver viral vectors include retroviruses (e.g., lentiviruses and gamma retroviruses), adenoviruses, arenaviruses, alphaviruses, adeno-associated viruses (AAVs), baculoviruses, vaccinia viruses, herpes simplex viruses, and poxviruses. Viral vectors delivered by such viruses or viral particles can be referred to by the type of virus delivering the viral vector (e.g., a lentiviral vector is a viral vector to be delivered by a lentivirus). The viral vector may contain viral elements (e.g., nucleotide sequences) necessary for packaging the viral vector into a virus or viral particle, replicating the virus, or other desired viral activities. Viruses containing viral vectors may be replicative, replication-deficient, or replication-defective. In some embodiments, the viral vector is delivered via an oncolytic virus.
[0106] General methods in molecular and cellular biochemistry can be found in standard textbooks such as: Molecular Cloning: A Laboratory Manual, 3rd edition (Sambrook et al., HaRBor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th edition (edited by Ausubel et al., John Wiley & Sons 1999); Protein Methods (Bollag et al., John Wiley & Sons 1996); Nonviral Vectors for Gene Therapy (edited by Wagner et al., Academic Press 1999); Viral Vectors (edited by Kaplift and Loewy, Academic Press 1995); Immunology Methods Manual (edited by I. Lefkovits, Academic Press 1997); and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle and Griffiths, John Wiley & Sons 1998), the contents of which are incorporated herein by reference. II. Engineered cancer antigens and homologous binding agents
[0107] This article provides engineered cancer antigens that can be used to label cancer cells for recognition by homologous binders. In some embodiments, the engineered cancer antigen is a chimeric cancer antigen containing a heterologous domain.
[0108] In some embodiments, the engineered cancer antigen is a chimeric protein containing a target domain and one or more heterologous transmembrane domain sequences. The target domain is an extracellular domain (hereinafter also referred to as "ectodomain") or a truncated portion thereof of the target antigen that can be recognized by a homologous binding agent. The one or more heterologous transmembrane domain sequences allow the engineered cancer antigen to be displayed or expressed on the surface of cancer cells. Therefore, an engineered cancer antigen having a heterologous transmembrane protein is a membrane-bound engineered cancer antigen that is capable of being membrane-bound when expressed from a cell. In the provided embodiments, the target antigen is an extracellular domain or a truncated portion thereof of a cell surface membrane protein. In some embodiments, this document provides an engineered cancer antigen comprising a target domain and a heterologous membrane-targeting domain, wherein the target domain is an extracellular domain or a truncated portion thereof of the target antigen. In one embodiment, the engineered cancer antigen is a membrane-bound protein containing an extracellular domain or a truncated portion thereof of the target antigen and a heterologous transmembrane domain. In the provided implementation, the expression of engineered cancer antigens on the surface of cancer cells allows for the exposure of extracellular domains or truncated portions of cancer antigen tags on the cell surface for recognition by homologous binders.
[0109] In another embodiment, the engineered cancer antigen is a secretible protein containing a target domain and a tumor-targeting domain, wherein the target domain is an extracellular domain or a truncated portion thereof of the target antigen that can be recognized by a homologous binding agent, and wherein the extracellular domain or the truncated portion thereof is linked to a tumor-targeting molecule. In such embodiments, the engineered cancer antigen does not contain transmembrane proteins, enabling it to be secreted from the cells expressing it. Thus, the engineered cancer antigen having a tumor-targeting domain is a secretible engineered cancer antigen that can be targeted via the tumor-targeting domain to be displayed on the surface of tumor cells upon expression and secretion from cells. In some embodiments, this document provides an engineered cancer antigen comprising a target domain and a tumor-targeting molecule, wherein the target domain is an extracellular domain or a truncated portion thereof of the target antigen. In such embodiments, the binding of the tumor-targeting molecule to a protein on the surface of a cancer cell directs the extracellular domain or truncated portion (i.e., the target domain) to the cancer cell for displaying the extracellular domain or truncated portion of the cancer antigen tag on the surface of the cell for recognition by a homologous binding agent.
[0110] In such embodiments, the homology binder can be any known binding molecule that is known or capable of binding to the extracellular domain or truncated region of an engineered cancer antigen, such as a membrane protein or secretible protein. For example, the extracellular domain or truncated region of a target antigen that is a target domain of an engineered cancer antigen contains an epitope recognized by the homology binder. In some embodiments, the homology binder may be included as part of the extracellular domain of a chimeric antigen receptor (CAR). A. Target domain
[0111] In some embodiments, the provided engineered cancer antigen includes a target domain, which is an extracellular domain or a truncated portion thereof containing the target antigen (e.g., a cell surface protein). In some embodiments, the target antigen is a cell surface protein. In some embodiments, the extracellular domain or a truncated portion thereof is derived from a natural cell surface protein. Such cell surface proteins include those that are typically expressed on cells as membrane proteins and can be targeted by homologous binding agents, such as antibodies (including their antigen-binding fragments), including those included as part of antibody therapies, such as those included as part of bispecific (e.g., BiTe), ADC, or CAR T-cell therapies. In some embodiments, the extracellular domain or a truncated portion thereof is derived from a target antigen that can be targeted by an antibody or antigen-binding fragment (e.g., scFv) contained in the extracellular domain of a CAR.
[0112] Non-limiting examples of cell surface protein antigens include carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cells infected by cytomegalovirus (CMV) (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); and a specialized glycoform of P-selectin glycoprotein ligand 1 (PSGL-1). Epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0113] In some implementations, the cell surface protein target antigen is an antigen recognized by a CAR present in any of a variety of known engineered cell products. The CAR may include, but is not limited to, CARs engineered into cells containing: idecabtagene vicleucel (ABECMA®), Orvacabtagene Autoleucel (JCARH125), ciltacabtagene autoleucel (CARVYKTI™, also known as NJ-68284528; Janssen / Legend), P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA-Allo1 (Poseida), Allo-715 (Pfizer / Allogene), CT053 (Carsgen), Descartes-08 (Cartesian), PHE885 (Novartis), CTX120 (CRISPR Therapeutics); and axicabtagene. ciloleucel (YESCARTA®), tisagenlecleucel (KYMRIAH®), brexucabtagene autoleucel (TECARTUS®), or lisocabtagenemaraleucel (BREYANZI®).
[0114] In certain embodiments, the target domain is not cleavable by γ-secretase. γ-secretase is a multi-subunit protease complex that cleaves single-transmembrane proteins at residues within the transmembrane domain. In the provided embodiments, the target domain contains a target domain that is not cleavable by γ-secretase. In some embodiments, the target domain is part of a membrane-engineered cancer antigen (as described in Section II.C) that contains a heterologous transmembrane domain that is not cleavable by γ-secretase inhibitors. In some embodiments, the target domain is part of any secretible engineered cancer antigen (as described in Section II.B) that lacks a transmembrane domain, thus preventing membrane binding of the tag molecule.
[0115] In some implementations, the target antigen is BCMA, such as human BCMA. B cell maturation antigen, also known as BCMA, CD269, TNFRSF17 (e.g., wild-type BCMA, UniProt Q02223; SEQ ID NO: 129), is a member of the tumor necrosis receptor superfamily preferentially expressed in differentiated plasma cells (Laabi et al. (1992) EMBO J 11(11):3897-3904; Madry et al. (1998) Int Immunol 10(11):1693-1702). BCMA is a non-glycosylated type I transmembrane protein involved in B cell maturation, growth, and survival. BCMA is the receptor for two ligands of the TNF superfamily: APRIL (proliferation-inducing ligand, CD256, TNFSF13), which is a high-affinity ligand of BCMA; and BAFF (THANK, BlyS, B lymphocyte stimulating factor, TALL-1, and zTNF4), which is a low-affinity ligand of BCMA.
[0116] In some embodiments, the extracellular domain of BCMA or a truncated portion thereof comprises at least about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% of the same amino acid sequence as SEQ ID NO: 3. In some embodiments, the extracellular domain of BCMA or a truncated portion thereof is a sequence of SEQ ID NO: 3 that can be recognized or bound by a homologous binding agent. In some embodiments, the extracellular domain of BCMA of SEQ ID NO: 3 or a truncated portion thereof is encoded by the nucleotide sequence shown in SEQ ID NO: 1, 175, 176, 180, or 181.
[0117] In some embodiments, the target antigen is CD19, such as human CD19. Differentiation group 19 (CD 19) is an antigenic determinant detectable on leukemia precursor cells. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt, and Swiss-Prot. For example, the amino acid sequence of human CD19 can be found with UniProt / Swiss-Prot accession number P15391, and the nucleotide sequence encoding human CD19 can be found with accession number NM_001178098. In some embodiments, the extracellular domain of CD19 or a truncated portion thereof is the sequence of SEQ ID NO: 71 or a truncated portion containing an epitope that can be recognized or bound by a homologous binding agent.
[0118] In some embodiments, the target antigen is CD20. Human CD20 is also known as the transmembrane 4-domain, subfamily A, member 1 (MS4A1). Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt, and SwissProt. For example, the amino acid sequence of human CD20 can be found with accession numbers NP_690605.1 (SEQ ID NO: 162) and NP_068769.2, and the nucleotide sequences encoding transcript variants 1 and 3 of human CD20 can be found with accession numbers NM_152866.2 and NM_021950.3, respectively. CD20 is a 33 kD type III four-transmembrane phosphoprotein with a 44-amino acid extracellular domain. In some embodiments, the extracellular domain of CD20 or a truncated portion thereof is the sequence of SEQ ID NO: 72 or a truncated portion containing an epitope that can be recognized or bound by a homologous binding agent. In some implementations, the extracellular domain of CD20 or a truncated portion thereof is a sequence containing an epitope that can be recognized or bound by a homologous binder, as specified in SEQ ID NO: 158.
[0119] In some embodiments, the target antigen is CD22. Human CD22 is also known as SIGLEC2 or BL-CAM. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt, and SwissProt. For example, the amino acid sequence of human CD22 can be found with UniProt accession number P20273. CD22 has seven extracellular IgG-like domains, which are generally identified as Ig domain 1 to Ig domain 7, with Ig domain 7 being closest to the B cell membrane and Ig domain 1 being furthest from the Ig cell membrane. In some embodiments, the extracellular domains of CD22 contain amino acids Asp20-Arg687 (accession number: P20273) or truncated portions thereof containing epitopes that can be recognized or bound by homologous binding agents. In some embodiments, the extracellular domains of CD22 or truncated portions thereof are the sequence of SEQ ID NO: 73 or truncated portions containing epitopes that can be recognized or bound by homologous binding agents.
[0120] In some embodiments, the target antigen is group 70 (CD70). In some embodiments, the target antigen is wild-type CD70. CD70 (also known as CD27LG or TNFSF7) is a member of the tumor necrosis factor (TNF) superfamily and a ligand for CD27 (a TNF superfamily receptor). Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt, and SwissProt. For example, the amino acid sequence of human CD70 (e.g., wild-type) can be found with UniProt accession number P32970 (SEQ ID NO: 106). In some embodiments, the extracellular domain of CD70 or a truncated portion thereof is the sequence of SEQ ID NO: 130 or a truncated portion containing an epitope that can be recognized or bound by a homologous binding agent. In some embodiments, the truncated portion of the CD70 target antigen is the sequence shown in SEQ ID NO: 107 or SEQ ID NO: 124. B. Can secrete engineered cancer antigens
[0121] In some embodiments, this document provides an engineered cancer antigen comprising a target domain containing at least one target domain as described in Section II.A and a tumor-targeting molecule (e.g., an antibody or antigen-binding fragment specific to a tumor-associated antigen). In some embodiments, this document provides an engineered cancer antigen comprising a target domain and a tumor-targeting molecule, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof. In such embodiments, it should be understood that the engineered cancer antigen is therefore a chimeric cancer antigen composed of sequences not normally present in proteins in nature. In some embodiments, the amino acid sequence of the target domain is directly linked to the tumor-targeting molecule. In some embodiments, the amino acid sequence of the target domain is indirectly linked to the tumor-targeting molecule via a linker (e.g., a peptide linker). In certain embodiments, this engineered cancer antigen is secretible and does not bind to the cell membrane. Therefore, it should be understood that the engineered cancer antigen provided herein containing a tumor-targeting molecule is a cancer antigen in which a transmembrane domain is absent, such that the engineered cancer antigen cannot be embedded in the lipid bilayer of the cell membrane in which it is expressed. In some embodiments of expressing engineered cancer antigens from cells, the engineered cancer antigens can be secreted from the cells. In some embodiments, the engineered cancer antigens are soluble. Therefore, it should be understood that secretible engineered cancer antigens are soluble.
[0122] In some embodiments, the tumor-targeting molecule of the engineered cancer antigen is capable of binding to an antigen expressed on a target cell (e.g., a tumor cell), thereby exposing a coupled target domain on the outer surface of the cell. In some embodiments, the tumor-targeting molecule is an antibody or antibody fragment. In some embodiments, the tumor-targeting molecule is a tumor-associated antigen (TAA) binding molecule. In some embodiments, the tumor-targeting molecule is an antibody or antigen-binding fragment that targets a tumor-associated antigen. In some embodiments, the tumor-targeting molecule is an antibody or antigen-binding fragment that targets a tumor-associated antigen expressed on the surface of tumor cells. In some embodiments, the tumor-targeting molecule is an antibody comprising means for binding to a tumor-associated antigen (such as a tumor-associated antigen expressed on the surface of tumor cells). In some embodiments, the antigen is associated with cancer. In some embodiments, the antigen is associated with a solid tumor.
[0123] For example, tumor-associated antigens include antigens expressed on tumors (including but not limited to adenomas, carcinomas, or sarcomas). In some embodiments, tumor-associated antigens are expressed on cancer cells, including but not limited to multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, medulloblastoma, liver cancer, gastric cancer, thyroid cancer, bile duct cancer, liver cancer, bone cancer, skin cancer, colon cancer, rectal cancer, endometrial cancer, or cervical cancer. In some embodiments, the cancer is bladder cancer, breast cancer, skin cancer, head and neck cancer, colorectal cancer, endometrial cancer, liver cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, thyroid cancer, or ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is endometrial cancer. In some implementations, the cancer is liver cancer. In some implementations, the cancer is kidney cancer. In some implementations, the cancer is lung cancer. In some implementations, the cancer is melanoma. In some implementations, the cancer is pancreatic cancer. In some implementations, the cancer is prostate cancer. In some implementations, the cancer is thyroid cancer. In some implementations, the cancer is ovarian cancer. In some implementations, the cancer is insensitive or resistant to drugs.
[0124] In some implementations, the tumor-associated antigen is selected from EpCAM, CEA (carcinoembryonic antigen), gpA33 (glycoprotein A33 (transmembrane)), mucin, TAG-72 (tumor-associated glycoprotein 72), CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), and FBP (folate-binding protein), EGFR / ERBB1 / HER1 (epidermal growth factor receptor 1), ERBB2 / HER2 (epidermal growth factor receptor 2), ERBB3 (epidermal growth factor receptor 3), MET (tyrosine protein kinase), IGF1R (insulin-like growth factor 1 receptor), EPHA3 (EPH receptor A3), TRAILR1 (death receptor 4), and RANK-L (nuclear factor κB receptor activator ligand).
[0125] In some embodiments, the tumor-targeting molecule is an antibody-derived molecule, said molecule being one or more functional fragments of the antibody. Non-limiting examples of functional fragments include heavy chains, light chains, heavy chain variable domains, light chain variable domains, single-chain Fv (scFv), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, biantibodies, triantibodies, tetraantibodies, and microantibodies. In some embodiments, the tumor-targeting molecule is an antibody lacking a heavy chain CH3 domain. In some embodiments, the tumor-targeting molecule is an antibody lacking a heavy chain CH2 domain. In some embodiments, the tumor-targeting molecule is Fab. In some embodiments, the tumor-targeting molecule is an antibody lacking both heavy chain CH2 and CH3 domains. In some embodiments, the tumor-targeting molecule is a single-chain variable fragment (scFv). In some embodiments, the tumor-targeting molecule is the heavy chain of an antibody. In some embodiments, the tumor-targeting molecule is the light chain of an antibody. In some embodiments, the tumor-targeting molecule is a variable domain of the heavy chain of an antibody. In some implementations, the tumor-targeting molecule is a variable domain of the antibody's light chain.
[0126] In some embodiments, the tumor-targeting molecule is a single-chain variable fragment (scFv). As used herein, the term "single-chain variable fragment" or "scFv" is a fusion protein of a variable region of a heavy chain (VH) and a light chain (VL) of an immunoglobulin (e.g., mouse or human) covalently linked to form a VH::VL heterodimer. The heavy chain (VH) and the light chain (VL) are directly coupled or coupled via a linker encoding a peptide (e.g., 10, 15, 20, 25 amino acids) that connects the N-terminus of VH to the C-terminus of VL, or vice versa. Exemplary linkers that may be used herein are disclosed in the Embodiments section of this application. Other linkers are known to those skilled in the art. In some embodiments, the linker comprises the amino acid sequence of SEQ ID NO: 9.
[0127] In some embodiments, the tumor-targeting molecule is a tumor-targeting antibody. In some embodiments, the tumor-targeting antibody binds to an antigen expressed on the surface of tumor cells. In some embodiments, the tumor-targeting antibody is an antibody or antibody fragment having means for binding to an antigen expressed on the tumor surface, as described in Table 1. In some embodiments, the tumor-targeting antibody or a molecule derived from an antibody provided herein contains VL, VH, or CDR, having the amino acid sequence of VL, VH, or CDR contained in certain known antibodies. In some embodiments, the tumor-targeting antibody or a molecule derived from an antibody provided herein contains VL, VH, or CDR, having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as VL, VH, or CDR contained in certain known antibodies.
[0128] Exemplary tumor-associated antigens and their exemplary known antibodies include, but are not limited to, those described in Table 1 below.
[0129] Table 1. Exemplary tumor-associated antigens and their known antibodies.
[0130] In some implementations, the tumor-associated antigens targeted by the tumor-targeting molecules are expressed on solid tumors.
[0131] In some implementations, tumor-associated antigens are expressed on solid tumors. Exemplary solid tumor-associated antigens include, but are not limited to, EPCAM (epithelial cell adhesion molecule), CEA (carcinoembryonic antigen), gpA33 (glycoprotein A33 (transmembrane)), mucin, TAG-72 (tumor-associated glycoprotein 72), CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), and FBP (folate-binding protein), EGFR / ERBB1 / HER1 (epidermal growth factor receptor 1), ERBB2 / HER2 (epidermal growth factor receptor 2), ERBB3 (epidermal growth factor receptor 3), MET (tyrosine protein kinase), IGF1R (insulin-like growth factor 1 receptor), EPHA3 (EPH receptor A3), TRAILR1 (death receptor 4), and MMP (stromal gold). These are proteases, such as MMP1, MMP2, MMP3, MMP4, MMP5, MMP6, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, MMP27, MMP28), GPC2, GPC3 (phosphatidylinositol proteoglycan-2 and phosphatidylinositol proteoglycan-3), mesothelin, PSCA (prostate stem cell antigen), occlusive protein 6 and occlusive protein 18.2, and RANK-L (receptor activator of nuclear factor κB ligand).
[0132] In some embodiments, the tumor-associated antigen targeted by the tumor-targeting molecule is epithelial cell adhesion / activation molecule (EpCAM), epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). In some embodiments, the tumor-associated antigen targeted by the tumor-targeting molecule is EpCAM.
[0133] Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that mediates Ca2+-independent homologous cell adhesion in epithelium. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Furthermore, EpCAM possesses oncogenic potential through its ability to upregulate c-myc, e-fabp, and cyclin A and E. Because EpCAM is expressed only in epithelial and epithelial-derived tumors, it can be used as a therapeutic marker for a variety of cancers, such as head and neck cancer, ovarian cancer, bladder cancer, breast cancer, colorectal cancer, prostate cancer, gastric cancer, liver cancer, esophageal cancer, and lung cancer.
[0134] In some embodiments, the tumor-targeting molecule is adelimumab or an antigen-binding fragment of adelimumab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of adelimumab.
[0135] In some embodiments, the tumor-targeting molecule is ezolizumab or an antigen-binding fragment of ezolizumab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of ezolizumab.
[0136] In some embodiments, the tumor-targeting molecule is tekutocilizumab or an antigen-binding fragment of tekutocilizumab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of tekutocilizumab.
[0137] In some embodiments, the tumor-targeting molecule binds to a tumor-associated antigen that serves as EpCAM. In some embodiments, the tumor-targeting molecule is an antibody or its antigen-binding fragment that binds to the tumor-associated antigen that serves as EpCAM.
[0138] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: the VH region comprises heavy chain complementarity-determining regions 1 (CDR-H1), CDR-H2, and CDR-H3 as shown in SEQ ID NO: 10, and the VL region comprises light chain complementarity-determining regions 1 (CDR-L1), CDR-L2, and CDR-L3 as shown in CL as shown in SEQ ID NO: 8. In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: the VH region comprises heavy chain complementarity-determining regions 1 (CDR-H1), 1D-H2, and 1D-H3 containing the amino acid sequences shown in SEQ ID NO: 15, 16, and 17, respectively, and the VL region comprises light chain complementarity-determining regions 1 (CDR-L1), 1D-L2, and 1D-L3 containing the amino acid sequences shown in SEQ ID NO: 18, 19, and 20, respectively.
[0139] In some embodiments, the tumor-targeting molecule comprises a light chain containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the tumor-targeting molecule comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 10.
[0140] In some embodiments, the tumor-targeting molecule comprises a light chain containing the amino acid sequence of SEQ ID NO: 8 and a heavy chain containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 70% of the amino acid sequence identical to SEQ ID NO: 8, and the heavy chain contains at least 70% of the amino acid sequence identical to SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 75% of the amino acid sequence identical to SEQ ID NO: 8, and the heavy chain contains at least 75% of the amino acid sequence identical to SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 80% of the amino acid sequence identical to SEQ ID NO: 8, and the heavy chain contains at least 80% of the amino acid sequence identical to SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 85% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 85% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 90% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 90% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 91% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 91% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 92% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 92% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 93% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 93% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 94% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 94% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 95% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 95% of the same amino acid sequence as SEQ ID NO: 10.In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 96% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 96% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 97% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 97% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 98% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 98% of the same amino acid sequence as SEQ ID NO: 10. In some embodiments, the tumor-targeting molecule comprises a light chain and a heavy chain, wherein the light chain contains at least 99% of the same amino acid sequence as SEQ ID NO: 8, and the heavy chain contains at least 99% of the same amino acid sequence as SEQ ID NO: 10.
[0141] In some embodiments, the VL region of SEQ ID NO: 8 is encoded by the nucleotide sequence of SEQ ID NO: 5, and the VH region of SEQ ID NO: 10 is encoded by the nucleotide sequence of SEQ ID NO: 7. In some embodiments, the VL region of SEQ ID NO: 8 and the VH region of SEQ ID NO: 10 are linked via a linker comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, the linker of SEQ ID NO: 9 is encoded by the nucleotide sequence shown in SEQ ID NO: 6.
[0142] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is GPC2.
[0143] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is mesothelin.
[0144] In some embodiments, the tumor-targeting molecule is annetumab or an antigen-binding fragment of annetumab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of annetumab.
[0145] In some embodiments, the tumor-targeting molecule is amatoxins or an antigen-binding fragment of amatoxins. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of amatoxins.
[0146] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is the prostate stem cell antigen (PSCA).
[0147] In some embodiments, the tumor-targeting molecule is AGS-PSCA or an antigen-binding fragment of AGS-PSCA. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of AGS-PSCA.
[0148] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is sealing protein 6.
[0149] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is GPC3.
[0150] In some embodiments, the tumor-targeting molecule is cotrastuzumab or an antigen-binding fragment of cotrastuzumab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of cotrastuzumab.
[0151] In some embodiments, the tumor-targeting molecule comprises a light chain containing the amino acid sequence of SEQ ID NO: 135 (e.g., anti-GPC3 VL). In some embodiments, the tumor-targeting molecule comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 134 (e.g., anti-GPC3 VH). In some embodiments, the tumor-targeting molecule comprises a light chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 135. In some embodiments, the tumor-targeting molecule comprises a heavy chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 134.
[0152] In some implementations, the tumor-associated antigen targeted by the tumor-targeting molecule is sealing protein 18.2.
[0153] In some embodiments, the tumor-targeting molecule is zotuximab or an antigen-binding fragment of zotuximab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of zotuximab.
[0154] In some embodiments, the tumor-targeting molecule comprises a light chain containing the amino acid sequence of SEQ ID NO: 137 (e.g., anti-sealing protein 18.2 VL). In some embodiments, the tumor-targeting molecule comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 136 (e.g., anti-sealing protein 18.2 VH). In some embodiments, the tumor-targeting molecule comprises a light chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 137. In some embodiments, the tumor-targeting molecule comprises a heavy chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 136.
[0155] In some embodiments, the tumor-associated antigen targeted by the tumor-targeting molecule is an MMP. In some embodiments, the tumor-associated antigen targeted by the tumor-targeting molecule is selected from MMP1, MMP2, MMP3, MMP4, MMP5, MMP6, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, MMP27, and MMP28. In some embodiments, the tumor-associated antigen targeted by the tumor-targeting molecule is MMP9.
[0156] In some embodiments, the tumor-targeting molecule is andliximab or an antigen-binding fragment of andliximab. In some embodiments, the tumor-targeting molecule comprises a variable light chain and a variable heavy chain of andliximab.
[0157] In some embodiments, the tumor-targeting molecule comprises a light chain containing the amino acid sequence of SEQ ID NO: 133 (e.g., anti-MMP9 VL). In some embodiments, the tumor-targeting molecule comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 132 (e.g., anti-MMP9 VH). In some embodiments, the tumor-targeting molecule comprises a light chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 133. In some embodiments, the tumor-targeting molecule comprises a heavy chain containing at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 132.
[0158] In some embodiments, the different elements of the secretible engineered cancer antigen are operatively linked. In some embodiments, the different elements are directly linked to each other. In some embodiments, the different elements are linked via a connector. Thus, in some embodiments, the extracellular domain of the target antigen is directly linked to a tumor-targeting molecule. In some embodiments, the extracellular domain of the target antigen is linked to a tumor-targeting molecule via a connector. Exemplary connectors that may be used herein are disclosed in the Embodiments section of this application. Other connectors are known to those skilled in the art.
[0159] In some embodiments, the linker may be a flexible linker. Linkers include peptides, polymers, nucleotides, nucleic acids, polysaccharides, and lipid organics (such as polyethylene glycol). In some embodiments, the linker is a peptide linker. The length of the peptide linker can be about 2-100, 10-50, or 15-30 amino acids. In some embodiments, the length of the peptide linker can be at least 10, at least 15, or at least 20 amino acids, and the length does not exceed 80, 90, or 100 amino acids. In some embodiments, the linker length is between 1 and 100 amino acids, between 1 and 75 amino acids, between 1 and 50 amino acids, between 1 and 25 amino acids, between 5 and 100 amino acids, between 5 and 75 amino acids, between 5 and 50 amino acids, between 5 and 25 amino acids, between 10 and 100 amino acids, between 10 and 75 amino acids, between 10 and 50 amino acids, or between 10 and 25 amino acids. In some embodiments, the linker length is between 5 and 50 amino acids.
[0160] Linkers can be naturally occurring, synthetic, or a combination of both. Particularly suitable linker peptides primarily comprise amino acid residues selected from glycine (Gly), serine (Ser), alanine (Ala), and threonine (Thr). For example, a linker may contain at least 75% (based on the total number of residues present in the peptide linker) (e.g., at least 80%, at least 85%, or at least 90%) amino acid residues selected from Gly, Ser, Ala, and Thr. Linkers may also consist only of Gly, Ser, Ala, and / or Thr residues. In some embodiments, the linker contains 1-25 glycine residues, 5-20 glycine residues, 5-15 glycine residues, or 8-12 glycine residues. In some aspects, suitable peptide linkers typically contain at least 50% glycine residues, such as at least 75% glycine residues. In some embodiments, the peptide linker contains only glycine residues. In some embodiments, the peptide linker contains only glycine and serine residues.
[0161] In some embodiments, these linkers are primarily composed of the amino acids glycine and serine, referred to herein as GS linkers. In some embodiments, the linker contains (GGS)n, where n is 1 to 10, such as 1 to 5, for example 1 to 3, such as GGS(GGS)n (SEQ ID NO: 145), where n is 1 to 10. In a particular embodiment, the linker contains the sequence (GGGGS)n (SEQ ID NO: 146), where n is 1 to 10 or n is 1 to 5, such as 1 to 3. In other embodiments, the linker contains (GGGGGS)n (SEQ ID NO: 147), where n is 1 to 4, such as 1 to 3. The linker may contain any combination of the above, such as combinations of 2, 3, 4, or 5 repeats of GS, GGS, GGGGS, and / or GGGGGS linkers. In some implementations, the length of this connector is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 amino acids.
[0162] In some embodiments, the linker is or comprises (by single-letter amino acid code): GGS, GGGGS (SEQ ID NO: 148), or GGGGGS (SEQ ID NO: 149). In some embodiments, the GS linker is or comprises the following amino acid sequences: GGSGGS, i.e., (GGS)2 (SEQ ID NO: 150); GGSGGSGGS, i.e., (GGS)3 (SEQ ID NO: 151); GGSGGSGGSGGS, i.e., (GGS)4 (SEQ ID NO: 152); GGSGGSGGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 153); GGGGGSGGGGGSGGGGS, i.e., (G5S)3 (SEQ ID NO: 154); GGSGGGGSGGGGSGGGS (SEQ ID NO: 155); and GGGGSGGGGSGGGS (SEQ ID NO: 156). In some embodiments, the linker is or contains GGGG (SEQ ID NO: 157). In some embodiments, the linker is or contains GGGGG (SEQ ID NO: 142). In some embodiments, the linker is or contains GGGGGGGG (SEQ ID NO: 143). In some of the above examples, serine may be replaced by alanine (e.g., (Gly4Ala) or (Gly3Ala)).
[0163] In some embodiments, the connector is or contains GSAGSAAGSGEF (SEQ ID NO: 144). In some embodiments, the connector is or contains GSGSGS (SEQ ID NO: 139).
[0164] In some cases, it may be desirable to provide a certain rigidity to the peptide linker. This can be accomplished by including proline residues in the amino acid sequence of the peptide linker. Therefore, in some embodiments, the linker includes at least one proline residue in the amino acid sequence of the peptide linker. For example, the peptide linker may have an amino acid sequence in which at least 25% (e.g., at least 50% or at least 75%) of the amino acid residues are proline residues. In one particular embodiment, the peptide linker contains only proline residues. In some embodiments, the linker is or contains PAPAP (SEQ ID NO: 141).
[0165] In some implementations, the connector is or contains EAAAK (SEQ ID NO: 140).
[0166] In some embodiments, the linker comprises an amino acid sequence selected from SEQ ID NO: 9 or 138-157, or comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from SEQ ID NO: 9 or 138-157. In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 9. In some embodiments, the linker comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of SEQ ID NO: 9.
[0167] In some embodiments, the connector is or contains GGGGSGGGGSGGGGSGGGGSGGGSGGGS (SEQ ID NO: 110). In some embodiments, the connector is or contains GGGGGSGGGGSGGGGSGGGS (SEQ ID NO: 128).
[0168] In some implementations, the secretible engineered cancer antigens provided herein may include any of the target domains and tumor-targeting molecules described herein.
[0169] In some embodiments, the secretible engineered cancer antigen comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 85% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 90% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 91% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 92% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 93% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 94% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 95% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 96% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 97% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 98% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises at least 99% of the same amino acid sequence as SEQ ID NO: 164. In some embodiments, the secretible engineered cancer antigen comprises the amino acid sequence shown in SEQ ID NO: 164. In some embodiments, the amino acid sequence of SEQ ID NO: 164 is encoded by the nucleotide sequence of SEQ ID NO: 187-191.
[0170] In some embodiments, the secretible engineered cancer antigen comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 166. In some embodiments, the amino acid sequence of SEQ ID NO: 166 is encoded by the nucleotide sequences of SEQ ID NO: 182-186.
[0171] In some implementations, the secretible engineered cancer antigen is encoded by the nucleotide sequence of SEQ ID NO: 163, 165 or 182, 187. C. Membrane-engineered cancer antigens
[0172] In some embodiments, this document provides an engineered cancer antigen comprising at least one target domain and a heterologous membrane targeting domain as described in Section II.A. In some embodiments, the amino acid sequence of the target domain is directly linked to the heterologous membrane targeting domain. In some embodiments, the amino acid sequence of the target domain is indirectly linked to the heterologous membrane targeting domain via a linker (e.g., a peptide linker). In the provided embodiments where the engineered cancer antigen contains a heterologous membrane targeting domain, the engineered cancer antigen is a cancer antigen capable of embedding in the lipid bilayer of the cell membrane in which it is expressed. In some embodiments, the heterologous membrane target domain guides the display of the target domain on the surface of a cell that has already expressed the target domain. In some embodiments, the membrane-engineered cancer antigen is expressed on the surface of a cell in which the target domain is exposed on the outer surface of the cell. In some embodiments, the heterologous membrane target domain is a transmembrane domain. In some embodiments, the target domain is any of those described in Section II.A.
[0173] The heterologous membrane-targeting domains of the engineered cancer antigens provided herein can be transmembrane domains of any known transmembrane protein or domains derived from synthetic sources. The transmembrane domains disclosed herein for engineered cancer antigens can also be used as transmembrane domains of the CAR molecules disclosed below.
[0174] Transmembrane domains can be classified based on their three-dimensional structure. For example, transmembrane domains can form α-helices, complexes with more than one α-helix, β-barrels, or any other stable structure capable of crossing the phospholipid bilayer of the cell. Alternatively, transmembrane domains can be classified based on their topology, which includes the number of times the transmembrane domain crosses the membrane and the orientation of the protein. For example, a single-transmembrane protein crosses the cell membrane once, and a multi-transmembrane protein crosses the cell membrane at least twice (e.g., 2, 3, 4, 5, 6, 7, or more times). Membrane proteins can be defined as type I, type II, or type III based on the topology of their terminals and one or more transmembrane segments relative to the cell interior and exterior. Type I membrane proteins have a single transmembrane domain and are oriented such that the N-terminus of the protein is located on the extracellular side of the lipid bilayer and the C-terminus is located on the cytoplasmic side. Type II membrane proteins also have a single transmembrane domain, but are oriented such that the C-terminus of the protein is located on the extracellular side of the lipid bilayer and the N-terminus is located on the cytoplasmic side. Type III membrane proteins have multiple transmembrane segments and can be further subdivided based on the number of transmembrane segments and the positions of the N-terminus and C-terminus.
[0175] In some embodiments, the transmembrane domain is derived from a type I single-transmembrane protein. In some embodiments, the transmembrane domain from a multi-transmembrane protein may also be compatible. Multi-transmembrane proteins may comprise complex (at least 2, 3, 4, 5, 6, 7 or more) α-helices or β-sheet structures. In some embodiments, the N-terminus and C-terminus of the multi-transmembrane protein are located on opposite sides of the lipid bilayer; for example, the N-terminus of the protein is located on the cytoplasmic side of the lipid bilayer, and the C-terminus of the protein is located on the extracellular side.
[0176] The transmembrane domain may also comprise at least a portion of a synthetic, non-naturally occurring protein segment. In some embodiments, the transmembrane domain is a synthetic, non-naturally occurring α-helix or β-sheet. In some embodiments, the protein segment is about 15-100 amino acids. In some embodiments, the protein segment is at least about 20 amino acids, for example, at least 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more amino acids. Examples of synthetic transmembrane domains are known in the art, for example in U.S. Patent No. 7,052,906 and PCT Publication No. WO 2000 / 032776, the relevant disclosures of which are incorporated herein by reference.
[0177] In some embodiments, the transmembrane domain is at least about 15 amino acids in size. In some embodiments, the transmembrane domain is about 15 amino acids to about 45 amino acids in size. In some embodiments, the transmembrane domain is at most about 45 amino acids in size. In some embodiments, the size of the transmembrane domain is about 15 amino acids to about 20 amino acids, about 15 amino acids to about 25 amino acids, about 15 amino acids to about 30 amino acids, about 15 amino acids to about 35 amino acids, about 15 amino acids to about 40 amino acids, about 15 amino acids to about 45 amino acids, about 20 amino acids to about 25 amino acids, about 20 amino acids to about 30 amino acids, about 20 amino acids to about 35 amino acids, about 20 amino acids to about 40 amino acids, about 20 amino acids to about 45 amino acids, about 25 amino acids to about 30 amino acids, about 25 amino acids to about 35 amino acids, about 25 amino acids to about 40 amino acids, about 25 amino acids to about 45 amino acids, about 30 amino acids to about 35 amino acids, about 30 amino acids to about 40 amino acids, about 30 amino acids to about 45 amino acids, about 35 amino acids to about 40 amino acids, about 35 amino acids to about 45 amino acids, or about 40 amino acids to about 45 amino acids. In some implementations, the size of the transmembrane domain is about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 35 amino acids, about 40 amino acids, or about 45 amino acids.
[0178] In some embodiments, the length of the transmembrane domain is about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, or about 33 amino acids. In some embodiments, the length of the transmembrane domain is 21 amino acids. In some embodiments, the length of the transmembrane domain is 22 amino acids. In some embodiments, the length of the transmembrane domain is 23 amino acids. In some embodiments, the length of the transmembrane domain is 24 amino acids. In some embodiments, the length of the transmembrane domain is 25 amino acids. In some embodiments, the length of the transmembrane domain is 26 amino acids. In some embodiments, the length of the transmembrane domain is 27 amino acids. In some embodiments, the length of the transmembrane domain is 28 amino acids. In some embodiments, the length of the transmembrane domain is 29 amino acids. In some embodiments, the length of the transmembrane domain is 30 amino acids. In some embodiments, the transmembrane domain is 31 amino acids long. In some embodiments, the transmembrane domain is 32 amino acids long. In some embodiments, the transmembrane domain is 33 amino acids long.
[0179] The transmembrane domains provided herein may comprise a transmembrane region and a cytoplasmic region located on the C-terminal side of the transmembrane domain. The cytoplasmic region of the transmembrane domain may contain three or more amino acids and, in some embodiments, facilitates the orientation of the transmembrane domain within a lipid bilayer. In some embodiments, one or more cysteine residues are present in the transmembrane region of the transmembrane domain. In some embodiments, one or more cysteine residues are present in the cytoplasmic region of the transmembrane domain. In some embodiments, the cytoplasmic region of the transmembrane domain comprises positively charged amino acids. In some embodiments, the cytoplasmic region of the transmembrane domain comprises the amino acids arginine, serine, and lysine.
[0180] In some embodiments, the transmembrane region of the transmembrane domain contains hydrophobic amino acid residues. In some embodiments, the transmembrane domains provided herein contain artificially hydrophobic sequences. For example, a triplet of phenylalanine, tryptophan, and valine may be present at the C-terminus of the transmembrane domain. In some embodiments, the transmembrane region primarily contains hydrophobic amino acid residues such as alanine, leucine, isoleucine, methionine, phenylalanine, tryptophan, or valine. In some embodiments, the transmembrane region is hydrophobic. In some embodiments, the transmembrane region contains a polyleucine-alanine sequence. The hydrophilic or hydrophobic / hydrophilic characteristics of a protein or protein segment can be assessed by any method known in the art, such as Kyte and Doolittle hydrophilicity assays.
[0181] In some embodiments, the transmembrane domain contains hydrophobic amino acid residues and allows engineered cancer antigens to anchor to the cell membrane. In some embodiments, the transmembrane domain contains an amino acid sequence derived from a transmembrane protein.
[0182] In some embodiments, the transmembrane domain and the extracellular target domain are heterologous, such that the transmembrane domain originates from a natural protein that has a different extracellular domain from the target domain. In such embodiments, the provided membrane-engineered cancer antigen is a chimeric antigen comprising both the target domain and the heterologous transmembrane domain. In such embodiments, it should be understood that the chimeric cancer antigen consists of sequences that are not normally present in proteins in nature.
[0183] In some embodiments, the transmembrane domain (such as a heterologous transmembrane domain) is derived from a transmembrane glycoprotein. In some embodiments, the transmembrane domain (such as a heterologous transmembrane domain) comprises a transmembrane domain selected from: the α, β, or ζ chain of the T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, CD1 lα, CD18, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL-2Rβ, IL-2Rγ, IL-7Rα, ITG A1, VLA1, CD49a, ITGA4, IA4, CD49d, ITGA6, VLA-6, CD49f, ITGAD, CD1D, ITGAE, CD103, ITGAL, ITGAM, CD1B, ITGAX, CD1C, ITGB1, CD29, ITGB2, CD 18. LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, CD229, CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D, and / or NKG2C. In some embodiments, the transmembrane domain is the CD8 transmembrane domain.
[0184] In some implementations, the transmembrane domain comprises an amino acid sequence derived from the following transmembrane domains: the α, β, or ζ chain of the T cell receptor, CD27, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.
[0185] In some embodiments, the transmembrane domain is a CD8 transmembrane domain. In some embodiments, the transmembrane domain has an amino acid sequence derived from a CD8 transmembrane domain. In some embodiments, the transmembrane domain has an amino acid sequence derived from a human CD8α transmembrane domain. In some embodiments, the CD8α transmembrane domain has the amino acid sequence shown in SEQ ID NO: 68 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 68. In some embodiments, the transmembrane domain is shown in SEQ ID NO: 68.
[0186] In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 70% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 75% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 80% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 85% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 90% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 91% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 92% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 93% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 94% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 95% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 96% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 97% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 98% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 99% of the same amino acid sequence as SEQ ID NO: 4.
[0187] In some implementations, the CD8 transmembrane domain of SEQ ID NO: 4 is encoded by the nucleotide sequence shown in SEQ ID NO: 2.
[0188] In some embodiments, the transmembrane domain has an amino acid sequence derived from a transmembrane domain of CD28. In some embodiments, the transmembrane domain has an amino acid sequence derived from a transmembrane domain of human CD28. In some embodiments, the transmembrane domain of CD28 has the amino acid sequence shown in SEQ ID NO: 62 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 62. In some embodiments, the transmembrane domain is shown in SEQ ID NO: 62.
[0189] In some embodiments, the size of the transmembrane domain is from about 40 amino acids to about 90 amino acids. In some embodiments, the size of the transmembrane domain is at least about 40 amino acids. In some embodiments, the size of the transmembrane domain is at most about 90 amino acids. In some embodiments, the size of the transmembrane domain is from about 40 amino acids to about 50 amino acids, from about 40 amino acids to about 60 amino acids, from about 40 amino acids to about 70 amino acids, from about 40 amino acids to about 80 amino acids, from about 40 amino acids to about 90 amino acids, from about 50 amino acids to about 60 amino acids, from about 50 amino acids to about 70 amino acids, from about 50 amino acids to about 80 amino acids, from about 50 amino acids to about 90 amino acids, from about 60 amino acids to about 70 amino acids, from about 60 amino acids to about 80 amino acids, from about 60 amino acids to about 90 amino acids, from about 70 amino acids to about 80 amino acids, from about 70 amino acids to about 90 amino acids, or from about 80 amino acids to about 90 amino acids. In some implementations, the size of the transmembrane domain is about 40 amino acids, about 50 amino acids, about 60 amino acids, about 70 amino acids, about 80 amino acids, or about 90 amino acids.
[0190] The engineered cancer antigens disclosed herein may further include additional elements. In some embodiments, the engineered cancer antigen includes a detection tag. In some embodiments, the detection tag is located at the N-terminus of the engineered cancer antigen. In some embodiments, the detection tag is located at the C-terminus of the engineered cancer antigen. In some embodiments, the detection tag is a flag tag. In some embodiments, the detection tag is a c-Myc tag. In some embodiments, the detection tag is a His tag. In some embodiments, the detection tag includes the amino acid sequence of SEQ ID NO: 111. In some embodiments, the detection tag is an HA tag. In some embodiments, the detection tag includes the amino acid sequence of SEQ ID NO: 29. In some embodiments, the detection tag includes the amino acid sequence of SEQ ID NO: 30.
[0191] In some embodiments, the different elements of the engineered cancer antigen are operatively connected. In some embodiments, the different elements are directly connected to each other. In some embodiments, the different elements are connected via connectors. Exemplary connectors that may be used herein are disclosed in the Embodiments section of this application. Other connectors are known to those skilled in the art.
[0192] In some embodiments, the adapter comprises the amino acid sequence of SEQ ID NO: 110. In some embodiments, the adapter comprises at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 110. In some embodiments, the adapter of SEQ ID NO: 110 is encoded by the nucleotide sequence shown in SEQ ID NO: 114. In some embodiments, the adapter comprises the amino acid sequence of SEQ ID NO: 128. In some embodiments, the adapter comprises at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as SEQ ID NO: 128.
[0193] In some implementations, the membrane-bound engineered cancer antigens provided herein may include any target domains described herein and any heterologous membrane-targeting domains described herein.
[0194] In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 85% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 90% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 91% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 92% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 93% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises at least 94% of the same amino acid sequence as SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence that is at least 95% identical to that of SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence that is at least 96% identical to that of SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence that is at least 97% identical to that of SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence that is at least 98% identical to that of SEQ ID NO: 70. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 113.
[0195] In some embodiments, the membrane-bound engineered cancer antigen of SEQ ID NO: 70 is encoded by the nucleotide sequence shown in SEQ ID NO: 69, 179, or 187-191. In some embodiments, the membrane-bound engineered cancer antigen comprises a nucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the nucleotide sequence shown in SEQ ID NO: 69, 179, or 187-191. 1. Intracellular domains
[0196] In some embodiments, engineered cancer antigens comprising a target domain containing at least one target domain as described in section II.A and a heterologous membrane-targeting domain (as described above) further comprise an intracellular domain. For example, in some embodiments, the engineered cancer antigen further comprises an intracellular domain (such as a death domain) that promotes apoptosis in cancer (e.g., tumor) cells expressing the engineered cancer antigen on a membrane. This may be advantageous in the provided respect, especially since such engineered cancer antigens promote cell death in tumor cells through at least two mechanisms: (1) including a target domain recognized by a therapy (e.g., CAR-T cell therapy), and (2) triggering a cell death signaling cascade in response to the binding of the target domain to a therapy (e.g., CAR-T cell therapy). In some embodiments, the intracellular domain comprises a death domain.
[0197] In other embodiments, the engineered cancer antigen does not contain an intracellular domain, or does not contain a native intracellular domain of the target antigen. For example, in some embodiments, the engineered cancer antigen does not contain an intracellular domain in an effort to avoid or eliminate intracellular signaling that has the potential to promote tumor growth. For example, a native intracellular domain associated with a target antigen (e.g., BCMA) has the potential to promote tumor growth and / or survival by activating certain signaling pathways (e.g., NFκB signaling). Therefore, in some aspects, it would be advantageous to eliminate such an intracellular domain and / or replace it with an intracellular domain containing a pro-apoptotic death domain.
[0198] In some implementations, the engineered cancer antigen includes an intracellular domain, wherein the intracellular domain includes a signal transduction domain that serves as a death domain.
[0199] In some implementations, the death domain is derived from a death receptor. Typically, death receptors are membrane-bound receptors characterized by their ability to induce apoptosis via their intracellular death domain in response to ligand binding. For example, the death receptor of the tumor necrosis factor (TNF) receptor superfamily (TNF-SF) contains a death domain as an intracellular sequence of about 80 amino acids. See, for example, Ashkenzai et al., Science. Aug 28, 1998; 281(5381):1305-8; Locksley et al., Cell. Feb 23, 2001; 104(4):487-501; Wajant Cell Death Differ. Nov 2015; 22(11):1727-41; and Nagata et al., Cell. Feb 7, 1997; 88(3):355-65. Activation of the death domain by ligand is known to trigger apoptosis, such as by activating caspase cascades that lead to cell death.
[0200] In some embodiments where the intracellular domain includes a signal transduction domain that serves as a death domain, the engineered cancer antigen is capable of mediating apoptosis signaling upon binding to the target domain. In some embodiments, apoptosis signaling induces the killing of cancer or tumor cells expressing the membrane-engineered cancer antigen. Therefore, in some embodiments, the engineered cancer antigen further includes an intracellular domain. In some embodiments, the intracellular domain includes a death domain.
[0201] In some implementations, the death domain is the death domain of a TNF-SF member. In some implementations, the death domain is or is derived from a death receptor selected from the following: FAS (CD95), DR3, tumor necrosis factor receptor superfamily member 10A (TNFRSF10A; also known as death receptor 4 (DR4)), DR5, DR6, TNFR1, leucine-rich repeat sequence and death domain-containing protein 1, ankyrin repeat sequence and death domain-containing protein IB, interleukin-1 receptor-associated kinase-like protein 2, tumor necrosis factor receptor superfamily member 21, Netrin receptor UNC5A, Netrin receptor UNC5B, Netrin receptor UNC5C, Netrin receptor UNC5D, UNC5C-like protein, tumor necrosis factor receptor superfamily member 16, ankyrin 1, ankyrin 2, ankyrin 3, nuclear factor NF-κB p105 subunit, tumor necrosis factor receptor superfamily member 6, interleukin-1 receptor-associated kinase 1, death-associated protein kinase 1, death domain-containing protein CRADD, nuclear factor NF-κB p The protein contains the following components: 100 subunit, FAS-associated death domain protein (FADD), receptor-interacting serine / threonine protein kinase 1, ankyrin repeat sequence and death domain-containing protein 1A, death domain-containing protein 1, exoprotein A receptor, exoprotein A receptor-associated adaptor protein, tumor necrosis factor receptor superfamily member 25, THO complex subunit 1, myeloid differentiation primary response protein MyD88, p53-induced death domain-containing protein 1, interleukin-1 receptor-associated kinase 3, and nerve growth factor receptor (NGFR). In some embodiments, the death domain is derived from FAS, FADD, or TNFRSF10A.
[0202] In some embodiments, the death domain is derived from FAS. In some embodiments, the death domain is derived from FAS and contains at least 85%, 90%, 95%, or 97% of the same amino acid sequence as the sequence shown in any one of SEQ ID NO: 93, 97, and 99. In some embodiments, the FAS amino acid sequences shown in SEQ ID NO: 93, 97, and 99 are encoded by the sequences shown in SEQ ID NO: 92, 96, and 98, respectively.
[0203] In some embodiments, the death domain derived from FAS also has an amino acid sequence of a transmembrane domain derived from FAS. In some embodiments, the transmembrane domain has an amino acid sequence of a transmembrane domain derived from human FAS. In some embodiments, the transmembrane domain of FAS has the amino acid sequence shown in SEQ ID NO: 95 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 95. In some embodiments, the transmembrane domain is shown in SEQ ID NO: 95. In some embodiments, the amino acid sequence of SEQ ID NO: 95 is encoded by the nucleotide sequence of SEQ ID NO: 94.
[0204] In some embodiments, the death domain is derived from FADD. In some embodiments, the death domain is derived from FADD and contains at least 85%, 90%, 95%, or 97% of the same amino acid sequence as the sequence shown in SEQ ID NO: 101. In some embodiments, the death domain is derived from FADD and contains the amino acid sequence of SEQ ID NO: 101. In some embodiments, the death domain is derived from FADD and is encoded by a nucleotide sequence that is at least 85%, 90%, 95%, or 97% identical to the sequence shown in SEQ ID NO: 100. In some embodiments, the death domain is derived from FADD and is encoded by the nucleotide sequence of SEQ ID NO: 100.
[0205] In some embodiments, the death domain is derived from TNFRSF10A. In some embodiments, the death domain is derived from TNFRSF10A and contains at least 85%, 90%, 95%, or 97% of the same amino acid sequence as the sequence shown in SEQ ID NO: 103 or 105. In some embodiments, the death domain is derived from TNFRSF10A and contains the amino acid sequence of SEQ ID NO: 103 or 105. In some embodiments, the death domain is derived from TNFRSF10A and is encoded by at least 85%, 90%, 95%, or 97% of the same nucleotide sequence as the sequence shown in SEQ ID NO: 102 or 104. In some embodiments, the death domain is derived from TNFRSF10A and is encoded by the nucleotide sequence of SEQ ID NO: 102 or 104.
[0206] In some implementations, the membrane-bound engineered cancer antigens provided herein may include any of the target domains, transmembrane domains, and intracellular domains provided herein.
[0207] In some embodiments, the membrane-bound engineered cancer antigen comprises at least about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid sequence selected from SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 89, 91, and 115-123. In some embodiments, the membrane-bound engineered cancer antigen comprises an amino acid sequence selected from SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 89, 91, and 115-123.
[0208] In some embodiments, the membrane-bound engineered cancer antigen comprises at least about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% of the sequence selected from SEQ ID NO: 74, 76, 78, 80, 82, 84, 86, 88, and 90. In some embodiments, the membrane-bound cancer antigen comprises the nucleotide sequence selected from SEQ ID NO: 74, 76, 78, 80, 82, 84, 86, 88, and 90. D. Homologous binders
[0209] In the provided embodiments, the embodiments also relate to homologous binding agents that specifically bind to the engineered cancer antigens disclosed herein. The target domain containing an extracellular domain of the target antigen or a truncated portion thereof can be recognized by the homologous binding agent. Specifically, in the provided embodiments, the homologous binding agent specifically binds to the extracellular domain of the engineered cancer antigen disclosed herein or a truncated portion thereof.
[0210] In some embodiments, the homologous binder binds to the extracellular domain or truncated portions of the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein ligand. Specialized glycoforms of PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
[0211] The binding of a homologous binder (e.g., scFv) to a target domain (such as the extracellular domain of a target antigen or a truncated portion thereof) can be confirmed, for example, by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays typically detects the presence of a binding complex of particular interest (e.g., a protein-antibody complex) using a reagent (e.g., an antibody or scFv) specifically labeled for the complex of interest.
[0212] In some embodiments, the size of the homologous binding agent is from about 20 amino acids to about 700 amino acids. In some embodiments, the size of the homologous binding agent is at least about 20 amino acids. In some embodiments, the size of the homologous binding agent is at most about 700 amino acids. In some embodiments, the size of the homologous binding agent is from about 20 amino acids to about 40 amino acids, from about 20 amino acids to about 60 amino acids, from about 20 amino acids to about 100 amino acids, from about 20 amino acids to about 150 amino acids, from about 20 amino acids to about 200 amino acids, from about 20 amino acids to about 250 amino acids, from about 20 amino acids to about 300 amino acids, from about 20 amino acids to about 400 amino acids, from about 20 amino acids to about 500 amino acids, from about 20 amino acids to about 600 amino acids, from about 20 amino acids to about 700 amino acids, from about 40 amino acids to about 60 amino acids, or about 40 amino groups. Acids of about 100 amino acids, about 40 amino acids of about 150 amino acids, about 40 amino acids of about 200 amino acids, about 40 amino acids of about 250 amino acids, about 40 amino acids of about 300 amino acids, about 40 amino acids of about 400 amino acids, about 40 amino acids of about 500 amino acids, about 40 amino acids of about 600 amino acids, about 40 amino acids of about 700 amino acids, about 60 amino acids of about 100 amino acids, about 60 amino acids of about 150 amino acids, about 60 amino acids of about 200 amino acids, about 60 amino acids of about 250 amino acids, about 60 amino acids of about 300 amino acids. 0 amino acids, approximately 60 amino acids to approximately 400 amino acids, approximately 60 amino acids to approximately 500 amino acids, approximately 60 amino acids to approximately 600 amino acids, approximately 60 amino acids to approximately 700 amino acids, approximately 100 amino acids to approximately 150 amino acids, approximately 100 amino acids to approximately 200 amino acids, approximately 100 amino acids to approximately 250 amino acids, approximately 100 amino acids to approximately 300 amino acids, approximately 100 amino acids to approximately 400 amino acids, approximately 100 amino acids to approximately 500 amino acids, approximately 100 amino acids to approximately 600 amino acids, approximately 100 amino acids to approximately 700 amino acids, approximately 150 amino acids Approximately 200 amino acids, approximately 150 amino acids to approximately 250 amino acids, approximately 150 amino acids to approximately 300 amino acids, approximately 150 amino acids to approximately 400 amino acids, approximately 150 amino acids to approximately 500 amino acids, approximately 150 amino acids to approximately 600 amino acids, approximately 150 amino acids to approximately 700 amino acids, approximately 200 amino acids to approximately 250 amino acids, approximately 200 amino acids to approximately 300 amino acids, approximately 200 amino acids to approximately 400 amino acids, approximately 200 amino acids to approximately 500 amino acids, approximately 200 amino acids to approximately 600 amino acids, approximately 200 amino acids to approximately 700 amino acids.About 250 amino acids to about 300 amino acids, about 250 amino acids to about 400 amino acids, about 250 amino acids to about 500 amino acids, about 250 amino acids to about 600 amino acids, about 250 amino acids to about 700 amino acids, about 300 amino acids to about 400 amino acids, about 300 amino acids to about 500 amino acids, about 300 amino acids to about 600 amino acids, about 300 amino acids to about 700 amino acids, about 400 amino acids to about 500 amino acids, about 400 amino acids to about 600 amino acids, about 400 amino acids to about 700 amino acids, about 500 amino acids to about 600 amino acids, about 500 amino acids to about 700 amino acids, or about 600 amino acids to about 700 amino acids. In some embodiments, the size of the homology binder is approximately 20 amino acids, approximately 40 amino acids, approximately 60 amino acids, approximately 100 amino acids, approximately 150 amino acids, approximately 200 amino acids, approximately 250 amino acids, approximately 300 amino acids, approximately 400 amino acids, approximately 500 amino acids, approximately 600 amino acids, or approximately 700 amino acids.
[0213] In some embodiments, the homology binder is an antibody. In some embodiments, the homology binder is a molecule derived from an antibody. In some embodiments, the molecule derived from an antibody is one or more functional fragments of an antibody. Non-limiting examples of functional fragments include heavy chains, light chains, heavy chain variable domains, light chain variable domains, single-chain Fv (scFv), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, biantibodies, triantibodies, tetraantibodies, and microantibodies. In some embodiments, the homology binder is an antibody or antibody fragment having means for binding to a target domain.
[0214] Homologous binders based on antibodies or antibody-derived molecules can be prepared using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-7, or by recombinant DNA methods (see, for example, U.S. Patent No. 4,816,567).
[0215] In the hybridoma approach, mice or other suitable host animals (such as hamsters) are immunized as described above to induce lymphocytes that produce or are capable of producing antibodies that will specifically bind to proteins used for immunization. Alternatively, lymphocytes can be immunized in vitro. Following immunization, the lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusion agent (such as polyethylene glycol) to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice 59-103 (1986)).
[0216] The hybridoma cells thus prepared are inoculated and grown in a suitable culture medium, which in some embodiments contains one or more substances that inhibit the growth or survival of unfused parental myeloma cells (also known as fusion couples). For example, if the parental myeloma cells lack the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT), the selection medium for hybridomas will typically include hypoxanthine, aminopterin, and thymidine (HAT medium), which prevent the growth of HGPRT-deficient cells.
[0217] Exemplary fusion-couple myeloma cells are those that fuse efficiently, support stable high levels of antibody production from selected antibody-producing cells, and are sensitive to selective media selected for the unfused parental cells. Exemplary myeloma cell lines are mouse myeloma lines, such as SP-2 and derivatives, for example, X63-Ag8-653 cells available from the American Type Culture Collection (Manassas, Virginia), and those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center (San Diego, California). Human myeloma and mouse-human hybrid myeloma cell lines have also been described for the production of human monoclonal antibodies (Kozbor, Immunol. 1984, 133:3001-05; and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, 1987, 51-63).
[0218] The production of monoclonal antibodies against antigens in the culture medium in which hybridoma cells are grown is measured. The binding specificity of the monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by in vitro binding assays (such as RIA or ELISA). The binding affinity of monoclonal antibodies can be determined, for example, by Scatchard analysis as described in Munson et al., Anal. Biochem., 1980, 107:220-39.
[0219] Once hybridoma cells that produce antibodies with the desired specificity, affinity, and / or activity are identified, the clones can be subcloned using a limiting dilution procedure and grown using standard methods (Goding, ibid.). Suitable media for this purpose include, for example, DMEM or RPMI-1640. Alternatively, hybridoma cells can be grown in animals as ascites tumors, for example, by intraperitoneal injection of cells into mice.
[0220] Monoclonal antibodies secreted by subclones are isolated from culture medium, ascites fluid, or serum in a suitable manner using conventional antibody purification procedures, such as affinity chromatography (e.g., using protein A-agarose or protein G-agarose) or ion exchange chromatography, hydroxyapatite chromatography, gel electrophoresis, dialysis, etc.
[0221] DNA encoding monoclonal antibodies can be readily isolated and sequenced using standard procedures, such as by using oligonucleotide probes that specifically bind to genes encoding the heavy and light chains of mouse antibodies. Hybridoma cells can be used as a source of this DNA. Once isolated, the DNA can be placed into an expression vector, which is then transfected into host cells that do not normally produce antibody proteins (such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells) to obtain the synthesis of monoclonal antibodies in recombinant host cells. Review articles on the recombinant expression of antibody-encoding DNA in bacteria include Skerra et al., Curr. Opinion in Immunol., 1993, 5:256-62 and Pluckthun, Immunol. Revs., 1992, 130:151-88.
[0222] Homologous binders based on antibodies or antibody-derived molecules can be prepared from antibody phage libraries generated using techniques described, for example, in the following literature: Antibody Phage Display: Methods and Protocols (edited by O'Brien and Aitken, 2002). In the phage display method, the functional antibody domain is displayed on the surface of a phage particle carrying a multinucleotide sequence encoding a functional antibody domain. Examples of phage display methods that can be used to prepare the antibodies described herein include those disclosed in the following literature: Brinkman et al., J. Immunol. Methods, 1995, 182:41-50; Ames et al., Immunol. Methods, 1995, 184:177-86; Kettleborough et al., Eur. J. Immunol., 1994, 24:952-8; Persic et al., Gene, 1997, 187:9-18; Burton et al., Advances in Immunology, 1994, 57:191-280; PCT application number PCT / GB91 / 01 134; International Publication Numbers WO 90 / 02809, WO 91 / 10737, WO 92 / 01047, WO 92 / 18619, WO 93 / 11236, WO WO 95 / 15982, WO 95 / 20401, and WO97 / 13844; and U.S. Patent Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743, and 5,969,108.
[0223] In principle, synthetic antibody clones are selected by screening phage libraries containing various fragments (Fv) of antibody variable regions fused with phage-coated proteins. Such phage libraries are screened against desired antigens. Clones expressing Fv fragments capable of binding to the desired antigen are adsorbed onto the antigen, thereby separating them from non-binding clones in the library. Binding clones are then eluted from the antigen and can be further enriched through additional antigen adsorption / elution cycles.
[0224] Variable domains can be functionally displayed on phages as single-chain Fv (scFv) fragments (where VH and VL are covalently linked via short flexible peptides) or as Fab fragments (where they are each fused to constant domains and interact non-covalently), as described, for example, in Winter et al., 1994, Ann. Rev. Immunol. 12:433-55.
[0225] Libraries of the VH and VL genes can be cloned individually by PCR and randomly recombinated in a phage library, allowing for the search for antigen-binding clones within the phage library, as described by Winter et al., as above. Libraries derived from immunogenic sources provide high-affinity antibodies against immunogens without the need for hybridoma construction. Alternatively, natural libraries can be cloned to provide a single source of human antibodies against a wide variety of non-self antigens and self antigens without any immunization, as described by Griffiths et al., EMBO J, 1993, 12:725-34. Finally, natural libraries can also be prepared synthetically by cloning an unrearranged V gene segment from stem cells and using PCR primers containing random sequences to encode a highly variable CDR3 region and performing rearrangements in vitro, as described, for example, by Hoogenboom and Winter, J. Mol. Biol., 1992, 227:381-88.
[0226] Library screening can be accomplished using a variety of techniques known in the art. For example, the engineered cancer antigens disclosed herein can be used to coat the wells of an adsorption plate, expressed on host cells attached to an adsorption plate or used for cell sorting, conjugated with biotin for capture with streptavidin-coated beads, or used in any other method for panning and displaying libraries. The selection of antibodies with slow dissociation kinetics (e.g., good binding affinity) can be facilitated by using long washes and monovalent phage display (as described in Bass et al., Proteins, 1990, 8:309-14 and WO 92 / 09690) and by using low antigen coating densities (as described in Marks et al., BiotechnoL, 1992, 10:779-83).
[0227] In some embodiments, the homologous binder is an antibody or antigen-binding fragment thereof targeting BCMA, CD19, CD20, CD22, ROR1, or GPRC5D. In some embodiments, the homologous binder is an antibody or antigen-binding fragment having means for binding BCMA, CD19, CD20, CD22, ROR1, or GPRC5D.
[0228] In some embodiments, the homology binder may be part of an antibody therapy for targeting engineered cancer antigens displayed on cancer cells. In some embodiments, the homology binder is part of an antibody-drug conjugate containing both a homology binder and a cytotoxic payload. In some embodiments, the homology binder is part of a bispecific antibody. In some embodiments, the bispecific antibody is a bispecific T-cell adaptor (BiTe) containing both a homology binder and an antibody targeting T cells (such as an anti-CD3 antibody). In some embodiments, the homology binder is part of the extracellular domain of a chimeric antigen receptor. Exemplary CARs containing homology binders are further described in Section II.D.2 below. 1. Exemplary homologous binding antibody or antigen-binding fragment
[0229] In some embodiments, the homologous conjugate is an antibody against BCMA (such as human BCMA) or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the homologous conjugate is part of the extracellular binding domain of any known CAR, as described in Section II.D.1. In some embodiments, the homologous conjugate is derived from an antibody specific to BCMA, including, for example, belanatamab, erlanatamab, taritumab, LCAR-B38M, C11D5.3, C12A3.2, BB2121, or FHVH33. In any of these embodiments, the homologous conjugate may comprise a variable heavy chain (V) of any known anti-BCMA antibody. H ), variable light chain (V L ( ) and / or one or more CDRs or composed of them.
[0230] In some implementations, the homologous binder contains a variable heavy chain (V H ) and variable light chains (V L In some embodiments, the homology binder is a single-chain antibody. In some embodiments, the homology binder is an scFv antibody, which contains antibodies that are connected via a linker in any order (e.g., V). H -V L or V L -V H ) connected V H and V L In some embodiments, the connector separating VH and VL in the scFv is the GS connector shown in SEQ ID NO: 9. In some embodiments, the connector separating VH and VL in the scFv is the Whitlow connector shown in SEQ ID NO: 34. Exemplary connectors separating the VH chain and VL chain of the scFv are shown in Table 2. Table 2: Exemplary joints separating the VH chain and VL chain of scFv
[0231] In some implementations, the homologous binder is a variable heavy chain fragment only (VH antibody), such as a single variable fragment (VHH) of two heavy chains or a fully human heavy chain variable domain (FHVH).
[0232] In some embodiments, the homologous binding agent comprises an scFv derived from C11D5.3 (e.g., BCMA) (such as the mouse monoclonal antibody described in Carpenter et al., Clin. Cancer Res. 19(8):2048-2060 (2013)). See also PCT application publication number WO2010 / 104949. The C11D5.3-derived scFv may contain the heavy chain variable region (V) of C11D5.3. H ) and light chain variable region (V L In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 31, and VL has the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv contains the amino acid sequence shown in SEQ ID NO: 35. In some embodiments, it should be understood that the homology binder may include any sequence that exhibits a certain sequence difference (e.g., has at least 85%, 90%, 95% or higher sequence identity with) and retains binding to BCMA. Exemplary sequences of homology binders are shown in Table 3. Table 3: Exemplary sequences of homologous binders
[0233] In some embodiments, the homologous binding agent comprises an scFv derived from another mouse monoclonal antibody C12A3.2 (as described in Carpenter et al., Clin. Cancer Res. 19(8):2048-2060 (2013) and PCT application publication number WO2010 / 104949). In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 36, and VL has the amino acid sequence shown in SEQ ID NO: 37. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 38. In some implementations, it should be understood that the homologous binder may include any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA. Exemplary sequences of homologous binders are shown in Table 4. Table 4: Exemplary sequences of homologous binders
[0234] In some embodiments, the homologous binder comprises a mouse monoclonal antibody highly specific for human BCMA (referred to as BB2121 in Friedman et al., Hum. Gene Ther. 29(5):585-601 (2018)). See also PCT application publication number WO 2012163805. BB2121 is also known as an anti-BCMA02 CAR. In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 39, and VL has the amino acid sequence shown in SEQ ID NO: 40. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 41. In some implementations, it should be understood that the homologous binder may include any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA. Exemplary sequences of homologous binders are shown in Table 5. Table 5: Exemplary sequences of homologous binders
[0235] In some embodiments, the homologous binder comprises a single variable segment (VHH) of two heavy chains that can bind to two epitopes of BCMA, as described by Zhao et al., J. Hematol. Oncol. 11(1):141 (2018), also known as LCAR-B38M. See also PCT application publication number WO2018 / 028647.
[0236] In some embodiments, the extracellular binding domain of the BCMA CAR comprises a fully human heavy chain variable domain (FHVH), as described in Lam et al., Nat. Commun. 11(1):283 (2020), also known as FHVH33. In some embodiments, the extracellular binding domain comprises the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, it should be understood that the homologous binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA. Exemplary sequences of homologous binders are shown in Table 6. Table 6: Exemplary sequences of homologous binders
[0237] In some embodiments, the homology binder comprises an scFv derived from CT103A (or CAR0085) as described in U.S. Patent No. 11,026,975 B2. In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 43, and VL has the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference (e.g., has at least 85%, 90%, 95% or higher sequence identity) with any of the above or any of the SEQ ID NOs and retains binding to BCMA. Exemplary sequences of homology binders are shown in Table 7. Table 7: Exemplary sequences of homologous binders
[0238] In some embodiments, the homologous binder comprises an scFv derived from CT053 (or Zevorcabtagene autoleucel) as described in Yang et al., Haematologica, 107(8):1960-1965 (2022). In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 168, and VL has the amino acid sequence shown in SEQ ID NO: 169. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 170. In some implementations, it should be understood that the homologous binder may include any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA. Exemplary sequences of homologous binders are shown in Table 8. Table 8: Exemplary sequences of homologous binders
[0239] In some embodiments, the homologous binder is an antibody against CD19 (such as human CD19) or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the homologous binder is part of the extracellular binding domain of any known CAR, as described in Section II.D.1. In some implementations, the homologous binding agent is derived from antibodies specific to CD19, including, for example, SJ25C1 (Bejcek et al., Cancer Res. 55:2346-2351 (1995)), HD37 (Pezutto et al., J. Immunol. 138(9):2793-2799 (1987)), 4G7 (Meeker et al., Hybridoma 3:305-320 (1984)), B43 (Bejcek (1995)), BLY3 (Bejcek (1995)), B4 (Freedman et al., 70:418-427 (1987)), B4 HB12b (Kansas & Tedder, J. Immunol. 147:4094-4102 (1991); Yazawa et al., Proc. Natl. Acad. Sci. USA). 102:15178-15183 (2005); Herbst et al., J. Pharmacol. Exp. Ther. 335:213-222 (2010)), BU12 (Callard et al., J. Immunology, 148(10): 2983-2987 (1992)), and CLB-CD19 (De Rie Cell. Immunol. 118:368-381 (1989)); each of these is incorporated herein by reference in its entirety. Other homologous binding agents include fully human or humanized antibodies, as described in WO2014153270, WO 2018068766, WO 2019159193, or U.S. Patent Publication No. US 2016 / 0152723, each of which is incorporated herein by reference in its entirety. In any of these embodiments, the homology binder may comprise any known anti-CD19 antibody variable heavy chain (V1). H ), variable light chain (V L ( ) and / or one or more CDRs or composed of them.
[0240] In some embodiments, the homology binder is derived from the mouse-derived antibody FMC63. In some embodiments, the homology binder comprises V derived from FMC63. H and / or V L In some implementations, the homologous binding agent is an scFv antibody, which contains antibodies that bind via a linker in any order (e.g., V...). H-V L or V L -V H ) connected V H and V L In some embodiments, the linker separating VH and VL in the scFv is the GS linker shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker shown in SEQ ID NO: 34. In some embodiments, the FMC63 antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 46. H ) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 47. L In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 48. In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD19. Exemplary sequences of homology binders are shown in Table 9. Table 9: Exemplary sequences of homologous binders
[0241] In some embodiments, the homologous binder is derived from the mouse-derived antibody SJ25C1, which binds to CD19. In some embodiments, the homologous binder comprises V derived from SJ25C1. H and / or V L In some implementations, the homologous binding agent is an scFv antibody, which contains antibodies that bind via a linker in any order (e.g., V...). H -V L or V L -V H ) connected V H and V L In some embodiments, the linker separating VH and VL in the scFv is the GS linker shown in SEQ ID NO: 33. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker shown in SEQ ID NO: 34. In some embodiments, the SJ25C1 antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 50. H ) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 51. LIn some embodiments, scFv comprises the amino acid sequence shown in SEQ ID NO: 52. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD19. Exemplary sequences of homology binders are shown in Table 10. Table 10: Exemplary sequences of homologous binders
[0242] In some embodiments, the homologous conjugate is an antibody against CD20 (such as human CD20) or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the homologous conjugate is part of the extracellular binding domain of any known CAR, as described in Section II.D.1. In some embodiments, the homologous conjugate is derived from an antibody specific for CD20, including, for example, Leu16 as described in Rufener et al., Cancer Immunol. Res. 2016 4:509-519. See also GenBank accession number KX055828, IF5, 1.5.3, rituximab, oxotuzumab, teimozumab, ofamumab, tosimob, odronextamab, vetouzumab, utoximab, and oligrizumab. In any of these embodiments, the homologous conjugate may comprise a variable heavy chain (V) of any known anti-CD20 antibody. H ), variable light chain (V L ( ) and / or one or more CDRs or composed of them.
[0243] In some implementations, the homologous binder comprises V derived from Leu16. H and / or V L In some implementations, the homologous binding agent is an scFv antibody, which contains antibodies that bind via a linker in any order (e.g., V...). H -V L or V L -V H ) connected V H and V L In some embodiments, the linker separating VH and VL in the scFv is the GS linker shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker shown in SEQ ID NO: 34. In some embodiments, the antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 53. H) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 54. L In some embodiments, scFv comprises the amino acid sequence shown in SEQ ID NO: 55. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains binding to CD20. Exemplary sequences of homology binders are shown in Table 11. Table 11: Exemplary sequences of homologous binders
[0244] In some embodiments, the homology binder is an antibody against CD22 (such as human CD22) or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the homology binder is part of the extracellular binding domain of any known CAR, as described in Section II.D.1. In some embodiments, the homology binder is derived from antibodies specific to CD22, including, for example, SM03, ovatuzumab, epazuzumab, moxetumomab, pinotuzumab, and m971 monoclonal antibody (m971) or m971-L7. Exemplary anti-CD22 antibodies include those described in US2023 / 0174654, WO2009124109, WO 2014065961, and WO 2020014482, which are incorporated herein by reference in their entirety. In any of these embodiments, the homology binder may comprise a variable heavy chain (V) of any known anti-CD22 antibody. H ), variable light chain (V L ) and / or one or more CDRs or composed thereof. In some embodiments, the homologous binding agent is an scFv antibody, which contains, via a linker, in any order (e.g., V H -V L or V L -V H ) connected V H and V L In some embodiments, the connector separating VH and VL in the scFv is the GS connector shown in SEQ ID NO: 9. In some embodiments, the connector separating VH and VL in the scFv is the Whitlow connector shown in SEQ ID NO: 34.
[0245] In some embodiments, the antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 56. H ) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 57.L In some embodiments, the scFv comprises the amino acid sequence shown in SEQ ID NO: 58. In some embodiments, the antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 59. H ) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 60. L In some embodiments, scFv comprises the amino acid sequence shown in SEQ ID NO: 61. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains binding to CD22. Exemplary sequences of homology binders are shown in Table 12. Table 12: Exemplary sequences of homologous binders
[0246] In some embodiments, the homologous conjugate is an antibody against CD70 (such as human CD70) or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the homologous conjugate is part of the extracellular binding domain of any known CAR, as described in Section II.D.2. In some embodiments, the homologous conjugate is derived from an antibody specific for CD70, including, for example, any one described in WO2022 / 078344, WO2022 / 150831 (e.g., Table 3 therein), WO2022 / 238962, WO2021 / 047208, WO2021 / 055437, WO2019 / 152742, or US2023 / 0399412. In any of these embodiments, the homologous conjugate may comprise a variable heavy chain (V) of any known anti-CD70 antibody. H ), variable light chain (V L ) and / or one or more CDRs or composed thereof. In some embodiments, the homologous binding agent is an scFv antibody, which contains, via a linker, in any order (e.g., V H -V L or V L -V H ) connected V H and V L In some embodiments, the linker separating VH and VL in the scFv is the GS linker shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker shown in SEQ ID NO: 34. In some embodiments, the antibody comprises a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 160.H ) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 159. L In some embodiments, scFv comprises the amino acid sequence shown in SEQ ID NO: 161. In some embodiments, it should be understood that the homology binder may comprise any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD70. Exemplary sequences of homology binders are shown in Table 13. Table 13: Exemplary sequences of homologous binders 2. Chimeric antigen receptor
[0247] In some embodiments, the homologous binder of the engineered cancer antigen is part of or is present as part of the extracellular domain of a chimeric antigen receptor (CAR). In some embodiments, the CAR is expressed by genetically engineered cells and is capable of binding to the target domain of the engineered cancer antigen (containing the extracellular domain of the target antigen or a truncated portion thereof) via its extracellular domain. In some embodiments, the CAR further includes a transmembrane domain and an intracellular signaling domain. In some embodiments, the CAR is expressed on the surface of immune effector cells. In some embodiments, the immune effector cells are cytotoxic T cells. In some embodiments, the immune effector cells are natural killer cells. In the provided embodiments, engineered cells (e.g., T cells) containing the CAR can be used in immunotherapy to target and destroy cancer cells that have been labeled to express an engineered cancer antigen recognized by the CAR.
[0248] In some embodiments, the CAR is a fusion protein comprising an extracellular domain containing a homologous binder as an extracellular antigen-binding domain for recognizing a target domain; a transmembrane domain; and an intracellular signaling domain. The extracellular and transmembrane domains can be connected by flexible linkers (also called spacers). In some embodiments, the extracellular domain of the CAR is any of the homologous binders described above. In some embodiments, the intracellular signaling domain includes an immune receptor tyrosine activation motif (ITAM). Activation of the CAR fusion protein in response to the recognition of the target domain of the engineered cancer antigen by the homologous binder leads to cell activation. When a cell expresses this CAR, it can recognize and kill target cells expressing engineered cancer antigens or labeled to display engineered cancer antigens on their surface.
[0249] In some embodiments, the CAR is typically encoded by a nucleic acid sequence (polynucleotide) including a leader sequence for guiding the expression of the CAR at the cell membrane. In some embodiments, the antigen receptor (e.g., CAR) is encoded by a polynucleotide having an NH2-terminal leader sequence. The leader sequence (also called a signal peptide) allows the expressed CAR construct to enter the endoplasmic reticulum (ER) and target the cell surface. The leader sequence is cleaved in the ER, and mature cell surface CARs do not have a leader sequence. Typically, the leader sequence will be in the range of 5 to 30 amino acids in length and contains a hydrophobic amino acid segment. In some embodiments, the leader sequence is 5, 10, 15, 20, or 25 amino acids in length, or any value between any of the foregoing. Suitably, the leader sequence comprises a sequence derived from any secreted protein. In some embodiments, the leader sequence can be any of the signal peptide sequences described herein. An exemplary CD8α signal peptide is shown in SEQ ID NO: 64. In some embodiments, the leader sequence or signal peptide sequence comprises the amino acid sequence of SEQ ID NO: 64. An exemplary GM-CSFRa signal peptide is shown in SEQ ID NO: 65. An exemplary IgK signal peptide is shown in SEQ ID NO: 66. An exemplary IgK signal peptide is shown in SEQ ID NO: 67. In some embodiments, the signal peptide sequence described herein can be from any mammalian species. In some embodiments, the signal peptide sequence can be a mouse signal peptide sequence. In some embodiments, the mouse signal peptide can be a mouse heavy chain signal peptide. An exemplary mouse heavy chain signal peptide is shown in SEQ ID NO: 109 (the corresponding nucleotide sequence is shown in SEQ ID NO: 14).
[0250] The CAR disclosed in this paper includes a transmembrane domain that can fuse directly or indirectly with an extracellular domain. The transmembrane domain disclosed above for engineered cancer antigens can be used as the transmembrane domain of the CAR disclosed in this paper.
[0251] In some implementations, the transmembrane domain of the CAR contains hydrophobic amino acid residues and allows the CAR to anchor into the cell membrane of engineered cells. Suitably, the transmembrane domain contains an amino acid sequence derived from a transmembrane protein. Suitably, the transmembrane domain contains an amino acid sequence derived from the following transmembrane domains: the α, β, or ζ chain of the T cell receptor, CD27, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.
[0252] In some embodiments, the transmembrane domain is a CD8 transmembrane domain. In some embodiments, the CAR comprises a transmembrane domain having an amino acid sequence derived from a CD8 transmembrane domain. In some embodiments, the CAR comprises a transmembrane domain having an amino acid sequence derived from a human CD8α transmembrane domain. In some embodiments, the CAR contains a CD8α transmembrane domain having the amino acid sequence shown in SEQ ID NO: 68 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 68. In some embodiments, the transmembrane domain is shown in SEQ ID NO: 68.
[0253] In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 70% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 75% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 80% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 85% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 90% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 91% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 92% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 93% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain comprises at least 94% of the amino acid sequence identical to SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 95% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 96% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 97% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 98% of the same amino acid sequence as SEQ ID NO: 4. In some embodiments, the transmembrane domain contains at least 99% of the same amino acid sequence as SEQ ID NO: 4.
[0254] In some embodiments, suitably, the CAR comprises a transmembrane domain having an amino acid sequence having a transmembrane domain derived from CD28. Suitably, the CAR comprises a transmembrane domain having an amino acid sequence having a transmembrane domain derived from human CD28. In some embodiments, the CAR contains a transmembrane domain of CD28 having the amino acid sequence shown in SEQ ID NO: 62 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 62. In some embodiments, the transmembrane domain is shown in SEQ ID NO: 62.
[0255] In some embodiments, the CAR may further comprise a spacer region located between the homologous binder of the extracellular antigen-binding domain and the transmembrane domain. In some embodiments, the spacer region comprises hydrophilic amino acids and allows for flexibility of the targeting domain relative to the cell surface. In some embodiments, the spacer region comprises more than 5, 10, 15, 20, 25, or 30 amino acids. In some embodiments, the spacer region comprises fewer than 10, 15, 20, 25, 30, or 35 amino acids. In some embodiments, the spacer region is a hinge domain.
[0256] The CAR disclosed herein can comprise a hinge domain located between an extracellular domain and a transmembrane domain. A hinge domain is an amino acid segment typically found between two domains of a protein and allows for protein flexibility and movement of one or both said domains relative to each other. Any amino acid sequence can be used that provides this flexibility and movement of the extracellular domain relative to the transmembrane domain of the effector molecule.
[0257] In some embodiments, the hinge domain is a hinge domain of a naturally occurring protein. The hinge domain of any protein known in the art to contain a hinge domain is suitable for use in the chimeric receptor described herein. In some embodiments, the hinge domain is at least a portion of the hinge domain of a naturally occurring protein and imparts flexibility to the chimeric receptor. In some embodiments, the hinge domain is derived from CD8a. In some embodiments, the hinge domain is a portion of the hinge domain of CD8a, for example, a fragment containing about 15-100 (e.g., 20, 25, 30, 35, or 40) consecutive amino acids of the hinge domain of CD8a. In some embodiments, the CAR contains a CD8 hinge spacer sequence having the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 21. In some embodiments, the spacer sequence is shown in SEQ ID NO: 21.
[0258] In some embodiments, the hinge domain is a hinge domain of an antibody (such as an IgG, IgA, IgM, IgE, or IgD antibody). In some embodiments, the hinge domain is a hinge domain that binds to the constant structural domains CHI and CH2 of the antibody. In some embodiments, the hinge domain belongs to the antibody and includes the hinge domain of the antibody and one or more constant regions of the antibody. In some embodiments, the hinge domain includes the hinge domain of the antibody and the CH3 constant region of the antibody. In some embodiments, the hinge domain includes the hinge domain of the antibody and the CH2 and CH3 constant regions of the antibody. In some embodiments, the antibody is an IgG, IgA, IgM, IgE, or IgD antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the hinge region includes the hinge region of an IgG1 antibody and the CH2 and CH3 constant regions. In some embodiments, the hinge region includes the hinge region of an IgG1 antibody and the CH3 constant region.
[0259] In some embodiments, the spacer region comprises all or a portion of IgG1 Fc or IgG4 Fc containing a hinge domain. In some embodiments, the spacer is an IgG4 Fc spacer. In some embodiments, the CAR contains an IgG4 Fc spacer having the amino acid sequence shown in SEQ ID NO: 22 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 22. In some embodiments, the sequence of the spacer is shown in SEQ ID NO: 22. In some embodiments, the sequence of the spacer is a hinge portion of IgG1 Fc or IgG4 Fc. In some embodiments, the CAR contains an IgG4 hinge spacer. In some embodiments, the IgG4 hinge spacer has the amino acid sequence shown in SEQ ID NO: 23 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 23. In some embodiments, the sequence of the spacer is shown in SEQ ID NO: 23.
[0260] Non-naturally occurring peptides can also be used as hinge domains. In some embodiments, the hinge domain located between the C-terminus of the extracellular ligand-binding domain of the Fc receptor and the N-terminus of the transmembrane domain is a peptide linker, such as a (GxS)n linker, where x and n can independently be integers between 3 and 12 (including 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) or larger.
[0261] The hinge domain may contain approximately 10-100 amino acids, for example, any one of approximately 15-75 amino acids, 20-50 amino acids, or 30-60 amino acids. In some embodiments, the length of the hinge domain may be any one of at least approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 75 amino acids.
[0262] The intracellular signaling domain in the CAR described herein is responsible for activating at least one normal effector function in immune effector cells expressing the CAR. The term "effector function" refers to a specialized function of a cell. Effector functions of T cells can be, for example, cytolytic or helper activities, including cytokine secretion. Therefore, the term "cytoplasmic signaling domain" refers to a portion of a protein that transduces effector function signals and directs the cell to perform its specialized function. While the entire cytoplasmic signaling domain can generally be used, in many cases, the entire strand is not required. Regarding the use of a truncated portion of a cytoplasmic signaling domain, such a truncated portion can be used instead of the complete strand, as long as it transduces effector function signals. Therefore, the term "cytoplasmic signaling domain" is intended to include any truncated portion of the cytoplasmic signaling domain sufficient to transduce effector function signals.
[0263] In some embodiments, the intracellular signaling domain comprises the primary intracellular signaling domain of immune effector cells. In some embodiments, the CAR comprises an intracellular signaling domain that is substantially composed of the primary intracellular signaling domain of immune effector cells. "Primary intracellular signaling domain" refers to a cytoplasmic signaling sequence that acts in a stimulatory manner to induce the function of an immune effector. In some embodiments, the primary intracellular signaling domain contains a signaling motif called an immune receptor tyrosine activation motif or ITAM. As used herein, "ITAM" is a conserved protein motif commonly found in the tail of signaling molecules expressed in many immune cells. The motif may comprise two repeats of the amino acid sequence YxxL / I separated by 6-8 amino acids, where each x is independently any amino acid, resulting in the conserved motif YxxL / Ix(6-8)YxxL / I. The ITAM within the signaling molecule is important for intracellular signal transduction, which is mediated at least in part by phosphorylation of tyrosine residues in the ITAM following activation of the signaling molecule. ITAM can also function as a docking site for other proteins involved in signal transduction pathways. Exemplary primary cytoplasmic signal transduction sequences containing ITAM include those derived from: CD3z, FcRγ (FCER1G), FcRβ (Fcε Rib), CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d.
[0264] In some embodiments, the intracellular signal transduction domain is derived from the CD3ζ chain (CD3z). In some embodiments, the intracellular signal transduction domain consists of the cytoplasmic signal transduction domain of CD3z. In some embodiments, the intracellular signal transduction domain is the cytoplasmic signal transduction domain of wild-type CD3z.
[0265] In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD3ζ signal transduction domain having the amino acid sequence shown in SEQ ID NO: 24 or an amino acid sequence showing at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 24. In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD3ζ signal transduction domain having the amino acid sequence shown in SEQ ID NO: 24. In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD3ζ signal transduction domain having the amino acid sequence shown in SEQ ID NO: 25 or an amino acid sequence showing at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 25. In some embodiments, the CAR contains an intracellular signal transduction domain, which contains a CD3ζ signal transduction domain having the amino acid sequence shown in SEQ ID NO: 25.
[0266] The CARs disclosed herein may further include at least one co-stimulatory signaling domain. Therefore, in some embodiments, the chimeric antigen receptor (CAR) includes: 1) a homologous binding agent; 2) a spacer, such as a hinge sequence; 3) a transmembrane domain; and 4) an intracellular signaling region comprising a first primary intracellular signaling domain (such as the CD3ζ intracellular signaling domain) and a second co-stimulatory intracellular signaling domain. As used herein, the term "co-stimulatory signaling domain" refers to at least a portion of a protein that mediates intracellular signal transduction to induce immune responses, such as effector functions. Many immune effector cells require co-stimulation in addition to antigen-specific signaling to promote cell proliferation, differentiation, and survival, as well as to activate cellular effector functions.
[0267] The costimulatory signal transduction domain of the chimeric receptor described herein can be a cytoplasmic signal transduction domain derived from a costimulatory protein, which transduces signals and regulates responses mediated by immune cells (such as T cells, NK cells, macrophages, neutrophils, or eosinophils). The "costimulatory signal transduction domain" can be the cytoplasmic portion of the costimulatory molecule.
[0268] In some embodiments, the intracellular signaling domain comprises a single co-stimulatory signaling domain. In some embodiments, the intracellular signaling domain comprises two or more (e.g., any one of about 2, 3, 4, or more) co-stimulatory signaling domains. In some embodiments, the intracellular signaling domain comprises two or more identical co-stimulatory signaling domains. In some embodiments, the intracellular signaling domain comprises two or more co-stimulatory signaling domains from different co-stimulatory proteins (e.g., any two or more co-stimulatory proteins described herein). In some embodiments, the intracellular signaling domain comprises a primary intracellular signaling domain (e.g., the cytoplasmic signaling domain of CD3z) and one or more co-stimulatory signaling domains (e.g., 4-1BB signaling). In some embodiments, one or more co-stimulatory signaling domains (e.g., 4-1BB signaling) and the primary intracellular signaling domain (e.g., the cytoplasmic signaling domain of CD3z) are fused to each other via an optional peptide linker. The primary intracellular signaling domain and one or more co-stimulatory signaling domains can be arranged in any suitable order. Multiple co-stimulatory signal transduction domains can provide additive or synergistic stimulation.
[0269] In some implementations, the co-stimulatory domains may be CD27, CD28, 4-1BB (CD137), OX40 (CD134), CD30, CD40, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C and / or B7-H3 co-stimulatory domains.
[0270] In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD28 co-stimulatory signal transduction domain having the amino acid sequence shown in SEQ ID NO: 26 or an amino acid sequence showing at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 26. In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD28 co-stimulatory signal transduction domain having the amino acid sequence shown in SEQ ID NO: 26. In some embodiments, the CAR contains an intracellular signal transduction domain, which includes a CD28 co-stimulatory signal transduction domain having the amino acid sequence shown in SEQ ID NO: 27 or an amino acid sequence showing at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 27. In some embodiments, the CAR contains an intracellular signal transduction domain containing a co-stimulatory signal transduction domain of CD28 having the amino acid sequence shown in SEQ ID NO: 27.
[0271] In some embodiments, the CAR contains an intracellular signal transduction domain comprising a 4-1BB co-stimulatory signal transduction domain having the amino acid sequence shown in SEQ ID NO: 28 or an amino acid sequence exhibiting at least 85%, 90%, or 95% sequence identity with SEQ ID NO: 28. In some embodiments, the CAR contains an intracellular signal transduction domain comprising a 4-1BB co-stimulatory signal transduction domain having the amino acid sequence shown in SEQ ID NO: 28.
[0272] In some embodiments, the intracellular signaling domain may be a CD3ζ, CD28, and / or 4-1BB domain. In some embodiments, the CAR comprises at least two intracellular signaling domains derived from CD3ζ and 4-1BB. In other embodiments, the CAR comprises at least two intracellular signaling domains derived from CD3ζ and CD28.
[0273] In some embodiments, the intracellular signal transduction domain comprises the amino acid sequence of SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 70% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 75% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 80% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 85% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 90% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 91% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 92% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 93% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 94% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 95% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 96% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 97% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 98% of the amino acid sequence identical to SEQ ID NO: 63. In some embodiments, the intracellular signal transduction domain comprises at least 99% of the amino acid sequence identical to SEQ ID NO: 63.
[0274] In some implementations, the CAR is an anti-BCMA CAR. Chimeric antigen receptors containing anti-BCMA antibodies and cells expressing such chimeric antigen receptors have been previously described. See Carpenter et al., Clin Cancer Res., 2013, 19(8):2048-2060; WO 2010104949, WO 2016090320, WO 2016090327, WO 2016094304, WO2016014789, WO 2017173256, WO 2017130223, WO 2018028647, WO2019 / 089968, WO2019089969, WO 2019085102, WO 2019241358, WO 2019108900, WO 2020014333, WO2020243546, WO 2020018825、WO 2020038147, WO 2021091978, WO 2021256724, WO2021057866, WO 2021146147, WO 2021121228, WO 2021162394, WO 2021231213, WO2022089353, WO 2022046730、WO 2022046730、WO 2022143870、WO 2022119923、WO2023226921、WO 2023288185、WO 2023193662、WO 2023109257、WO 2023016576、WO2023020474、WO WO 2023019398 and WO 2023068382, each incorporated herein by reference in its entirety. Any BCMA-resistant CAR previously described or known or based on any such CAR may be used in the provided embodiments.
[0275] In some embodiments, the anti-BCMA CAR comprises any homologous binding agent as described in Section II.D.1. In some embodiments, the anti-BCMA CAR comprises an extracellular binding domain, a hinge domain, a transmembrane domain containing any of the aforementioned anti-BCMA homologous binding agents, and an intracellular domain containing an intracellular co-stimulatory domain and a CD3ζ intracellular primary signaling domain. In some embodiments, the CAR may also comprise a signal peptide.
[0276] In some implementations, the extracellular binding domain of the BCMA CAR comprises an scFv derived from C11D5.3 (such as the mouse monoclonal antibody described in Carpenter et al., Clin. Cancer Res. 19(8):2048-2060 (2013)). See also PCT application publication number WO2010 / 104949. The C11D5.3-derived scFv may contain the heavy chain variable region (V) of C11D5.3. H ) and light chain variable region (V L In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 31, and VL has the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 35. In some embodiments, the spacer is a hinge sequence, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is any of those described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA and intracellular signaling and cytotoxic activity.
[0277] In some embodiments, the extracellular binding domain of the BCMA CAR comprises an scFv derived from another mouse monoclonal antibody C12A3.2 (as described in Carpenter et al., Clin. Cancer Res. 19(8):2048-2060 (2013) and PCT application publication number WO2010 / 104949). In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 36, and VL has the amino acid sequence shown in SEQ ID NO: 37. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the spacer is a hinge sequence, as described in any of the above, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is any of those described herein, such as the CD8 transmembrane domain or the CD28 transmembrane domain. In some embodiments, the intracellular signaling domain comprises a 4-1BB co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, the intracellular signaling domain comprises a CD28 co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or described SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains BCMA binding and intracellular signaling and cytotoxic activity.
[0278] In some embodiments, the extracellular binding domain of the BCMA CAR comprises a mouse monoclonal antibody highly specific for human BCMA, referred to as BB2121 in Friedman et al., Hum. Gene Ther. 29(5):585-601 (2018). See also PCT application publication number WO 2012163805. BB2121 is also known as an anti-BCMA02 CAR. In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 39, and VL has the amino acid sequence shown in SEQ ID NO: 40. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the spacer is a hinge sequence, such as any of those described herein, for example, a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is any of those described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signaling domain contains a 4-1BB co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, the intracellular signaling domain contains a CD28 co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or described SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains BCMA binding and intracellular signaling and cytotoxic activity.
[0279] In some embodiments, the extracellular binding domain of the BCMA CAR comprises a single variable segment (VHH) of two heavy chains that can bind to two epitopes of BCMA, as described in Zhao et al., J. Hematol. Oncol. 11(1):141(2018), also known as LCAR-B38M. See also PCT application publication number WO2018 / 028647. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain comprises a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain comprises a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA and intracellular signaling and cytotoxic activity.
[0280] In some embodiments, the extracellular binding domain of the BCMA CAR comprises a fully human heavy chain variable domain (FHVH), as described in Lam et al., Nat. Commun. 11(1):283 (2020), also known as FHVH33. In some embodiments, the extracellular binding domain comprises the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signaling domain comprises a 4-1BB co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, the intracellular signaling domain comprises a CD28 co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to BCMA and intracellular signaling and cytotoxic activity.
[0281] In some embodiments, the extracellular binding domain of the BCMA CAR comprises an scFv derived from CT103A (or CAR0085) as described in U.S. Patent No. 11,026,975 B2. In some embodiments, VH has the amino acid sequence shown in SEQ ID NO:39, and VL has the amino acid sequence shown in SEQ ID NO:40. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO:9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO:34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO:41. In some embodiments, the spacer is a hinge sequence, as described above, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described above, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signaling domain comprises a 4-1BB co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, the intracellular signaling domain comprises a CD28 co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs described (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains its binding to BCMA and its intracellular signaling and cytotoxic activities.
[0282] In some embodiments, the extracellular binding domain of the BCMA CAR comprises an scFv derived from CT053 (or Zevor-cel) as described in Yang et al., Haematologica, 107(8):1960-1965 (2022). In some embodiments, VH has the amino acid sequence shown in SEQ ID NO: 168, and VL has the amino acid sequence shown in SEQ ID NO: 169. In some embodiments, the linker separating VH and VL in the scFv is a GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is a Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 170. In some embodiments, the spacer is a hinge sequence, as described in any of the above, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is any of those described herein, such as the CD8 transmembrane domain or the CD28 transmembrane domain. In some embodiments, the intracellular signaling domain comprises a 4-1BB co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, the intracellular signaling domain comprises a CD28 co-stimulatory signaling domain and a CD3ζ signaling domain, as described herein. In some embodiments, it should be understood that the CAR comprises any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs described (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains BCMA binding and intracellular signaling and cytotoxic activity. In some embodiments, the anti-BCMA CAR comprises at least 85%, at least 90%, or at least 95% of the same amino acid sequence as the anti-BCMA CAR shown in SEQ ID NO: 167.
[0283] In some embodiments, the CAR includes an anti-BCMA CAR of a commercial CAR cell therapy. Non-limiting examples of anti-BCMA CARs in commercial cell-based therapies include anti-BCMA CARs engineered in the cells of ABECMA® or CARVYKTI™. In some embodiments, commercial cell-based therapies include anti-BCMA CARs engineered in the cells of Zevor-cel.
[0284] In some embodiments, the anti-BCMA CAR has the characteristics of the CAR in Aciviren. In some embodiments, the CAR has an amino acid sequence as shown in the FDA Unique Ingredient Identifier (UNII) code number H4ON8SV8LK (drugs.ncats.io / substance / H4ON8SV8LK). In some embodiments, the anti-BCMA CAR is represented by the amino acid sequence shown in SEQ ID NO: 192. In some embodiments, the anti-BCMA CAR is represented by an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity with SEQ ID NO: 192.
[0285] In some embodiments, the anti-BCMA CAR has the characteristics of the CAR in Cidario Orencar. In some embodiments, the CAR has an amino acid sequence as shown in FDA Unique Ingredient Identifier (UNII) code number 7S3Z5YP744 (drugs.ncats.io / substance / 7S3Z5YP744). The CAR is also described, for example, in International PCT Publication No. WO2023164695. In some embodiments, the anti-BCMA CAR is represented by the amino acid sequence shown in SEQ ID NO: 193. In some embodiments, the anti-BCMA CAR is represented by an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity with SEQ ID NO: 193.
[0286] In some embodiments, the anti-BCMA CAR has the characteristics of the CAR in Zwabie Olense. In some embodiments, the anti-BCMA CAR is represented by the amino acid sequence shown in SEQ ID NO: 167. In some embodiments, the anti-BCMA CAR is represented by the amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity with SEQ ID NO: 167.
[0287] In some embodiments, the CAR is an anti-CD19 CAR. Chimeric antigen receptors containing anti-CD19 antibodies and cells expressing such chimeric antigen receptors have been previously described. In some embodiments, the anti-CD19 CAR comprises any homologous binding agent as described in Section II.D.1. In some embodiments, the anti-CD19 CAR comprises an extracellular binding domain, a hinge domain, a transmembrane domain, and an intracellular domain containing any of the aforementioned anti-CD19 homologous binding agents, as well as an intracellular domain containing an intracellular co-stimulatory domain and a CD3ζ intracellular primary signaling domain. In some embodiments, the CAR may also comprise a signal peptide.
[0288] In some embodiments, the extracellular binding domain of the CD19 CAR is derived from the mouse-derived antibody FMC63. In some embodiments, the extracellular binding domain of the CD19 CAR may include the heavy chain variable region (V) shown in SEQ ID NO: 46. H ) and the light chain variable region (V) shown in SEQ ID NO: 47 L In some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 48. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD19 and intracellular signaling and cytotoxic activity.
[0289] In some embodiments, the extracellular binding domain of the CD19 CAR is derived from the mouse-derived antibody SJ25C1. In some embodiments, the extracellular binding domain of the CD19 CAR may include the heavy chain variable region (V) shown in SEQ ID NO: 50. H ) and the light chain variable region (V) shown in SEQ ID NO: 51 LIn some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the scFv has the amino acid sequence shown in SEQ ID NO: 52. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD19 and intracellular signaling and cytotoxic activity.
[0290] In some implementations, the CAR includes an anti-CD19 CAR of a commercial CAR cell therapy. Non-limiting examples of anti-CD19 CARs in commercial cell-based therapies include anti-CD19 CARs engineered in cells of YESCARTA®, KYMRIAH®, TECARTUS®, or BREYANZI®.
[0291] In some embodiments, the CAR is an anti-CD20 CAR. Chimeric antigen receptors containing anti-CD20 antibodies and cells expressing such chimeric antigen receptors have been previously described. In some embodiments, the anti-CD20 CAR comprises any homologous binding agent as described in Section II.D.1. In some embodiments, the anti-CD20 CAR comprises an extracellular binding domain, a hinge domain, a transmembrane domain, and an intracellular domain containing any of the aforementioned anti-CD20 homologous binding agents, as well as an intracellular domain containing an intracellular co-stimulatory domain and a CD3ζ intracellular primary signaling domain. In some embodiments, the CAR may also comprise a signal peptide.
[0292] In some implementations, the extracellular binding domain of the CD20 CAR may include the heavy chain variable region (V) shown in SEQ ID NO: 53. H ) and the light chain variable region (V) shown in SEQ ID NO: 54 LIn some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the anti-CD20 scFv is shown in SEQ ID NO: 55. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD20 and intracellular signaling and cytotoxic activity.
[0293] In some embodiments, the CAR is an anti-CD22 CAR. Chimeric antigen receptors containing anti-CD22 antibodies and cells expressing such chimeric antigen receptors have been previously described. In some embodiments, the anti-CD22 CAR comprises any homologous binding agent as described in Section II.D.1. In some embodiments, the anti-CD22 CAR comprises an extracellular binding domain, a hinge domain, a transmembrane domain, and an intracellular domain containing any of the aforementioned anti-CD22 homologous binding agents, as well as an intracellular domain containing an intracellular co-stimulatory domain and a CD3ζ intracellular primary signaling domain. In some embodiments, the CAR may also comprise a signal peptide.
[0294] In some implementations, the extracellular binding domain of the CD22 CAR may include the heavy chain variable region (V) shown in SEQ ID NO: 56. H ) and the light chain variable region (V) shown in SEQ ID NO: 57 LIn some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the anti-CD22 scFv is shown in SEQ ID NO: 58. In some embodiments, the extracellular binding domain of the CD22 CAR may include the heavy chain variable region (V) as shown in SEQ ID NO: 59. H ) and the light chain variable region (V) shown in SEQ ID NO: 60 L In some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the anti-CD22 scFv is shown in SEQ ID NO: 61. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some implementations, it should be understood that CAR includes any sequence that exhibits a certain sequence difference from any of the above or any of the SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity with it) and retains binding to CD22 and intracellular signaling and cytotoxic activity.
[0295] In some embodiments, the CAR is an anti-CD70 CAR. Chimeric antigen receptors containing anti-CD70 antibodies and cells expressing such chimeric antigen receptors have been previously described. In some embodiments, the anti-CD70 CAR comprises any homologous binding agent as described in Section II.D.1. In some embodiments, the anti-CD70 CAR comprises an extracellular binding domain, a hinge domain, a transmembrane domain, and an intracellular domain containing any of the aforementioned anti-CD70 homologous binding agents, as well as an intracellular domain containing an intracellular co-stimulatory domain and a CD3ζ intracellular primary signaling domain. In some embodiments, the CAR may also comprise a signal peptide. In some embodiments, the CAR may be a CAR having a CD70 binding domain as described in WO2022 / 150831 (exemplary CD70 binding domains and CARs are shown in, for example, Table 3). In some embodiments, the extracellular binding domain of the CD70 CAR may comprise the heavy chain variable region (V) shown in SEQ ID NO: 160. H ) and the light chain variable region (V) shown in SEQ ID NO: 159 L In some embodiments, the linker separating VH and VL in the scFv is the GS linker as shown in SEQ ID NO: 9. In some embodiments, the linker separating VH and VL in the scFv is the Whitlow linker as shown in SEQ ID NO: 34. In some embodiments, the anti-CD70 scFv is shown in SEQ ID NO: 161. In some embodiments, the spacer is a hinge sequence, as described herein, such as a CD8a hinge or an immunoglobulin hinge. In some embodiments, the transmembrane domain is as described herein, such as a CD8 transmembrane domain or a CD28 transmembrane domain. In some embodiments, the intracellular signal transduction domain contains a 4-1BB co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, the intracellular signal transduction domain contains a CD28 co-stimulatory signal transduction domain and a CD3ζ signal transduction domain, as described herein. In some embodiments, it should be understood that the CAR includes any sequence that exhibits a certain sequence difference from any of the above or stated SEQ ID NOs (e.g., has at least 85%, 90%, 95% or higher sequence identity) and retains binding to CD70 and intracellular signaling and cytotoxic activity. In some embodiments, the CAR has a sequence having at least 85%, 90%, 95% or 97% sequence identity with SEQ ID NO: 108. In some embodiments, the CAR has the sequence shown in SEQ ID NO: 108.
[0296] In some implementations, the extracellular binding domain of the CD70 CAR may include the heavy chain variable region (V) shown in SEQ ID NO: 125. H ) and the light chain variable region (V) shown in SEQ ID NO: 126 L In some implementations, anti-CD70 scFv is shown in SEQ ID NO: 127. III. Polynucleotides
[0297] This article also provides one or more polynucleotides encoding any engineered cancer antigens disclosed herein.
[0298] In some embodiments, this document provides a polynucleotide encoding any engineered cancer antigen comprising a target domain and a tumor-targeting molecule, such as disclosed in Section II.B. In some embodiments, this document provides a polynucleotide encoding any engineered cancer antigen comprising a target domain and a heterologous membrane-targeting domain, such as disclosed in Section II.C.
[0299] In some embodiments, this document provides a polynucleotide encoding an engineered cancer antigen comprising a target domain and a tumor-targeting molecule (e.g., any of those disclosed in Section II.B.), and an engineered cancer antigen comprising a target domain and a heterologous membrane-targeting domain (e.g., any of those disclosed in Section II.C.). In some embodiments, the engineered cancer antigen comprising a target domain and a tumor-targeting molecule is separated from the engineered cancer antigen comprising a target domain and a heterologous membrane-targeting domain by a cleavable linker. In some embodiments, the cleavable linker comprises a 2A self-cleaving peptide.
[0300] In some embodiments, this document provides a polynucleotide comprising a first nucleic acid sequence and a second nucleic acid sequence, the first nucleic acid sequence encoding any engineered cancer antigen (e.g., any of those disclosed in Section II.B.) comprising a target domain and a tumor-targeting molecule, and the second nucleic acid sequence encoding any engineered cancer antigen (e.g., any of those disclosed in Section II.C.) comprising a target domain and a heterologous membrane-targeting domain. In some embodiments, the first and second nucleic acid sequences are separated by a cleavable adapter. In some embodiments, the cleavable adapter is a self-cleaving adapter. In some embodiments, the self-cleaving adapter is or comprises a 2A peptide.
[0301] In some implementations, the polynucleotide is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a DNA / RNA hybrid. The polynucleotide can be single-stranded or double-stranded and can be recombinant, synthetic, or isolated. Polynucleotides include, but are not limited to: pre-messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, genomic DNA (gDNA), PCR-amplified DNA, complementary DNA (cDNA), synthetic DNA, or recombinant DNA. A polynucleotide is defined as a polymer of at least 5, 10, 15, 20, 25, 30, 40, 50, 100, 200, 300, 400, 500, 1000, 5000, 10000, or 15000 or more nucleotides (in modified forms of ribonucleotides or deoxyribonucleotides or any type of nucleotide) and all intermediate lengths of nucleotide polymers. It will be easy to understand that, in this context, "intermediate length" means any length between the referenced values, such as 6, 7, 8, 9, etc.; 101, 102, 103, etc.; 151, 152, 153, etc.; 201, 202, 203, etc.
[0302] In some implementations, the polynucleotide is codon-optimized. As used herein, the term "codon-optimized" refers to replacing codons in a polynucleotide encoding a polypeptide to increase the expression, stability, and / or activity of said polypeptide. Factors influencing codon optimization include, but are not limited to, one or more of the following: (i) variations in codon bias between bias tables constructed from two or more organisms or genes or composites; (ii) variations in the degree of codon bias within an organism, gene, or gene set; (iii) systematic variations of codons, including context; (iv) variations of codons according to their decoding of tRNA; (v) variations of codons according to GC% (overall or at a position in a triplet); (vi) variations in the degree of similarity to a reference sequence (e.g., a naturally occurring sequence); (vii) variations in codon frequency cutoff values; (viii) structural characteristics of mRNA transcribed from a DNA sequence; (ix) prior knowledge of the function of the DNA sequence, upon which codon substitution sets are designed; (x) systematic variations in the codon set for each amino acid; (xi) isolated removal of pseudo-translation initiation sites; and / or (xii) elimination of irregular polyadenylation sites that would otherwise lead to truncated RNA transcripts.
[0303] Those skilled in the art will understand that, due to the degeneracy of the genetic code, there are many nucleotide sequences encoding polypeptides or variant fragments thereof as described herein. Some of these polynucleotides share minimal homology with the nucleotide sequence of any natural gene. Nevertheless, polynucleotides that vary due to differences in codon selection, such as polynucleotides optimized for codon selection in humans and / or primates, are specifically considered in particular embodiments. Furthermore, alleles of genes containing the polynucleotide sequences provided herein can also be used. An allele is an endogenous gene that is altered due to one or more mutations in nucleotides, such as deletions, additions, and / or substitutions.
[0304] In some embodiments, regardless of the length of the coding sequence itself, the polynucleotides provided herein further comprise other DNA sequences, such as promoters and / or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, internal ribosome entry sites (IRES), recombinase recognition sites (e.g., LoxP, FRT, and Att sites), stop codons, transcription termination signals, and polynucleotides encoding self-cleaving polypeptides, epitope tags, as disclosed elsewhere herein or as known in the art, such that their overall length can vary significantly. Therefore, it is contemplated that almost any length of polynucleotide fragment can be used in a particular embodiment, wherein the total length is preferably limited by ease of preparation and use in the planned recombinant DNA scheme.
[0305] Polynucleotides can be prepared, manipulated, and / or expressed using any of a variety of well-established techniques known and available in the art. IV. Carriers for delivering engineered cancer antigens
[0306] This article provides a vector containing any polynucleotide encoding any engineered cancer antigen disclosed herein.
[0307] This document also provides vectors containing polynucleotides encoding two or more engineered cancer antigens disclosed herein, such as engineered cancer antigens containing tumor-targeting molecules and engineered cancer antigens containing heterologous membrane-targeting domains.
[0308] This document also provides a vector comprising a first polynucleotide and a second polynucleotide, the first polynucleotide encoding an engineered cancer antigen (e.g., any of those disclosed in Section II.B.) comprising a target domain and a tumor-targeting molecule, and the second polynucleotide encoding an engineered cancer antigen (e.g., any of those disclosed in Section II.C.) comprising a target domain and a heteromembrane-targeting domain. In some embodiments, the first polynucleotide and the second polynucleotide are separated by a cleavable linker. In some embodiments, the cleavable linker comprises a 2A self-cleaving peptide.
[0309] In some implementations, the engineered cancer antigen is delivered by a viral vector containing a polynucleotide encoding the engineered cancer antigen, such as any polynucleotide disclosed in Section II.
[0310] To express the engineered cancer antigen and / or homology binder described herein in cells (e.g., tumor cells), an expression cassette encoding the engineered cancer antigen can be inserted into a nucleic acid vector. The “expression cassette” contains a target gene, which is the engineered cancer antigen. The position and sequence orientation of the cassette within the vector are such that the nucleic acid in the cassette can be transcribed into RNA in transformed cells and translated into a protein or peptide when needed, undergoing post-translational modifications required for activity, and translocating to the appropriate compartment for biological activity by targeting to the appropriate intracellular compartment or secreting into the extracellular compartment. Preferably, the 3' and 5' ends of the cassette are adjusted for ready insertion into the vector, for example, having restriction endonuclease sites at each end. The cassette can be removed and inserted as a single unit into a plasmid or viral vector.
[0311] The term "nucleic acid vector" is used herein to refer to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is typically linked to a vector nucleic acid molecule, for example, inserted into the vector nucleic acid molecule. Nucleic acid vectors may include sequences that guide autonomous replication within the cell, or sequences sufficient to allow integration into the host cell's DNA.
[0312] In some embodiments, the vector includes, but is not limited to, plasmids, phage particles, granules, transposons, artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC), bacteriophages (such as λ phage or M13 phage), and animal viruses. In some embodiments, the coding sequence of the engineered cancer antigen disclosed herein can be ligated into such vectors for expression in mammalian cells.
[0313] In some implementations, the vector is a viral vector or a non-viral vector.
[0314] In some embodiments, the vector is a non-viral vector. In some embodiments, the non-viral vector is used to deliver one or more polynucleotides contemplated herein. In some embodiments, the recombinant vector containing the polynucleotide encoding the engineered cancer antigens described herein is a plasmid. Many suitable plasmid expression vectors are known to those skilled in the art, and many are commercially available. The following vectors are provided by way of example for eukaryotic host cells: pXT1, pSG5 (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other plasmid vector may be used, provided it is compatible with the host cell.
[0315] In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is used to deliver one or more polynucleotides contemplated herein. Suitable viral vectors include, but are not limited to, those based on: vaccinia virus; poliovirus; adenovirus (see, for example, Li et al., Invest Opthalmol Vis Sci 35:25432549, 1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS 92:77007704, 1995; Sakamoto et al., H Gene Ther 5:1088 1097, 1999; WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655); adeno-associated virus (see, for example, U.S. Patent No. 7,078,387; Ali et al., Hum Gene Ther 9:81 86, 1998, Flannery et al., PNAS 94:6916 6921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38:2857 2863, 1997; Jomary et al., Gene Ther 4:683 690, 1997; Rolling et al., Hum Gene Ther 10:641 648, 1999; Ali et al., Hum Mol Genet 5:591 594, 1996; Srivastava, WO 93 / 09239; Samulski et al., J. Vir. (1989) 63:3822-3828; Mendelson et al., Virol. (1988) 166:154-165; and Flotte et al., PNAS (1993). 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus (see, for example, Miyoshi et al., PNAS 94:10319 23, 1997; Takahashi et al., J Virol 73:7812 7816, 1999); retroviral vectors (e.g., murine leukosis virus, spleen necrosis virus, and vectors derived from retroviruses such as: Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); etc.Examples of vectors are the pClneo vector (Promega) for expression in mammalian cells; and pLenti4 / V5-DEST™, pLenti6 / V5-DEST™, and pLenti6.2 / V5-GW / lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells.
[0316] In some embodiments, the vector is a non-integrating vector, including but not limited to episodic vectors or vectors maintained extrachromosomally. As used herein, the term "episodic" refers to a vector capable of replicating without integrating into the host's chromosomal DNA and not being gradually lost from dividing host cells; it also means that the vector replicates extrachromosomally or episodicly. The vector is engineered to contain a sequence encoding the origin of DNA replication or "ori" (specifically, the origin of replication of lymphotrophic herpesvirus or gamma herpesvirus corresponding to oriP of EBV) from lymphotrophic herpesvirus or gamma herpesvirus. In some embodiments, the lymphotrophic herpesvirus may be Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), saimiri herpesvirus (HS), or Marek's disease virus (MDV). EBV and Kaposi's sarcoma herpesvirus (KSHV) are also examples of gamma herpesviruses.
[0317] In some embodiments, the vector is an integrative vector. In some embodiments, a transposon vector system is used to introduce polynucleotides into target cells or host cells. In some embodiments, the transposon vector system comprises a vector containing a transposable element and the polynucleotide contemplated herein; and a transposase. In one embodiment, the transposon vector system is a single transposase vector system, see, for example, WO 2008 / 027384. Exemplary transposases include, but are not limited to: piggyBac, Sleeping Beauty, Mos1, Tc1 / mariner, Tol2, mini-Tol2, Tc3, MuA, Himar I, FrogPrince, and derivatives thereof. The piggyBac transposon and transposase are described, for example, in U.S. Patent 6,962,810, which is incorporated herein by reference in its entirety. The Sleeping Beauty transposon and transposase are described, for example, in Izsvak et al., J.Mol.Biol.302: 93-102 (2000), which is incorporated herein by reference in its entirety. The Tol2 transposon, originally isolated from the killifish (Oryzias latipes) and belonging to the hAT transposon family, is described in Kawakami et al. (2000). Mini-Tol2 is a variant of Tol2 and is described in Balciunas et al. (2006). When in conjunction with the Tol2 transposase, Tol2 and Mini-Tol2 transposons promote transgene integration into the genome of an organism. The FrogPrince transposon and transposase are described, for example, in Miskey et al., Nucleic Acids Res. 31:6873-6881 (2003).
[0318] In some embodiments, the polynucleotide sequence encoding the engineered cancer antigen disclosed herein is operatively linked to one or more control elements that allow the polynucleotide to be expressed in both prokaryotic and eukaryotic cells. “Control elements” refer to those untranslated regions of the vector that interact with host cell proteins for transcription and translation. Non-limiting examples of control elements include origins of replication, selection cassettes, constitutive and inducible promoters, enhancers, translation initiation signal (ShineDalgarno or Kozak sequence) introns, transcription terminators, and 5' and 3' untranslated regions. See, for example, Bitter et al. (1987) Methods in Enzymology, 153:516-544. The strength and specificity of such elements can vary. Transcriptional control elements can be functional in eukaryotic cells (e.g., mammalian cells) or prokaryotic cells (e.g., bacterial or archaea cells).
[0319] In some embodiments, a polynucleotide encoding the engineered cancer antigen described herein is operatively linked to a promoter and / or enhancer. As used herein, the term "promoter" refers to a recognition site of a polynucleotide (DNA or RNA) that RNA polymerase binds to. RNA polymerase initiates and transcribes the polynucleotide operatively linked to the promoter. In some embodiments, a promoter effective in mammalian cells comprises an AT-rich region located approximately 25 to 30 bases upstream of the transcription start site and / or another sequence, the CNCAAT region, found 70 to 80 bases upstream of the transcription start site, where N can be any nucleotide. The term "enhancer" refers to a DNA segment containing a sequence capable of providing enhanced transcription and, in some cases, functional independently of its orientation relative to another control sequence. Enhancers can function cooperatively or additively with promoters and / or other enhancer elements.
[0320] Non-limiting examples of suitable eukaryotic promoters (promoters that function in eukaryotic cells) include those derived from: cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, simian virus 40 (SV40) (e.g., early and late SV40), spleen lesion-forming virus (SFFV) promoters, long terminal repeat (LTR) sequences from retroviruses (e.g., Moloney mouse leukemia virus (MoMLV) LTR promoters or Rous sarcoma virus (RSV) LTR promoters), monoclonal antibodies, and other similar viruses. Herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5 and P11 promoters from vaccinia virus, elongation factor 1-α (EF1α) promoter, early growth response 1 (EGR1) promoter, ferritin H (FerH) promoter, ferritin L (FerL) promoter, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, eukaryotic translation initiation factor 4A1 (EIF4A1) promoter, heat shock protein 70kDa (HSPA5) promoter, heat shock protein 90kDa The following promoters are suitable: β-member 1 (HSP90B1) promoter, heat shock protein 70kDa (HSP70) promoter, β-kinin (β-KIN) promoter, human ROSA 26 locus (Irions et al., Nature Biotechnology 25, 1477-1482 (2007)), ubiquitin C (UBC) promoter, phosphoglycerate kinase-1 (PGK) promoter, cytomegalovirus enhancer / chicken β-actin (CAG) promoter, β-actin promoter and myeloproliferative sarcoma virus enhancer, dl587rev primer binding site-substituted (MND) promoter with negative control region deletion, and mouse metallothionein-1. The selection of appropriate vectors and promoters is entirely within the skill of a person skilled in the art.
[0321] In some embodiments, the polynucleotide sequence encoding the engineered cancer antigen described herein is operatively linked to a constitutive promoter. In such embodiments, the polynucleotide encoding the engineered cancer antigen described herein is constitutively and / or universally expressed in cells.
[0322] In some embodiments, a polynucleotide sequence encoding the engineered cancer antigen described herein is operatively linked to an inducible promoter. In such embodiments, the polynucleotide encoding the engineered cancer antigen described herein is conditionally expressed. As used herein, “conditional expression” can refer to any type of conditional expression, including but not limited to inducible expression; repressive expression; expression in cells or tissues with a specific physiological, biological, or disease state (e.g., cell type or tissue-specific expression), etc. Exemplary examples of inducible promoters / systems include, but are not limited to, steroid-inducible promoters (such as promoters of genes encoding glucocorticoids or estrogen receptors (which can be induced by treatment with the corresponding hormone)), metallothionein promoters (which can be induced by treatment with various heavy metals), MX-1 promoters (which can be induced by interferon), the “GeneSwitch” mifepristone regulatory system (Sirin et al., 2003, Gene, 323:67), cumate-inducible gene switches (WO 2002 / 088346), tetracycline-dependent regulatory systems, etc.
[0323] In some embodiments, the vector described herein further includes a transcription termination signal. Elements that guide the efficient termination and polyadenylation of heterologous nucleic acid transcripts increase heterologous gene expression. Transcription termination signals are typically found downstream of polyadenylation signals. In some embodiments, the vector contains a 3′ polyadenylated sequence of a polynucleotide encoding the polypeptide to be expressed. As used herein, the term "polyA site" or "polyA sequence" refers to a DNA sequence that guides both the termination and polyadenylation of nascent RNA transcripts via RNA polymerase II. Polyadenylation sequences can promote mRNA stability by adding a polyA tail to the 3′ end of the coding sequence, thereby promoting increased translation efficiency. Cleavage and polyadenylation are guided by a poly(A) sequence in the RNA. The core poly(A) sequence of mammalian premRNA has two recognition elements located flanking the cleavage-polyadenylation site. Typically, the nearly invariant AAUAAA hexamer is located 20–50 nucleotides upstream of a more variable element rich in U or GU residues. The cleavage of the newly generated transcript occurs between these two elements and is coupled with the addition of up to 250 adenosines to the 5' cleavage product. In some embodiments, the core poly(A) sequence is preferably a poly(A) sequence (e.g., AATAAA, ATTAAA, AGTAAA). In some embodiments, the poly(A) sequence is the SV40 poly(A) sequence, the bovine growth hormone poly(A) sequence (BGHpA), the rabbit β-globin poly(A) sequence (rβgpA), variants thereof, or another suitable heterologous or endogenous poly(A) sequence known in the art.
[0324] In some embodiments, the vector may further comprise a sequence encoding a signal peptide (e.g., for nuclear, nucleolar, or mitochondrial localization), said sequence fused to a polynucleotide encoding an engineered cancer antigen or homologous binder. For example, the vector may comprise a nuclear localization sequence (e.g., from SV40) fused to a polynucleotide encoding an engineered cancer antigen or homologous binder. In some embodiments, the signal peptide is an IgK signal peptide. In some embodiments, the signal peptide is a CD8 signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 64. In some embodiments, the signal peptide comprises the nucleic acid sequence of SEQ ID NO: 12.
[0325] In some embodiments, the expression vector further comprises a nucleotide sequence encoding one or more protein tags (e.g., a 6xHis tag (SEQ ID NO: 111), a hemagglutinin tag, green fluorescent protein, etc.), said nucleotide sequence being fused with a polynucleotide encoding an engineered cancer antigen to obtain an engineered cancer antigen further comprising a protein tag.
[0326] Methods for introducing polynucleotides and recombinant vectors into host cells are known in the art. Suitable methods include, for example, viral or bacteriophage infection, transfection, conjugation, protoplast fusion, liposome transfection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery (see, for example, Panyam et al., Adv DrugDeliv Rev. 2012 Sep 13. pii: S0169-409X(12)00283-9), microfluidic delivery methods (see, for example, International PCT Publication No. WO 2013 / 059343), etc.
[0327] In some embodiments, delivery via electroporation involves mixing cells with a polynucleotide encoding an engineered cancer antigen or homologous binder in a cylinder, chamber, or cuvette, and applying one or more electrical pulses of defined duration and amplitude. In some embodiments, cells are mixed with a polynucleotide encoding an engineered cancer antigen or homologous binder in a vessel connected to a device (e.g., a pump) that feeds the mixture into a cylinder, chamber, or cuvette, where one or more electrical pulses of defined duration and amplitude are applied, followed by delivery of the cells to a second vessel. Illustrative examples of polynucleotide delivery systems suitable for the particular embodiments envisioned include, but are not limited to, those provided by Amaxa Biosystems, Maxcyte, Inc., BTX Molecular Delivery Systems, Neon™ Transfection Systems, and Copernicus Therapeutics Inc. Liposome transfection reagents are commercially available (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids suitable for efficient liposome transfection of polynucleotides have been described in the literature. See, for example, Liu et al. (2003) Gene Therapy. 10:180-187; and Balazs et al. (2011) Journal of Drug Delivery. 2011:1-12.
[0328] In some embodiments, a polynucleotide encoding the engineered cancer antigen described herein is introduced into the cell in a non-viral delivery medium, such as a transposon, nanoparticle (e.g., lipid nanoparticles), liposome, exosome, attenuated bacteria, or virus-like particles. In some embodiments, the medium is attenuated bacteria (e.g., naturally or artificially engineered to be invasive, but attenuated to prevent pathogenicity, including Listeria monocytogenes, certain Salmonella strains, Bifidobacterium longum, and modified Escherichia coli), bacteria with nutritional and tissue-specific tropism for target-specific cells, and bacteria with modified surface proteins to alter target cell specificity. In some embodiments, the medium is a genetically modified bacteriophage (e.g., an engineered bacteriophage with large packaging capacity, low immunogenicity, containing mammalian plasmid maintenance sequences, and having incorporated targeting ligands). In some embodiments, the medium is a bio-liposome. For example, bioliposomes are phospholipid-based particles derived from human cells (e.g., erythrocyte shadows, which are derived from red blood cells broken down into spherical structures by the subject, and in which tissue targeting can be achieved by attaching various tissue or cell-specific ligands), secretory exosomes, or membrane-bound nanovesicles (30-100 nm) derived from the subject's endocytosis (e.g., which can be produced by various cell types and thus can be absorbed by cells without the need for targeting ligands).
[0329] In some embodiments, a vector containing a polynucleotide encoding an engineered cancer antigen as described herein is introduced into cells via viral delivery methods (e.g., via viral transduction). Various virus-based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Heterologous nucleic acids can be inserted into vectors and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered in vitro or ex vivo to engineered mammalian cells. Various retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Various adenoviral vectors are known in the art. In some embodiments, lentiviral vectors are used. In some embodiments, self-inactivated lentiviral vectors are used. For example, self-inactivated lentiviral vectors carrying sequences encoding immunomodulators (such as immune checkpoint inhibitors) and / or self-inactivated lentiviral vectors carrying chimeric antigen receptors can be packaged using methods known in the art. The resulting lentiviral vectors can be used to transduce mammalian cells (such as primary human T cells) using methods known in the art. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they allow for the long-term stable integration of transgenes and their dissemination in progeny cells. Lentiviral vectors also exhibit low immunogenicity and can transduce non-proliferating cells.
[0330] In some implementations, the medium is a mammalian virus-like particle. For example, modified viral particles can be generated (e.g., by purifying “empty” particles and then assembling the virus with the desired cargo in vitro). The medium can also be engineered to incorporate a targeting ligand, thereby altering the specificity of the target tissue. A. Tumor-attracting viral vectors
[0331] In some implementations, engineered cancer antigens are delivered via vectors that are viral vectors exhibiting tumor tropism.
[0332] Therefore, in some embodiments, the vector containing the polynucleotide encoding the engineered cancer antigen is a viral vector that is tactile to tumor cells, i.e., a tumor-tactile viral vector. By having tactile affinity for tumor cells, the viral vector is able to deliver the polynucleotide encoding the engineered cancer antigen to the targeted tumor cells (e.g., tumor cells of a subject's cancer).
[0333] In some embodiments, the viral vector is a non-replicating viral vector, for example, a replication-defective one. In some embodiments, the viral vector is a replication-defective adenovirus vector that lacks the E1A gene, which is essential for adenovirus replication.
[0334] In some implementations, the viral vector is a replicating viral vector.
[0335] In some embodiments, the viral vector is a viral vector or a modified form of a viral vector, as disclosed in, for example, the following applications: WO2005 / 118825, WO2015 / 097220, WO2015 / 059303, WO2015 / 155370, WO2016 / 174200, WO2017 / 103291, WO2018 / 041838, WO2018 / 041827, WO2017 / 103290, WO2018 / 220207, WO2019 / 043020, WO2022 / 171853, the contents of which are incorporated herein by reference in their entirety.
[0336] In some implementations, the viral vector is an adenovirus vector, an adeno-associated virus (AAV) vector, a lentiviral vector, a retroviral vector, or a herpes simplex virus (HSV) vector.
[0337] Exemplary adenovirus vectors, AAV vectors, and lentiviral vectors, among others, are described, for example, in Bezeljak, Radiol Oncol., 2022, 56(1): 1-13. Exemplary adenovirus vectors include those disclosed, for example, in the following literature: Engelhardt et al., Hum Gene Ther 5.1217-1229, 1994; US 5,756,283; US 5,707,618; Tessarollo et al., Cancers (Basel), 2021, 13(8): 1863; Wold et al., Curr.Gene Ther., 2013, 13(6): 421-433; and WO 2014198852 A2. More than 50 known human adenovirus serotypes exist, including Ad2, Ad3, Ad5, Ad7, Ad9, Ad11, Ad12, Ad17, and Ad40.
[0338] In some embodiments, the viral vector is an adenovirus vector. In some embodiments, the viral vector is a non-replicating adenovirus vector such as any of those described in the following literature: Tessarollo et al., ibid.; and Wold et al., ibid. Adenoviruses are non-enveloped viruses that have a single linear strand of double-stranded DNA inside an icosahedral capsid.
[0339] Animal-derived adenoviruses can be obtained from preserved strains, amplified in competent cell lines, and optionally modified as needed. The complete genome sequences of adenoviruses have been determined for, for example, the following: human adenovirus type 2 (GenBank accession number J01917); human adenovirus type 5 (GenBank accession number M73260; and GenBank accession number NC). — 001406), Human adenovirus type 12 (GenBank accession number NC) — 001460, X73487); Human adenovirus type 17 (GenBank accession number NC) — 002067, AF108105); and human adenovirus type 40 (GenBank accession number L19443). Techniques for generating, isolating, and modifying adenoviruses have been described in the literature. See, for example, Akli et al., Nature Genetics 3 (1993) 224; Stratford-Perricaudet et al., Human Gene Therapy 1 (1990) 241; EP 185 573; Levrero et al., Gene 101 (1991) 195; Le Gal la Salle et al., Science 259 (1993) 988; Roemer and Friedmann, Eur. J. Biochem. 208 (1992) 211; Dobson et al., Neuron 5 (1990) 353; Chiocca et al., New Biol. 2 (1990) 739; Miyanohara et al., New Biol. 4 (1992) 238; WO 91 / 18088, WO 90 / 09441; WO 88 / 10311; and WO 91 / 11525. These adenoviruses can be modified, for example, by deletion, addition, and / or substitution.
[0340] In some embodiments, the adenovirus vector belongs to any of subgroups AG. In some embodiments, the adenovirus vector belongs to subgroup A. In some embodiments, the adenovirus vector belongs to subgroup B. In some embodiments, the adenovirus vector belongs to subgroup B, type 1. In some embodiments, the adenovirus vector belongs to subgroup B, type 2. In some embodiments, the adenovirus vector belongs to subgroup C. In some embodiments, the adenovirus vector belongs to subgroup D. In some embodiments, the adenovirus vector belongs to subgroup E. In some embodiments, the adenovirus vector belongs to subgroup F. In some embodiments, the adenovirus vector belongs to subgroup G.
[0341] Subgroup A adenoviruses include, for example, serotypes 12, 18, and 31; subgroup B, type 1 adenoviruses include, for example, serotypes 3, 7, 16, and 21; subgroup B, type 2 adenoviruses include, for example, serotypes 11, 14, 34, and 35; subgroup C adenoviruses include, for example, serotypes 1, 2, 5, and 6; subgroup D adenoviruses include, for example, serotypes 8–10, 13, 15, 17, 19, 20, 22–30, 32, 33, 36–39, and 42–49; subgroup E adenoviruses include, for example, serotype 4; subgroup F adenoviruses include, for example, serotypes 40 and 41; and subgroup G adenoviruses include, for example, serotype 52. See, for example, Ghebremedhin, Eur. J. Microbiol. Immunol., 2014, 4(1): 26–33.
[0342] Most adenoviruses (e.g., those in subgroups A, C, D, E, and F) enter target cells primarily by binding to the Coxsackievirus receptor. However, generally, adenoviruses in subgroup B, type 1 bind primarily to CD46, and generally, adenoviruses in subgroup B, type 2 bind primarily to desmosome mucin-2, with some exceptions. Ad11, Ad14, Ad16, Ad21, Ad35, and Ad50 of subgroup B bind to CD46, as do Ad17 and Ad47 of subgroup D. Ad3, Ad7, and Ad14 of subgroup B bind to desmosome mucin-2. See, for example, Hensen et al., Int. J. Mol. Sci., 2020, 21(18): 6828.
[0343] The level of the Coxsackievirus-Adenovirus receptor varies by tissue and tumor type, and can be upregulated or downregulated in tumor cells, depending on the cancer type. See, for example, Hensen et al., ibid.
[0344] All nucleated cells express CD46, making adenoviruses from subgroup B,1 desirable due to their broad tropism. Furthermore, CD46 expression has been reported to be low or intermediate in most normal tissues, but upregulated in many different types of cancer, making adenoviruses that primarily bind CD46 (e.g., Ad11, Ad14, Ad16, Ad17, Ad21, Ad35, Ad47, and Ad50) desirable for use in delivering engineered cancer antigens to tumor cells. See, for example, Do et al., Int. J. Mol. Sci., 2018, 19: 2694; Su et al., JCI Insight, 2018, 3: e121497; and Hensen et al., ibid.
[0345] Desmosome mucin-2 is a transmembrane glycoprotein expressed in multiple tissue types, including the bladder, colon, kidney, prostate, and stomach, and, like CD46, has been reported to be upregulated in cancer. See, for example, Hensen et al., ibid.; and Brennan et al., Cell Adhes. Migr., 2009, 3: 148-154. Therefore, adenoviruses that primarily bind to desmosome mucin-2, like those that primarily bind to CD46 (such as Ad3, Ad7, and Ad14), are desirable for use in delivering engineered cancer antigens to tumor cells.
[0346] Therefore, in some embodiments, the viral vector (e.g., an adenovirus vector) binds to CD46 and / or desmosome mucin-2. In some embodiments, the viral vector binding to CD46 and / or desmosome mucin-2 is Ad3, Ad7, Ad11, Ad14, Ad16, Ad17, Ad21, Ad35, Ad47, or Ad50.
[0347] In some embodiments, the adenovirus vector is based on Ad3, Ad7, Ad11, Ad14, Ad16, Ad17, Ad21, Ad35, Ad47, and Ad50, or any combination thereof. In some embodiments, the adenovirus vector is based on Ad2. In some embodiments, the adenovirus vector is based on Ad3. In some embodiments, the adenovirus vector is based on Ad5. In some embodiments, the adenovirus vector is based on Ad7. In some embodiments, the adenovirus vector is based on Ad9. In some embodiments, the adenovirus vector is based on Ad11. In some embodiments, Ad11 is Ad11p. In some embodiments, the adenovirus vector is based on Ad12. In some embodiments, the adenovirus vector is based on Ad14. In some embodiments, the adenovirus vector is based on Ad17. In some embodiments, the adenovirus vector is based on Ad35. In some embodiments, the adenovirus vector is based on Ad40. In some embodiments, the adenovirus vector is based on Ad50.
[0348] In some embodiments, the adenovirus vector is a chimeric virus based on any two or more adenovirus serotypes. When the adenovirus is chimeric, the serotype is determined by the characteristics of the outer capsid. As used herein, chimeric refers to a virus containing DNA from at least two different viral serotypes (including different serotypes within the same group). In some embodiments, the adenovirus vector is a chimeric virus based on serotype 3 (Ad3) and / or serotype 5 (Ad5) adenovirus vectors. In some embodiments, the adenovirus vector is a chimeric virus based on serotype 3 (Ad3) and / or serotype 11 (Ad11) adenovirus vectors.
[0349] In some embodiments, the adenovirus vector is Ad5. In some embodiments, the adenovirus vector is Ad5 or a variant or derivative thereof. Ad5 adenovirus vectors typically enter cells via the Coxsackievirus receptor.
[0350] In some implementations, the adenovirus is a chimeric adenovirus. In some implementations, the chimeric adenovirus is Ad3 / 11p or Ad5 / 3.
[0351] In some embodiments, the adenovirus vector is Ad3 / 11p, which is a chimeric adenovirus complex of Ad3 and Ad11p. In some embodiments, Ad3 / 11p is referred to as ColoAd1 (also known as "enadenotucirev"). ColoAd1 is a chimeric adenovirus in which the major coating protein is derived from Ad11p and, relative to Ad11, includes a nearly complete 2444-base-pair deletion of the E3 gene, a smaller 25-base-pair deletion of the E4 gene region, and a chimeric Ad3 / Ad11pm E3B gene region. See Kuhn et al., PLoS ONE, 2008, 3: e2409; WO 2014198852 A2; US8765463. In particular, ColoAd1 has a chimeric E2B region characterized by DNA derived from Ad11p and Ad3, and deletions in E3 / E4. The structural changes result in a genome that is approximately 3.5 kb smaller than Ad11p, thereby providing space for transgene insertion. In addition, ColoAd1 is a replicating oncolytic chimeric adenovirus with enhanced properties compared to wild-type adenoviruses, see, for example, WO2005 / 118825. Ad11 adenoviruses typically enter cells via the CD46 receptor, which is expressed at low levels in all nucleated cells but typically exhibits increased surface expression in tumor cells, thus preferentially infecting tumor cells. Ad3 and Ad11p are both subgroups of B adenoviruses (B1 and B2, respectively). Chimeric adenoviruses (such as Ad3 / 11p) are often generated using a method called “directed evolution,” as described, for example, by Kuhn et al., ibid., in which a library of Ad serotypes representing different Ad subgroups is passaged in human tumor cell lines representing major solid tumor indications (e.g., breast cancer, colon cancer, pancreatic cancer, or prostate cancer) to induce recombination and selection of potent viral variants or serotypes.
[0352] In some implementations, the Ad3 / 11p viral vector is ColoAd1. See, for example, Kuhn et al., ibid.; US8765463; and WO2005 / 118825. ColoAd1 has the nucleic acid sequence of SEQ ID NO: 13.
[0353] In some embodiments, the adenovirus vector is Ad5 / 3, as described in, for example, the following literature: Hemminki et al., Oncotarget, 2015, 6: 4467-81; and Safar et al., Cancer Gene Therapy, 2021, 28:442-454. The Ad5 / 3 chimeric adenovirus vector includes a serotype 3 fiber knob in the Ad5 capsid, thereby utilizing the Ad3 receptor (desmosome-2) which is highly expressed in advanced tumors. In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the AAV is any serotype of AAV, such as AAV1, AAV2, AAV3, or AAV4. In some embodiments, the AAV is AAV1. In some embodiments, the AAV is AAV2. In some embodiments, the AAV is AAV3. In some embodiments, the AAV is AAV4.
[0354] The genome of AAV has been determined. For example, the genome sequence of AAV2 is provided in GenBank accession number J01901 and GenBank accession number NC_001401.
[0355] In some embodiments, the viral vector is an oncolytic virus or exhibits oncolytic activity. Oncolytic viruses can infect and kill cancer cells. Oncolytic viruses can be, but are not limited to, adenoviruses, herpes simplex virus (HSV), parvoviruses, and poxviruses (such as vaccinia virus (VACV) and myxoma virus (MYXV)). In some embodiments, the oncolytic virus is selected from adenoviruses, herpes simplex virus, vaccinia virus, mumps virus, Newcastle disease virus, poliovirus, Seneca Valley virus, measles virus, Sindebes virus, parvovirus, Coxsackie virus, vesicular stomatitis virus, reovirus, and Malaba rhabdovirus. In some embodiments, the viral vector exhibits weak oncolytic activity.
[0356] In some embodiments, the viral vector comprises a tumor-specific promoter element that promotes increased expression of the engineered antigen tag when expressed in tumor cells or tumor cells of a specific cancer type, compared to expression of the encoded engineered antigen tag in non-tumor cells (e.g., normal non-cancer cells of the same cell or tissue type as tumor cells). In some embodiments, the tumor-specific promoter element is a STAT3 promoter, a survival protein promoter, a cyclooxygenase-2 (COX-2) promoter, a prostate-specific antigen (PSA) promoter, a CXCR4 promoter, or any other promoter that increases expression in tumor cells compared to normal cells of the same cell or tissue type. Examples of tumor-specific promoter elements and methods for modifying viral vectors to include said tumor-specific promoter elements can be found, for example, in US20190275093A1.
[0357] Determining the insertion site for the transgene within the oncolytic vector is within the skill of a skilled technician. Typically, the insert (such as a sequence encoding the transgene (e.g., an engineered cancer antigen)) is inserted into a non-coding region (such as an intron or intergenic sequence) of the viral genomic DNA. In some embodiments, the transgene is controlled by a promoter.
[0358] For example, regarding adenoviruses (including chimeric adenoviruses such as ColoAd1), the regions used for insertion include the L5 region, such as between the L5 and E4 regions.
[0359] In some implementations, the adenovirus (including chimeric adenoviruses such as ColoAd1) comprises the structural elements of an adenovirus as described in WO2018 / 041838 (which is incorporated herein by reference), including those represented by formulas (I), (Ia), I(b), I(c), or I(e), but wherein the transgene encodes an engineered cancer antigen as described herein.
[0360] In some embodiments, the transgenic adenovirus (including chimeric adenoviruses such as ColoAd1) has a sequence containing the following formula (I): 5' ITR-B1-B A -B2-B X -B B -B Y -B3-3' ITR.
[0361] In this implementation, the inverted terminal repeat (ITR) sequence is common to all known adenoviruses and is so named because of its symmetry, and is the origin of viral chromosome replication. Another characteristic of these sequences is their ability to form hairpins. As used herein, 5'ITR refers to part or all of the ITR from the 5' end of the adenovirus, which retains the function of the ITR when incorporated into the appropriate position within the adenovirus. In one implementation, the 5'ITR comprises about 1 bp to 138 bp of the sequence of SEQ ID NO: 13 or a sequence that is 90%, 95%, 96%, 97%, 98%, or 99% identical along its entire length to or composed of the sequence of SEQ ID NO: 13, particularly a sequence comprising about 1 bp to 138 bp of SEQ ID NO: 13. In some implementations, the 3'ITR of the adenovirus refers to part or all of the ITR from the 3' end of the adenovirus, which retains the function of the ITR when incorporated into the appropriate position within the adenovirus. In one embodiment, the 3'ITR comprises or consists of a sequence of about 32189 bp to 32326 bp of SEQ ID NO: 13 or a sequence that is 90%, 95%, 96%, 97%, 98% or 99% identical to or constitutes the sequence of SEQ ID NO: 13 along its entire length, particularly a sequence consisting of about 32189 bp to 32326 bp of SEQ ID NO: 13.
[0362] In an embodiment of formula (I), B1 is a bond or contains E1A, E1B, or E1A-E1B. In some embodiments, as used herein, B1 refers to a DNA sequence encoding: part or all of the E1A region from the adenovirus, part or all of the E18 region of the adenovirus, and part or all of the E1A and E1B regions of the adenovirus independently. When B1 is a bond, the E1A and E1B sequences are omitted from the virus. In one embodiment, B1 is a bond, and therefore the virus is a vector.
[0363] In one embodiment, B1 further comprises a transgene. It is known in the art that the B1 region can accommodate a transgene that can be inserted in a destructive manner into the E1 region (i.e., in the "middle" of the sequence), or that part or all of the E1 region can be deleted to provide more space to accommodate genetic material.
[0364] As used in this article, ElA refers to part or all of the DNA sequence encoding the ElA region of adenoviruses. Here, the latter refers to the polypeptide / protein ElA. It can be mutated, resulting in conserved or non-conserved amino acid changes in the protein encoded by the ElA gene, giving it: the same function as the wild-type (i.e., the corresponding non-mutated protein); increased function compared to the wild-type protein; decreased function compared to the wild-type protein, such as no function; or a new function or, as appropriate, a combination of new and new functions compared to the wild-type protein.
[0365] As used in this article, E1B refers to part or all of the DNA sequence encoding the E1B region (i.e., polypeptide or protein) of an adenovirus. It can be mutated to give the protein encoded by the E18 gene / region a conserved or non-conserved amino acid change, giving it: the same function as the wild type (i.e., the corresponding non-mutated protein); increased function compared to the wild type protein; decreased function compared to the wild type protein, such as no function; or new function compared to the wild type protein, or a combination of new functions as appropriate.
[0366] Therefore, B1 can be modified or unmodified relative to the wild-type E1 region (such as wild-type E1A and / or E1B). A technician can easily identify the presence, (partial) deletion, or mutation of E1A and / or E18.
[0367] In one embodiment, B1 has a sequence from 139 bp to 3932 bp of SEQ ID NO: 13.
[0368] In the implementation of formula (I), as used herein, B A This refers to a DNA sequence encoding the E2B-L1-L2-L3-E2A-L4 region, including any non-coding sequence (as appropriate). Typically, this sequence will not contain transgenes. In one embodiment, the sequence is substantially similar to or identical to a sequential sequence from a known adenovirus (e.g., serotypes of group B viruses, such as Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad35, Ad51, or combinations thereof, such as Ad3, Ad11, or combinations thereof). In one embodiment, E2B-L1-L2-L3-E2A-L4 refers to a sequence containing these elements and other structural elements associated with said region, such as those from group B viruses. A Typically, the sequence containing the encoding protein IV2a will be included, for example: IV2A IV2a-E2B-L1-L2-L3-E2A-L4.
[0369] In one embodiment, the E2B region is chimeric. That is, it contains DNA sequences from two or more different adenovirus serotypes (e.g., from Ad3 and Ad11, such as Ad11p). In one embodiment, the E2B region has a sequence from 5068 bp to 10355 bp of SEQ ID NO: 13 or a sequence that is 95%, 96%, 97%, 98%, or 99% identical in length to SEQ ID NO: 13.
[0370] In one implementation, B A A sequence from 3933 bp to 27184 bp with SEQ ID NO: 13.
[0371] As used in this article, E3 refers to part or all of the DNA sequence encoding the E3 region (i.e., protein or polypeptide) of an adenovirus. It can be mutated to give the protein encoded by the E3 gene conserved or non-conserved amino acid changes, giving it: the same function as the wild type (the corresponding non-mutated protein); increased function compared to the wild type protein; decreased function compared to the wild type protein, such as no function; or new function or, as appropriate, a combination of new and new functions compared to the wild type protein.
[0372] In one implementation, the E3 region is derived from an adenovirus serotype, particularly group B serotypes, such as Ad3, Ad7, Ad11 (especially Ad11p), Ad14, Ad16, Ad21, Ad34, Ad35, Ad5l, or combinations thereof, such as Ad3, Ad11 (especially Ad11p), or combinations thereof.
[0373] In one implementation, the E3 region is partially deleted, for example, by 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%. In one implementation, B2 of formula (I) is a bond in which the DNA encoding the E3 region is absent.
[0374] In one implementation, the DNA encoding the E3 region may be genetically replaced or interrupted. As used herein, “E3 region genetically replaced” includes partial or complete genetic replacement of the E3 region.
[0375] In one embodiment, region B2 comprises the sequence from 27185 bp to 28165 bp of SEQ ID NO: 13. In another embodiment, region B2 consists of the sequence from 27185 bp to 28165 bp of SEQ ID NO: 13.
[0376] In the implementation of equation (I), Bx as used herein refers to B B The DNA sequence near the 5' end of the L5 gene. As used herein, "near" or "close to" the 5' end of the L5 gene means adjacent to (contiguous to) the 5' end of the L5 gene or its inherently associated non-coding region, i.e., adjacent to or contiguous to the 5' end of the L5 gene or its inherently associated non-coding region. Alternatively, "near" or "close to" can mean close to the L5 gene such that there is no coding sequence between the Bx region and the 5' end of the L5 gene.
[0377] Therefore, in one implementation, Bx is directly linked to the base of L5 that represents the starting point of the coding sequence of, for example, the L5 gene.
[0378] Therefore, in one implementation, Bx is directly linked to a base representing, for example, the start of a non-coding sequence of L5, or directly linked to a non-coding region naturally associated with L5. As used herein, a non-coding region naturally associated with L5 refers to part or all of a non-coding region that is a part of the L5 gene, or a part of a non-coding region adjacent to the L5 gene but not a part of another gene.
[0379] In one embodiment, Bx has a sequence from 28166 bp to 28366 bp of SEQ ID NO: 13. One or more inserts may be present at any position at the 5' end, 3' end, or at any point between bp 1 and 201 of the sequence (corresponding to 28166 bp to 28366 bp of SEQ ID NO: 13). In one embodiment, Bx has a DNA sequence inserted between positions corresponding to positions 28192 bp and 28193 bp of SEQ ID NO: 13.
[0380] In one implementation, Bx is a key.
[0381] This sequence is an artificial non-coding sequence into which a DNA sequence (e.g., containing a transgene (or transgene cassette), restriction site, or a combination thereof) can be inserted. This sequence is advantageous because it acts as a buffer, allowing for some flexibility in the exact location of the transgene while minimizing destructive effects on viral stability and viability.
[0382] In the implementation of formula (I), as used herein, B B This refers to the DNA sequence encoding the L5 region. As used herein, the L5 region refers to a DNA sequence containing, depending on the context, a gene encoding a fibrin polypeptide / protein. The fibrin gene / region encodes fibrin, a major capsid component of adenoviruses. Fibrin plays a role in receptor recognition and contributes to the adenovirus's ability to selectively bind and infect cells.
[0383] In the viruses of this disclosure, the fibers can originate from any adenovirus serotype, and this disclosure also envisions chimeric adenoviruses resulting from altering the fibers to fibers of different serotypes. In one embodiment, the fibers originate from group B viruses, particularly Ad 11, such as Ad11p.
[0384] In one implementation, B B A sequence from 28367 bp to 29344 bp with SEQ ID NO: 13.
[0385] As used in this article, B in equation (I) Y The relevant DNA sequence refers to B B The DNA sequence near the 3' end of the L5 gene. As used herein, "near or adjacent to the 3' end of the L5 gene" means adjacent to (contiguous to) the 3' end of the L5 gene or its inherently associated non-coding region, i.e., adjacent to or contiguous to the 3' end of the L5 gene or its inherently associated non-coding region (i.e., all or part of the endogenous non-coding sequence of L5). Alternatively, "near or adjacent to the L5 gene" can mean close to the L5 gene, such that in B... Y There is no coding sequence between the region and the 3' end of the L5 gene.
[0386] Therefore, in one implementation, B Y The bases that are directly connected to the "endpoint" of the L5 coding sequence.
[0387] Therefore, in one implementation, B Y The bases that are directly linked to the "endpoint" of the non-coding sequence of L5, or directly linked to the non-coding region that is naturally associated with L5.
[0388] In one implementation, B Y The sequence having SEQ ID NO: 13, from 29345 bp to 29379 bp. This sequence is a non-coding sequence in which DNA sequences (e.g., containing transgenes (or transgene cassettes), restriction sites, or combinations thereof) can be inserted. This sequence is advantageous because it acts as a buffer, allowing for some flexibility in the exact location of the transgene while minimizing destructive effects on viral stability and viability. One or more inserts may be present at any position within the 5' end, 3' end, or at any point between bp 1 and 35 of the sequence of SEQ ID NO: 13, from 29345 bp to 29379 bp. In one embodiment, B YThe device has a DNA sequence inserted between positions 29356 bp and 29357 bp corresponding to SEQ ID NO: 13. In one embodiment, the insert is located at approximately position 29356 bp of SEQ ID NO: 13. In one embodiment, the insert is a restriction site insert. In one embodiment, the insert is a transgene cassette containing one or more transgenes (such as engineered cancer antigens described herein). In some embodiments, the transgenes are under the control of a promoter.
[0389] As used herein, the term "insertion" refers to a DNA sequence incorporated at the 5' end, 3' end, or within a given DNA sequence reference region, such that it interrupts the reference sequence. The reference sequence serves as a reference point relative to which the insert is positioned. The insert can be a restriction site insert, a transgenic cassette, or both. In the context of this disclosure, the insert is typically present near or after position 29356 bp corresponding to SEQ ID NO: 13, or within the sequence between positions 28192 bp and 28193 bp of SEQ ID NO: 13. When the sequence is interrupted, the virus will still contain the original sequence, but it will typically act as two fragments clamping the insert.
[0390] In an embodiment of equation (I), B3 is a sequence of partially missing E4 regions. In some embodiments, B3 is a key, i.e., where E4 is absent.
[0391] As used in this article, E4 refers to part or all of the DNA sequence encoding the E4 region (i.e., the polypeptide / protein region) of an adenovirus. It can be mutated to give the protein encoded by the E4 gene conserved or non-conserved amino acid changes (e.g., changes, additions, and / or deletions of 1, 2, 3, 4, or 5 amino acids) and the following functions: the same as the wild-type (corresponding non-mutated protein); increased function compared to the wild-type protein; decreased function compared to the wild-type protein, such as no function; or new function or, as appropriate, a combination of new and new functions compared to the wild-type protein.
[0392] In one embodiment, the E4 region is partially deleted, for example, by 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%. In one embodiment, the E4 region has the sequence from 32188 bp to 29380 bp of SEQ ID NO: 13.
[0393] In one implementation, E4 is present, but the E4orf4 region is missing.
[0394] In one implementation, B3 is a key, meaning that E4 does not exist.
[0395] In one embodiment, B3 has a sequence consisting of SEQ ID NO: 13 from 32188 bp to 29380 bp.
[0396] The L5-associated sites identified in this paper (e.g., between the L5 and E4 regions) are suitable for accommodating transgenic sequences, such as engineered cancer antigens as described herein. In some embodiments, the transgene is under the control of a promoter.
[0397] In some embodiments, this document provides a replication-defective or replication-capable oncolytic adenovirus comprising a transgenic cassette encoding any engineered cancer antigen described herein, located between the viral fibrillation gene L5 and the viral E4 gene, and wherein said transgenic gene is under the control of a promoter. In some embodiments, the virus is a group B adenovirus, such as Ad11. In some embodiments, the virus is a chimeric virus, such as a virus comprising a modified E2B region. In some embodiments, the virus is ColAd11 (enadenotucirev).
[0398] In some embodiments, the promoter is endogenous to the virus. Therefore, as used herein, an endogenous promoter refers to a promoter that is naturally present in the adenovirus (or construct) in which the transgene is inserted (i.e., is natural to the adenovirus). In one or more embodiments, the endogenous promoter used is a promoter naturally present in the virus, located at its original position in the viral genome, specifically the primary or sole promoter used in the expression of one or more transgenes. In one embodiment, the endogenous promoter used to promote the translation and optionally transcription of the transgene is a resident promoter, i.e., a promoter integrated into the adenovirus genome and not pre-introduced by recombination technology.
[0399] As used in this article, "under the control of an endogenous promoter" refers to the situation where the transgene / transgene cassette is inserted in an appropriate orientation to be under the control of an endogenous promoter. That is, in cases where the promoter is normally on the antisense strand, for example, the cassette is inserted in an antisense orientation.
[0400] That said, genes can be expressed in one of two orientations. However, for a given (specific) transgene, one orientation typically provides an increased expression level relative to the other. In one implementation, the cassette is in a sense orientation, that is, transcribed in the 5' to 3' direction. In another implementation, the cassette is in an antisense orientation, that is, transcribed in the 3' to 5' direction.
[0401] In one implementation, one or more transgenes or transgene cassettes are under the control of an E4 promoter or a major late promoter (such as a major late promoter (ML promoter)). As used herein, "under the control of" means that the transgene is activated, i.e., transcribed, when regulated by a particular promoter.
[0402] In some implementations, the promoter is an MLP. As used herein, the major late promoter (ML promoter or MLP) refers to the adenovirus promoter that controls the expression of "late-expressed" genes (such as the L5 gene). An MLP is a "sense strand" promoter; that is, the promoter affects genes located downstream of the promoter in the 5'-3' direction. As used herein, the major late promoter refers to the original major late promoter located within the viral genome.
[0403] In some implementations, the promoter is the E4 promoter. As used herein, the E4 promoter refers to the adenoviral promoter in the E4 region. The E4 region is an antisense region; therefore, the promoter is an antisense promoter. That is, the promoter is located upstream of the E4 region in the 3'-5' direction. Therefore, any transgenic cassette under the control of the E4 promoter may require appropriate orientation. In one implementation, the cassette under the control of the E4 promoter is in an antisense orientation. In another implementation, the cassette under the control of the E4 promoter is in a sense orientation. As used herein, the E4 promoter refers to the original E4 promoter located in the viral genome.
[0404] Therefore, in one embodiment, a replicable oncolytic adenovirus serotype 11 (e.g., Ad11p) or a viral derivative thereof is provided, wherein the fibrils, hexapods, and capsid are serotype 11 (e.g., Ad11p), wherein the viral genome contains a transgene (DNA sequence) encoding any provided engineered cancer antigen, wherein the DNA sequence is under the control of a promoter selected from E4 and major late promoters (i.e., the E4 promoter or the major late promoter) that is endogenous to the adenovirus, such that the transgene does not interfere with viral replication, for example, associated with the L5 region (i.e., located before or after the region), such as after L5 in the viral genome, particularly between the L5 region and the E4 region.
[0405] In one implementation, the transgene cassette contains a foreign promoter. As used herein, a foreign promoter refers to a promoter that is not naturally present in the adenovirus into which the transgene is inserted. Typically, foreign promoters are derived from other viruses or mammalian promoters. As used herein, a foreign promoter refers to a DNA element that regulates the transcription of the target gene and is typically located upstream of it.
[0406] In one implementation, the regulator of gene expression is an exogenous promoter, such as CMV (cytomegalovirus promoter), CBA (chicken β-actin promoter), or PGK (phosphoglycerate kinase 1 promoter), such as the CMV promoter.
[0407] In one embodiment, a replicating oncolytic adenovirus serotype 11 (e.g., Ad11p) or a viral derivative thereof is provided, wherein the fibrils, hexapods, and capsid are serotype 11 (e.g., Ad11p), wherein the viral genome contains a DNA sequence encoding any provided engineered cancer antigen located in a portion of the viral genome, said DNA sequence being expressed late in the viral replication cycle and such that transgenes do not interfere with viral replication, wherein said DNA sequence is under the control of a promoter that is foreign to the adenovirus (e.g., a CMV promoter). In one embodiment, the DNA sequence encoding the engineered cancer antigen is associated with the L5 region, as described elsewhere herein, particularly located between the L5 and E4 regions.
[0408] Other characteristics of viral vectors (such as adenoviruses) known to those skilled in the art are also present as part of adenovirus vectors. These include regulatory sequences, splice acceptor sequences, polyadenylation sequences, and other sequences well known to those skilled in the art. Any such sequences are known and described in, for example, the following applications: WO2005 / 118825, WO2015 / 097220, WO2015 / 059303, WO2015 / 155370, WO2016 / 174200, WO2017 / 103291, WO2018 / 041838, WO2018 / 041827, WO2017 / 103290, WO2018 / 220207, WO2019 / 043020, WO2022 / 171853, the contents of which are hereby incorporated by reference in their entirety. V. Compositions and Kits
[0409] This document provides compositions (e.g., pharmaceutical compositions) that comprise one or more of any vectors disclosed herein (e.g., any vector comprising one or more polynucleotides encoding one or more engineered cancer antigens disclosed herein).
[0410] In some embodiments, the composition is a pharmaceutical composition comprising one or more of any carriers disclosed herein (e.g., any carrier comprising one or more polynucleotides encoding one or more engineered cancer antigens disclosed herein), and a pharmaceutically acceptable carrier.
[0411] In some embodiments, the pharmaceutical composition includes a carrier containing a polynucleotide that encodes any engineered cancer antigen containing a tumor-targeting molecule.
[0412] In some embodiments, the pharmaceutical composition comprises a carrier containing a polynucleotide encoding any engineered cancer antigen containing a heterologous membrane-targeting domain.
[0413] This document provides compositions (e.g., pharmaceutical compositions) comprising a population of lymphocytes expressing a CAR, such as any CAR disclosed in section ID. In some embodiments, the lymphocytes are T cells. In some embodiments, the T cells are CD4+ and / or CD8+ T cells.
[0414] This document also provides compositions (e.g., pharmaceutical compositions) comprising any CAR-T cell therapy disclosed herein, such as any CAR-T cell therapy comprising CAR-T cells that specifically bind to a target domain of any engineered cancer antigen disclosed herein.
[0415] This document also provides compositions (e.g., pharmaceutical compositions) comprising: (i) one or more of any vectors disclosed herein (e.g., any vector comprising one or more polynucleotides encoding one or more engineered cancer antigens disclosed herein); and (ii) any CAR-T cell therapy disclosed herein, such as any CAR-T cell therapy comprising CAR-T cells that specifically bind to a target domain of any engineered cancer antigen disclosed herein.
[0416] This document also provides a kit comprising: (i) a first composition (e.g., a first pharmaceutical composition) comprising one or more of any vectors disclosed herein (e.g., any vector comprising one or more polynucleotides encoding one or more engineered cancer antigens disclosed herein); and (ii) a second composition (e.g., a second pharmaceutical composition) comprising any CAR-T cell therapy disclosed herein, such as any CAR-T cell therapy comprising CAR-T cells that specifically bind to a target domain of any engineered cancer antigen disclosed herein.
[0417] In some embodiments, the kit further includes instructions for use of the first composition and the second composition, ...
Claims
1. An engineered cancer antigen comprising a target domain and a tumor-targeting molecule, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof.
2. The engineered cancer antigen according to claim 1, wherein the engineered cancer antigen is secretible when expressed from cells.
3. The engineered cancer antigen according to claim 1 or claim 2, wherein the tumor-targeting molecule binds to a tumor-associated antigen expressed on the surface of tumor cells.
4. The engineered cancer antigen according to claim 3, wherein the tumor-associated antigen is selected from EpCAM, CEA (carcinoembryonic antigen), gpA33 (glycoprotein A33 (transmembrane)), mucin, TAG-72 (tumor-associated glycoprotein 72), CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), and FBP (folate-binding protein), EGFR / ERBB1 / HER1 (epidermal growth factor receptor 1), ERBB3 (epidermal growth factor receptor 3), MET (tyrosine protein kinase), IGF1R (insulin-like growth factor 1 receptor), EPHA3 (EPH receptor A3), TRAILR1 (death receptor 4), and RANK-L (nuclear factor κB receptor activator ligand).
5. The engineered cancer antigen according to claim 3 or claim 4, wherein the tumor cells are tumor cells of a solid tumor.
6. The engineered cancer antigen according to any one of claims 3-5, wherein the tumor cells are tumor cells selected from the following cancers: multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, medulloblastoma, liver cancer, gastric cancer, thyroid cancer, bile duct cancer, liver cancer, bone cancer, skin cancer, colon cancer, rectal cancer, endometrial cancer, and cervical cancer.
7. The engineered cancer antigen according to any one of claims 3-6, wherein the tumor cells are tumor cells selected from the following cancers: bladder cancer, breast cancer, skin cancer, head and neck cancer, colorectal cancer, endometrial cancer, liver cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, thyroid cancer, and ovarian cancer.
8. The engineered cancer antigen according to any one of claims 1-7, wherein the tumor-targeting molecule comprises an antibody or an antigen-binding fragment thereof.
9. The engineered cancer antigen of claim 8, wherein the antibody or its antigen-binding fragment is a single-chain variable fragment (scFv), DARPin, a variable heavy chain (VH) domain, or VHH, more preferably a single-chain variable fragment (scFv).
10. The engineered cancer antigen according to any one of claims 1-9, wherein the tumor-associated antigen is EpCAM.
11. The engineered cancer antigen according to any one of claims 8-10, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: The VH region comprises heavy chain complementarity-determining regions 1 (CDR-H1), CDR-H2, and CDR-H3, which respectively contain the amino acid sequences shown in SEQ ID NO:15, 16, and 17, and The VL region includes light chain complementarity-determining regions 1 (CDR-L1), CDR-L2, and CDR-L3, which contain the amino acid sequences shown in SEQ ID NO:18, 19, and 20, respectively.
12. The engineered cancer antigen according to any one of claims 8-11, wherein the antibody or its antigen-binding fragment comprises a VH region, the VH region comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 10; and a VL region, the VL region comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO:
8.
13. The engineered cancer antigen according to any one of claims 8-12, wherein the antibody or antigen-binding fragment thereof comprises a VH region containing the amino acid sequence of SEQ ID NO: 10 and a VL region containing the amino acid sequence of SEQ ID NO:
8.
14. The engineered cancer antigen according to any one of claims 1-13, wherein the target domain and the tumor-targeting molecule are directly linked.
15. The engineered cancer antigen according to any one of claims 1-13, wherein the target domain and the tumor-targeting molecule are connected by a connector.
16. The engineered cancer antigen of claim 15, wherein the length of the linker is between 1 and 100 amino acids, between 1 and 75 amino acids, between 1 and 50 amino acids, between 1 and 25 amino acids, between 5 and 100 amino acids, between 5 and 75 amino acids, between 5 and 50 amino acids, between 5 and 25 amino acids, between 10 and 100 amino acids, between 10 and 75 amino acids, between 10 and 50 amino acids, or between 10 and 25 amino acids.
17. The engineered cancer antigen according to claim 15 or claim 16, wherein the linker comprises an amino acid sequence of any one of SEQ ID NO: 9 and 138-144.
18. The engineered cancer antigen according to any one of claims 1-17, wherein the target antigen is a membrane-expressed antigen.
19. The engineered cancer antigen according to any one of claims 1-18, wherein the target antigen is a cell surface receptor.
20. The engineered cancer antigen according to any one of claims 1-19, wherein the target domain is recognized by a homologous binding agent.
21. The engineered cancer antigen according to any one of claims 1-20, wherein the target domain is a truncated portion of the extracellular domain of the target antigen, retaining an epitope that can be recognized by a homologous binder.
22. The engineered cancer antigen according to any one of claims 1-21, wherein the target antigen is selected from carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cells infected with cytomegalovirus (CMV) (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein ligand 1 (PS) Specialized glycoforms of GL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
23. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is BCMA.
24. The engineered cancer antigen according to any one of claims 1-23, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
3.
25. The engineered cancer antigen of claim 23 or claim 24, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: The heavy chain variable (VH) region containing the amino acid sequence of SEQ ID NO: 31 and the light chain variable (VL) region containing the amino acid sequence of SEQ ID NO: 32; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
35.
26. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is CD70.
27. The engineered cancer antigen according to any one of claims 1-22 and 26, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
106.
28. The engineered cancer antigen according to claim 26 or claim 27, wherein the target domain comprises the amino acid sequence of SEQ ID NO: 107 or 124.
29. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is CD19.
30. The engineered cancer antigen according to any one of claims 1-22 and 29, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
71.
31. The engineered cancer antigen of claim 29 or claim 30, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: (a) A heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO: 48 or 49; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 50 and a VL region containing the amino acid sequence of SEQ ID NO: 51; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
52.
32. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is CD20.
33. The engineered cancer antigen according to any one of claims 1-22 and 32, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
72.
34. The engineered cancer antigen of claim 32 or claim 33, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: The VH region containing the amino acid sequence of SEQ ID NO: 53 and the VL region containing the amino acid sequence of SEQ ID NO: 54; and / or scFv containing the amino acid sequence of SEQ ID NO:
55.
35. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is CD22.
36. The engineered cancer antigen according to any one of claims 1-22 and 35, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
73.
37. The engineered cancer antigen of claim 35 or claim 36, wherein the target domain is recognized by a homology binding agent, the homology binding agent comprising: (a) A VH region containing the amino acid sequence of SEQ ID NO: 56 and a VL region containing the amino acid sequence of SEQ ID NO: 57; and / or scFv containing the amino acid sequence of SEQ ID NO: 58; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 59 and a VL region containing the amino acid sequence of SEQ ID NO: 60; and / or scFv containing the amino acid sequence of SEQ ID NO:
61.
38. The engineered cancer antigen according to any one of claims 1-22, wherein the target antigen is CD70.
39. The engineered cancer antigen according to any one of claims 1-22 and 38, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
124.
40. The engineered cancer antigen of claim 38 or claim 39, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: The VH region containing the amino acid sequence of SEQ ID NO: 125 and the VL region containing the amino acid sequence of SEQ ID NO: 126; and / or scFv containing the amino acid sequence of SEQ ID NO:
127.
41. The engineered cancer antigen according to any one of claims 20-40, wherein the homologous binder is a chimeric antigen receptor (CAR) that binds to the target domain.
42. The engineered cancer antigen of claim 41, wherein the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA; P-select). Specialized glycoforms of glycoprotein ligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
43. The engineered cancer antigen according to any one of claims 1-42, wherein the engineered cancer antigen does not contain an intracellular domain.
44. An engineered cancer antigen comprising a target domain and a heterologous membrane target domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof.
45. The engineered cancer antigen of claim 44, wherein the engineered cancer antigen is membrane-bound when expressed from a cell.
46. The engineered cancer antigen according to claim 44 or claim 45, wherein the heterologous membrane targeting domain is a heterologous transmembrane domain.
47. The engineered cancer antigen of claim 46, wherein the heterologous transmembrane domain is derived from the transmembrane domains of: the α, β, or ζ chain of a T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, CD1 lα, CD18, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF 1), CD160, CD19, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49d, ITGA6, VLA-6 , CD49f, ITGAD, CD1D, ITGAE, CD103, ITGAL, ITGAM, CD1B, ITGAX, CD1C, ITGB1, CD29, ITGB2, CD18 , LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, CD229, CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and / or NKG2C.
48. The engineered cancer antigen according to claim 46 or claim 47, wherein the transmembrane domain is the CD8 transmembrane domain.
49. The engineered cancer antigen of claim 48, wherein the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO:
4.
50. The engineered cancer antigen according to any one of claims 44-49, wherein the target domain and the heterologous membrane targeting domain are each derived from different cell surface receptors.
51. The engineered cancer antigen according to any one of claims 44-50, wherein the target antigen is a membrane-expressed antigen.
52. The engineered cancer antigen according to any one of claims 44-51, wherein the target antigen is a cell surface receptor.
53. The engineered cancer antigen according to any one of claims 44-52, wherein the target antigen is recognized by a homologous binding agent.
54. The engineered cancer antigen according to any one of claims 44-53, wherein the target domain is a truncated portion of the extracellular domain of the target antigen, retaining an epitope that can be recognized by a homologous binder.
55. The engineered cancer antigen according to any one of claims 44-54, wherein the target antigen is selected from carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA); P-selectin glycoprotein ligand 1 (P Specialized glycoforms of SGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
56. The engineered cancer antigen according to any one of claims 44-55, wherein the target antigen is BCMA.
57. The engineered cancer antigen according to any one of claims 44-56, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
3.
58. The engineered cancer antigen of claim 56 or claim 57, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: The heavy chain variable (VH) region containing the amino acid sequence of SEQ ID NO: 31 and the light chain variable (VL) region containing the amino acid sequence of SEQ ID NO: 32; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
35.
59. The engineered cancer antigen according to any one of claims 44-55, wherein the target antigen is CD70.
60. The engineered cancer antigen according to any one of claims 44-55 and 59, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
106.
61. The engineered cancer antigen according to claim 59 or claim 60, wherein the target domain comprises the amino acid sequence of SEQ ID NO: 107 or 124.
62. The engineered cancer antigen according to any one of claims 59-61, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
124.
63. The engineered cancer antigen according to any one of claims 59-62, wherein the target domain is recognized by a homologous binding agent, the homologous binding agent comprising: The VH region containing the amino acid sequence of SEQ ID NO: 125 and the VL region containing the amino acid sequence of SEQ ID NO: 126; and / or scFv containing the amino acid sequence of SEQ ID NO:
127.
64. The engineered cancer antigen according to any one of claims 44-55, wherein the target antigen is CD19.
65. The engineered cancer antigen according to any one of claims 44-55 and 64, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
71.
66. The engineered cancer antigen of claim 64 or claim 65, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: (a) A heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO: 48 or 49; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 50 and a VL region containing the amino acid sequence of SEQ ID NO: 51; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
52.
67. The engineered cancer antigen according to any one of claims 44-55, wherein the target antigen is CD20.
68. The engineered cancer antigen according to any one of claims 44-55 and 67, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
72.
69. The engineered cancer antigen of claim 67 or claim 68, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: The VH region containing the amino acid sequence of SEQ ID NO: 53 and the VL region containing the amino acid sequence of SEQ ID NO: 54; and / or scFv containing the amino acid sequence of SEQ ID NO:
55.
70. The engineered cancer antigen according to any one of claims 44-55, wherein the target antigen is CD22.
71. The engineered cancer antigen according to any one of claims 44-55 and 70, wherein the target domain comprises the amino acid sequence of SEQ ID NO:
73.
72. The engineered cancer antigen of claim 70 or claim 71, wherein the target domain is recognizable by a homologous binding agent, the homologous binding agent comprising: (a) A VH region containing the amino acid sequence of SEQ ID NO: 56 and a VL region containing the amino acid sequence of SEQ ID NO: 57; and / or scFv containing the amino acid sequence of SEQ ID NO: 58; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 59 and a VL region containing the amino acid sequence of SEQ ID NO: 60; and / or scFv containing the amino acid sequence of SEQ ID NO:
61.
73. The engineered cancer antigen according to any one of claims 53-72, wherein the homologous binder is a chimeric antigen receptor (CAR) that binds to the target domain.
74. The engineered cancer antigen of claim 73, wherein the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), skin lymphocyte-associated antigen (CLA; P-select). Specialized glycoforms of glycoprotein ligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
75. The engineered cancer antigen according to any one of claims 44-74, wherein the engineered cancer antigen does not contain an intracellular domain.
76. The engineered cancer antigen according to any one of claims 44-74, wherein the engineered cancer antigen further comprises an intracellular domain.
77. The engineered cancer antigen of claim 75 or claim 76, wherein the intracellular domain is a heterologous intracellular domain derived from the target antigen or a truncated portion thereof.
78. The engineered cancer antigen according to claim 76 or claim 77, wherein the intracellular domain is a truncated and / or non-functional intracellular domain.
79. The engineered cancer antigen according to any one of claims 76-78, wherein the intracellular domain comprises a death domain.
80. The engineered cancer antigen of claim 79, wherein the death domain is derived from a death receptor selected from: FAS (CD95), tumor necrosis factor receptor superfamily member 10A (TNFRSF10A; also known as death receptor 4 (DR4)), DR5, TNFR1, DR3, leucine-rich repeat sequence and death domain-containing protein 1, ankyrin repeat sequence and death domain-containing protein IB, interleukin-1 receptor-associated kinase-like protein 2, tumor necrosis factor receptor superfamily member 21, Netrin receptor UNC5A, Netrin receptor UNC5B, Netrin receptor UNC5C, Netrin receptor UNC5D, UNC5C-like protein, tumor necrosis factor receptor superfamily member 16, ankyrin 1, ankyrin 2, ankyrin 3, nuclear factor NF-κB p105 subunit, tumor necrosis factor receptor superfamily member 6, interleukin-1 receptor-associated kinase 1, death-associated protein kinase 1, death domain-containing protein CRADD, nuclear factor NF-κB p100 subunit, FAS-associated death domain protein (FADD), receptor-interacting serine / threonine protein kinase 1, ankyrin repeat sequence and death domain protein 1A, death domain protein 1, exoprotein A receptor-associated adaptor protein, tumor necrosis factor receptor superfamily member 25, THO complex subunit 1, myeloid differentiation primary response protein MyD88, p53-induced death domain protein 1, and interleukin-1 receptor-associated kinase 3.
81. The engineered cancer antigen of claim 79 or claim 80, wherein the death domain is derived from FAS, FADD, or TNFRSF10A.
82. The engineered cancer antigen according to any one of claims 79-81, wherein the death domain is derived from FAS.
83. The engineered cancer antigen according to claim 82, wherein the death domain comprises an amino acid sequence selected from SEQ ID NO: 93, 97 and 99.
84. The engineered cancer antigen according to any one of claims 79-81, wherein the death domain is derived from FADD.
85. The engineered cancer antigen of claim 84, wherein the death domain comprises the amino acid sequence of SEQ ID NO:
101.
86. The engineered cancer antigen according to any one of claims 79-81, wherein the death domain is derived from TNFRSF10A.
87. The engineered cancer antigen according to claim 86, wherein the death domain comprises the amino acid sequence of SEQ ID NO: 103 or 105.
88. A cell expressing an engineered cancer antigen according to any one of claims 1-43.
89. A cell comprising an engineered cancer antigen according to any one of claims 44-87.
90. A cell expressing an engineered cancer antigen according to any one of claims 1-43, and comprising an engineered cancer antigen according to any one of claims 44-87.
91. The cell according to any one of claims 88-90, wherein the cell is a tumor cell.
92. The cell of claim 91, wherein the tumor cell is a tumor cell selected from the following cancers: non-Hodgkin lymphoma (NHL), diffuse large cell lymphoma (DLCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma, multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, skin cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, medulloblastoma, liver cancer, gastric cancer, thyroid cancer, bile duct cancer, liver cancer, bone cancer, colon cancer, rectal cancer, endometrial cancer, and cervical cancer.
93. The cell according to claim 91 or claim 92, wherein the tumor cell is a tumor cell selected from the following cancers: bladder cancer, breast cancer, skin cancer, head and neck cancer, colorectal cancer, endometrial cancer, liver cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, thyroid cancer, and ovarian cancer.
94. A polynucleotide encoding an engineered cancer antigen according to any one of claims 1-43.
95. A polynucleotide encoding an engineered cancer antigen according to any one of claims 44-87.
96. A polynucleotide comprising a nucleic acid sequence encoding an engineered cancer antigen according to any one of claims 1-43 and a nucleic acid sequence encoding an engineered cancer antigen according to any one of claims 44-87.
97. The polynucleotide of claim 96, wherein the nucleic acid sequence encoding the engineered cancer antigen of any one of claims 1-43 and the nucleic acid sequence encoding the engineered cancer antigen of any one of claims 44-87 are separated by a cleavable adapter.
98. The polynucleotide of claim 97, wherein the cleavable adapter is a self-cleaving adapter.
99. The polynucleotide of claim 98, wherein the self-cleaving linker is or comprises a 2A peptide.
100. A vector comprising the polynucleotide according to claim 94 or claim 95.
101. A vector comprising a polynucleotide according to any one of claims 96-99.
102. A vector comprising the polynucleotides according to claim 94 and according to claim 95.
103. The vector according to any one of claims 100-102, wherein the vector is used for specifically delivering the polynucleotide to cancer cells.
104. The vector of claim 103, wherein the vector is used for specific delivery to blood cancer cells.
105. The vector of claim 103, wherein the vector is used for specific delivery to solid tumor cancer cells.
106. The vector according to any one of claims 100-105, wherein the vector is a viral vector.
107. The vector according to claim 106, wherein the viral vector is an oncolytic virus.
108. The vector according to claim 107, wherein the oncolytic virus is selected from adenovirus, herpes simplex virus, vaccinia virus, mumps virus, Newcastle disease virus, poliovirus, Seneca Valley virus, measles virus, Sindbis virus, parvovirus, Coxsackie virus, vesicular stomatitis virus, reovirus, and Malaba rhabdovirus.
109. The vector according to any one of claims 106-108, wherein the viral vector exhibits tropism towards tumor cells.
110. The vector according to any one of claims 106-109, wherein the viral vector enters the cell by binding to a cell surface receptor expressed by the tumor cell.
111. The vector according to any one of claims 106-110, wherein the viral vector is an adenovirus vector, an adeno-associated virus (AAV) vector, a lentiviral vector, a retroviral vector, or a herpes simplex virus (HSV) vector.
112. The vector according to any one of claims 106-111, wherein the viral vector is an adenovirus vector.
113. The vector according to any one of claims 106-111, wherein the viral vector is a lentiviral vector.
114. A pharmaceutical composition comprising a polynucleotide according to any one of claims 94-99 or a carrier according to any one of claims 100-113.
115. The pharmaceutical composition of claim 114, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
116. A combination comprising a vector according to any one of claims 100-113 and a population of lymphocytes expressing a chimeric antigen receptor (CAR) that recognizes a target domain of the engineered cancer antigen.
117. A combination comprising A vector containing a polynucleotide encoding an engineered cancer antigen, the engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is the extracellular domain of the target antigen or a truncated portion thereof, and A population of lymphocytes that express chimeric antigen receptors (CARs) that recognize the target domains of the engineered cancer antigen.
118. The combination according to claim 116 or claim 117, wherein the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), and skin lymphocyte-associated antigen (CLA); Specialized glycoforms of P-selectin glycoprotein ligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
119. The combination according to any one of claims 116-118, wherein the CAR is bound to the extracellular domain of BCMA or a truncated portion thereof.
120. The combination of claim 119, wherein the CAR comprises: The heavy chain variable (VH) region containing the amino acid sequence of SEQ ID NO: 31 and the light chain variable (VL) region containing the amino acid sequence of SEQ ID NO: 32; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
35.
121. The combination according to any one of claims 116-118, wherein the CAR binds to the extracellular domain of CD19 or a truncated portion thereof.
122. The combination of claim 121, wherein the CAR comprises: (a) A heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO: 48 or 49; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 50 and a VL region containing the amino acid sequence of SEQ ID NO: 51; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
52.
123. The combination according to any one of claims 116-118, wherein the CAR binds to the extracellular domain of CD20 or a truncated portion thereof.
124. The combination of claim 123, wherein the CAR comprises: The VH region containing the amino acid sequence of SEQ ID NO: 53 and the VL region containing the amino acid sequence of SEQ ID NO: 54; and / or scFv containing the amino acid sequence of SEQ ID NO:
55.
125. The combination according to any one of claims 116-118, wherein the CAR binds to the extracellular domain of CD22 or a truncated portion thereof.
126. The combination of claim 125, wherein the CAR comprises: (a) A VH region containing the amino acid sequence of SEQ ID NO: 56 and a VL region containing the amino acid sequence of SEQ ID NO: 57; and / or scFv containing the amino acid sequence of SEQ ID NO: 58; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 59 and a VL region containing the amino acid sequence of SEQ ID NO: 60; and / or scFv containing the amino acid sequence of SEQ ID NO:
61.
127. The combination according to any one of claims 116-118, wherein the CAR binds to the extracellular domain of CD70 or a truncated portion thereof.
128. The combination of claim 127, wherein the CAR comprises: The VH region containing the amino acid sequence of SEQ ID NO: 125 and the VL region containing the amino acid sequence of SEQ ID NO: 126; and / or scFv containing the amino acid sequence of SEQ ID NO:
127.
129. A kit comprising a pharmaceutical composition according to claim 114 or claim 115 and instructions for using the polynucleotide or the carrier.
130. A kit comprising the combination of any one of claims 116-128.
131. The kit of claim 130, further comprising instructions for using the vector and the lymphocyte population.
132. A treatment method, the method comprising: Administering a therapeutically effective amount of the polynucleotide according to any one of claims 94-99, the carrier according to any one of claims 100-113, or the pharmaceutical composition according to claim 114 or claim 115 to a subject suffering from cancer, and A therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR) that binds to the target domain of the engineered cancer antigen is administered.
133. A treatment method, the method comprising: Administering a therapeutically effective amount of a carrier to a subject with cancer, the carrier comprising a polynucleotide encoding an engineered cancer antigen, the engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof, and A therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR) that binds to the target domain of the engineered cancer antigen is administered.
134. A treatment method comprising administering to a subject suffering from cancer a therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR), the subject having previously been administered a polynucleotide according to any one of claims 94-99, a carrier according to any one of claims 100-113, or a pharmaceutical composition according to claim 114 or claim 115, wherein the CAR binds to a target domain of the engineered cancer antigen.
135. A treatment method comprising administering to a subject with cancer a therapeutically effective amount of a population of lymphocytes expressing a chimeric antigen receptor (CAR), the subject having previously been administered a vector comprising a polynucleotide encoding an engineered cancer antigen comprising a target domain and a membrane-targeting domain, wherein the target domain is an extracellular domain of the target antigen or a truncated portion thereof, wherein the CAR binds to the target domain of the engineered cancer antigen.
136. The method according to any one of claims 132-135, wherein the lymphocytes are T cells.
137. The method according to any one of claims 132-135, wherein the CAR binds to an extracellular domain or a truncated portion thereof selected from the following cell surface protein antigens: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49c, CD49f, CD56, CD66c, CD70, CD73, CD74, CD104, CD133, CD138, CD123, CD142, CD44V6, antigens of cytomegalovirus (CMV)-infected cells (e.g., cell surface antigens), and skin lymphocyte-associated antigen (CLA); Specialized glycoforms of P-selectin glycoprotein ligand 1 (PSGL-1), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate-binding protein (EBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), G protein-coupled receptor class C5 member D (GPRC5D), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Rα2), κ-light chain, kinase insertion domain receptor (KDR), Lewis Y (LeY), LI cell adhesion molecule (L1CAM), melanoma antigen family A member 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGE A3, p53, MARTI, GP100, protease 3 (PR1), tyrosinase, survival protein, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), ROR1, tetraspan protein 8 (TSPAN8), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), nephroblastoma protein (WT-1), cytokine receptor-like factor 2 (CRLF2), BCMA, GPC3, NKCS1, EGF1R, EGFR-VIII, and ERBB.
138. The method according to any one of claims 132-137, wherein the CAR binds to the extracellular domain of BCMA or a truncated portion thereof.
139. The method of claim 138, wherein the CAR comprises: The heavy chain variable (VH) region containing the amino acid sequence of SEQ ID NO: 31 and the light chain variable (VL) region containing the amino acid sequence of SEQ ID NO: 32; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
35.
140. The method according to any one of claims 132-137, wherein the CAR binds to the extracellular domain of CD19 or a truncated portion thereof.
141. The method of claim 140, wherein the CAR comprises: (a) A heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 47; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO: 48 or 49; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 50 and a VL region containing the amino acid sequence of SEQ ID NO: 51; and / or A single-stranded variable fragment (scFv) containing the amino acid sequence of SEQ ID NO:
52.
142. The method according to any one of claims 132-137, wherein the CAR binds to the extracellular domain of CD20 or a truncated portion thereof.
143. The method of claim 142, wherein the CAR comprises: The VH region containing the amino acid sequence of SEQ ID NO: 53 and the VL region containing the amino acid sequence of SEQ ID NO: 54; and / or scFv containing the amino acid sequence of SEQ ID NO:
55.
144. The method according to any one of claims 132-137, wherein the CAR binds to the extracellular domain of CD22 or a truncated portion thereof.
145. The method of claim 144, wherein the CAR comprises: (a) A VH region containing the amino acid sequence of SEQ ID NO: 56 and a VL region containing the amino acid sequence of SEQ ID NO: 57; and / or scFv containing the amino acid sequence of SEQ ID NO: 58; or (b) A VH region containing the amino acid sequence of SEQ ID NO: 59 and a VL region containing the amino acid sequence of SEQ ID NO: 60; and / or scFv containing the amino acid sequence of SEQ ID NO:
61.
146. The method according to any one of claims 132-137, wherein the target antigen is CD70.
147. The method of claim 146, wherein the target antigen is recognizable by a homologous binding agent, the homologous binding agent comprising: The VH region containing the amino acid sequence of SEQ ID NO: 125 and the VL region containing the amino acid sequence of SEQ ID NO: 126; and / or scFv containing the amino acid sequence of SEQ ID NO:
127.
148. A method for labeling tumor cells in vivo, the method comprising contacting the tumor cells with: a polynucleotide according to any one of claims 94-99, a carrier according to any one of claims 100-113, or a pharmaceutical composition according to claim 114 or claim 115.
149. A method for labeling tumor cells of a subject suffering from cancer, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide according to any one of claims 94-99, a carrier according to any one of claims 100-113, or a pharmaceutical composition according to claim 114 or claim 115.
Citation Information
Patent Citations
Expression and excretion of polypeptides in eucaryotes under the control of an adenovirus promoter
EP0185573A1
Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
US11026975B2
Halogenated pyranthrone and process of making same
US1975256A
Administration of growth factors for the treatment of CNS disorders
US20070254842A1
Implantable Medical Device with Apertures for Delivery of Bioactive Agents
US20080081064A1
